



(86) Date de dépôt PCT/PCT Filing Date: 2012/11/23
(87) Date publication PCT/PCT Publication Date: 2013/05/30
(85) Entrée phase nationale/National Entry: 2014/05/22
(86) N° demande PCT/PCT Application No.: EP 2012/073483
(87) N° publication PCT/PCT Publication No.: 2013/076253
(30) Priorité/Priority: 2011/11/25 (EP11190690.5)

(51) Cl.Int./Int.Cl. *A61K 38/47* (2006.01),
C11D 3/386 (2006.01), *C12N 15/56* (2006.01),
C12N 9/24 (2006.01), *C12N 9/36* (2006.01)

(71) Demandeur/Applicant:
NOVOZYMES A/S, DK

(72) Inventeurs/Inventors:
SCHNORR, KIRK MATTHEW, DK;
NIELSEN, JENS ERIK, DK;
KLAUSEN, MIKKEL, DK

(74) Agent: DIMOCK STRATTON LLP

(54) Titre : POLYPEPTIDES AYANT UNE ACTIVITE DE LYSOZYME ET POLYNUCLEOTIDES CODANT POUR CES
POLYPEPTIDES

(54) Title: POLYPEPTIDES HAVING LYSOZYME ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

(57) **Abrégé/Abstract:**

The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2013/076253 A1

(43) International Publication Date
30 May 2013 (30.05.2013)

(51) International Patent Classification:

A61K 38/47 (2006.01) C12N 15/56 (2006.01)
C12N 9/24 (2006.01) C11D 3/386 (2006.01)
C12N 9/36 (2006.01)

(21) International Application Number:

PCT/EP2012/073483

(22) International Filing Date:

23 November 2012 (23.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11190690.5 25 November 2011 (25.11.2011) EP

(71) Applicant: NOVOZYMES A/S [DK/DK]; Krogshøjvej
36, DK-2880 Bagsvaerd (DK).

(72) Inventors: SCHNORR, Kirk, Matthew; Soeller-
oedgaardsvej 38, DK-2840 Holte (DK). NIELSEN, Jens,
Erik; Hoejgaardsvej 15B, DK-3520 Farum (DK).
KLAUSEN, Mikkel; Ved Skansen 5, 2.th., DK-2300
Copenhagen S (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,

KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: POLYPEPTIDES HAVING LYSOZYME ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

(57) Abstract: The present invention relates to isolated polypeptides having lysozymeactivity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.



WO 2013/076253 A1

POLYPEPTIDES HAVING LYSOZYME ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME**REFERENCE TO A SEQUENCE LISTING**

This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference.

5

REFERENCE TO ATOMIC COORDINATES

This application sets forth in Figure 6, the atomic coordinates of the three-dimensional structure of the *Acremonium alkalophilum* CBS114.92 lysozyme.

BACKGROUND OF THE INVENTION**Field of the Invention**

10

The present invention relates to polypeptides having lysozyme activity, catalytic domains, and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains.

Description of the Related Art

15

Lysozyme is a O-glycosyl hydrolase produced as a defensive mechanism against bacteria by many organisms. The enzyme causes the hydrolysis of bacterial cell walls by cleaving the glycosidic bonds of peptidoglycan; an important structural molecule in bacteria. After having their cell walls weakened by lysozyme action, bacterial cells lyse resulting from osmotic pressure.

20

Lysozyme occurs in many organisms such as viruses, plants, insects, birds, reptiles and mammals. In mammals, Lysozyme has been isolated from nasal secretions, saliva, tears, intestines, urine and milk. The enzyme cleaves the glycosidic bond between carbon number 1 of N-acetylmuramic acid and carbon number 4 of N-acetyl-D-glucosamine. In vivo, these two carbohydrates are polymerized to form the cell wall polysaccharide.

25

There is an increasing interest in the potential of lysozyme enzymes as antimicrobial agents. For example, lysozyme activity has been shown against pathogens such as *Streptococcus pneumoniae*, *Bacillus anthracis*, *Enterococcus faecium*, *Bacillus stearothermophilus*, *Clostridium botulinum*, *Clostridium butyricum*, *Clostridium perfringens*, *Clostridium sporogenes*, *Clostridium tyrobutyricum*, and *Listeria monocytogenes*.

Lysozyme has been classified into five different glycoside hydrolase (GH) families (CAZy, www.cazy.org): hen egg-white lysozyme (GH22), goose egg-white lysozyme (GH23), bacteriophage T4 lysozyme (GH24), *Sphingomonas* flagellar protein (GH73) and *Chalaropsis* lysozymes (GH25). Lysozymes from the families GH23 and GH24 are primarily known from bacteriophages and have not been identified in fungi. The lysozyme family GH25 has been found to be structurally unrelated to the other lysozyme families.

Use of lysozyme has been suggested in animal feed (see for example WO 00/21381 and WO 04/026334), in cheese production (see for example WO 05/080559), food preservation (Hughey and Johnson (1987) *Appl Environ Microbiol* 53:2165), detergents (see for example US 5,041,236 and EP 0425016), in oral care (see for example US 4,355,022, WO 04/017988 and WO 08/124764), cosmetology and dermatology, contraception, urology, and gynaecology (see for example WO 08/124764).

A GH25 lysozyme has been reported from *Chalaropsis* (Felsch JW, Ingagami T, and Hash JH. (1975), "The *N,O*-Diacetylmuramidase of *Chalaropsis* species; V The complete amino acid sequence, *J. Biol. Chem.* 250(10):3713-3720).

Hen egg white lysozyme which is the primary product available on the commercial market, does not cleave *N*,6-*O*-diacetylmuramidase in e.g. *Staphylococcus aureus* cell walls and is thus unable to lyse this important human pathogen among others (Masschalck B, Deckers D, Michiels CW (2002), "Lytic and nonlytic mechanism of inactivation of gram-positive bacteria by lysozyme under atmospheric and high hydrostatic pressure", *J Food Prot.* 65(12):1916-23).

It has been observed that different lysozymes have different specificities towards different microorganisms. It is therefore desirable to have several lysozymes available in order to be able to select suitable enzymes for each particular application. New polypeptides having lysozyme activity is therefore desired.

SUMMARY OF THE INVENTION

The present invention relates to isolated fungal polypeptides belonging to the GH25 family and having lysozyme activity.

The present invention further relates to isolated polypeptides having lysozyme activity selected from the group consisting of:

(a) a polypeptide having at least 80% sequence identity to the mature polypeptide of SEQ ID NO: 4 or to the mature polypeptide of SEQ ID NO: 8;

(b) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3 or to the mature polypeptide coding sequence of SEQ ID NO: 7;

(c) a polypeptide encoded by a polynucleotide that hybridizes under medium-high stringency conditions with the mature polypeptide coding sequence of SEQ ID NO: 3 or SEQ ID NO: 7, or the full-length complement thereof;

(d) a variant of the mature polypeptide SEQ ID NO: 4 or SEQ ID NO: 8, comprising a substitution, deletion, and/or insertion at one or more (e.g., several) positions; and

(e) a fragment of the polypeptide of (a), (b), (c), or (d) that has lysozyme activity.

The present invention also relates to isolated polynucleotides encoding the polypeptides of the present invention; nucleic acid constructs; recombinant expression vectors; recombinant host cells comprising the polynucleotides; and methods of producing the polypeptides.

Furthermore, the present invention relates to compositions comprising the polypeptide of the present invention, such as detergent compositions, animal feed compositions and a bacterial genomic DNA extraction composition.

The present invention also relates to the polypeptides of the invention having antimicrobial activity and methods of using the polypeptides of the invention as inhibitors of bio-film formation, in detergents, in dental care, in animal feed and for breaking down the cell walls of bacteria.

The present invention also relates to a polynucleotide encoding a signal peptide comprising or consisting of amino acids 1 to 19 of SEQ ID NO: 4 or amino acids -23 to -1 of SEQ ID NO: 8, which is operably linked to a gene encoding a protein; nucleic acid constructs, expression vectors, and recombinant host cells comprising the polynucleotides; and methods of producing a protein.

Overview of Sequence Listing

SEQ ID NO: 1 is the DNA sequence of the P244A7 GH24 gene as isolated from *Acremonium alkalophilum* CBS114.92.

SEQ ID NO: 2 is the amino acid sequence as deduced from SEQ ID NO: 1.

SEQ ID NO: 3 is the DNA sequence of the P242M9 GH25 gene as isolated from *Acremonium alkalophilum* CBS114.92.

SEQ ID NO: 4 is the amino acid sequence as deduced from SEQ ID NO: 3.

SEQ ID NO: 5 is the forward primer F-P242M9.

SEQ ID NO: 6 is the reverse primer R-P242M9.

SEQ ID NO: 7 is the DNA sequence of the synthetically optimised GH25 gene.

SEQ ID NO: 8 is the amino acid sequence as deduced from SEQ ID NO: 7.

SEQ ID NO: 9 is the forward primer BamHI.

SEQ ID NO: 10 is the reverse primer EcoRI.

Short description of the figures

Figure 1 shows radial diffusion assays of *Acremonium alcalophilum* GH24 lysozyme (EXP03890, SEQ ID NO: 2), *Acremonium alcalophilum* GH25 lysozyme (EXP03864, SEQ ID NO: 4) and a reference lysozyme from *Aspergillus fumigatus* GH25 on *S. carnosus* and *E.coli*.

Figure 2 shows the temperature stability of the *Acremonium alcalophilum* GH25 lysozyme P242M9 (SEQ ID NO: 4) at 60, 76, 70, 75, 80 and 85°C after 30 or 60 seconds as determined by optical density drop of a solution of re-suspended *Micrococcus luteus* ATTC No. 4698 measured in a spectrophotometer at 540 nm.

Figure 3 shows the thermostability of the GH25 lysozyme P242M9 (SEQ ID NO: 4) as determined using Differential Scanning Calorimetry (DSC) in 50 mM Na-acetate pH4.5, 50 mM Na-acetate pH 5.5 and 50 mM MES (2-(*N*-morpholino)ethanesulfonic acid), pH 6.5.

Figure 4 shows the lysozyme activity of 4 concentrations of the GH25 lysozyme P242M9 (SEQ ID NO: 4), the synthetic GH25 lysozyme (SEQ ID NO: 8) and 11 variants of SEQ ID NO: 8 as determined by optical density drop of a solution of re-suspended *Clostridium perfringens* NN01260.

Figure 5 shows the lysozyme activity of 4 concentrations of the GH25 lysozyme P242M9 (SEQ ID NO: 4), the synthetic GH25 lysozyme (SEQ ID NO: 8) and 11 variants of SEQ ID NO: 8 as determined by optical density drop of a solution of re-suspended *Clostridium perfringens* clinical isolate.

Figure 6 sets forth the atomic coordinates of the three-dimensional structure of the *Acremonium alkalophilum* CBS114.92 GH25 lysozyme. These atomic coordinates can aid in generating a three dimensional model depicting the structure of the *Acremonium alkalophilum* CBS114.92 GH25 lysozyme and a three dimensional model of homologous structures, such as variants of the aforementioned lysozyme.

DEFINITIONS

Lysozyme: The term "lysozyme" activity is defined herein as an O-glycosyl hydrolase, which catalyses the hydrolysis of the glycosidic bond between two or more carbohydrates, or between a carbohydrate and a non-carbohydrate moiety. Lysozymes cleave the glycosidic bond between certain residues in mucopolysaccharides and mucopeptides of bacterial cell walls, such as 1,4-beta-linkages between *N*-acetylmuramic acid and *N*-acetyl-D-glucosamine residues in a peptidoglycan and between *N*-acetyl-D-glucosamine residues in chitodextrins, resulting in

bacteriolysis. Lysozyme belongs to the enzyme class EC 3.2.1.17. For purposes of the present invention, lysozyme activity is determined according to the turbidity assay described in example 4. In one aspect, the polypeptides of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the lysozyme activity of the mature polypeptide of one of SEQ ID NO: 4 or SEQ ID NO: 8.

Allelic variant: The term "allelic variant" means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

Antimicrobial activity: The term "antimicrobial activity" is defined herein as is an activity that kills or inhibits the growth of microorganisms, such as, algae, archaea, bacteria, fungi and/or protozoans. The antimicrobial activity can for example be bactericidal meaning the killing of bacteria or bacteriostatic meaning the prevention of bacterial growth. The antimicrobial activity can include catalyzing the hydrolysis of 1,4-beta-linkages between *N*-acetylmuramic acid and *N*-acetyl-D-glucosamine residues in a peptidoglycan and between *N*-acetyl-D-glucosamine residues in chitodextrins. Antimicrobial activity can also include the lysozyme binding to the surface of the microorganism and inhibiting its growth. The antimicrobial effect can also include the use of the lysozymes of the present invention for activation of bacterial autolysins, as an immunostimulator, by inhibiting or reducing bacterial toxins and by an opsonin effect. For purposes of the present invention, antimicrobial activity is determined according to the antimicrobial assay described in example 10.

Altered/modified property: The term "altered/modified property" is defined herein as a characteristic associated with a variant that is altered or modified, as compared relative to the parent lysozyme or an identified reference sequence. The altered or modified property may be a characteristic associated with a variant that is improved, unless otherwise stated, relative to another reference lysozyme or the parent lysozyme. Examples of properties which can be altered/modified or improved are given below.

Thermostability: The term "thermostability" refers to the lysozyme activity after a period of incubation at elevated temperature relative to the parent or an identified reference sequence, either in a buffer or under conditions such as those which exist during product storage/transport or conditions similar to those that exist during industrial use of the variant. A variant may or may not display an altered thermal activity profile relative to the parent. In one aspect, the thermostability of the variant having lysozyme activity is at least 1.0-fold, e.g., at least 1.1-fold, at least 1.5-fold, at least 1.8-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, and at

least 25-fold more thermostable than the parent or reference sequence at the selected temperature. Preferably the activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.

Temperature profile/temperature stability: The term "temperature profile/temperature stability" refers to the variant enzyme showing a modified temperature profile as compared to the parent or an identified reference sequence, wherein the temperature profile is determined as lysozyme activity as a function of temperature. The activity at each temperature is preferably indicated as relative activity (in %) normalized to the value at optimum temperature. The optimum temperature is that temperature within the tested temperatures (i.e. those with 5-10°C jumps) where the activity is highest.

pH stability: The term "pH stability" refers to the variant enzyme displaying structural stability relative to the parent lysozyme or an identified reference sequence, after a period of incubation at a pH which is outside the pH range where the enzyme is active (pH activity range). Such a variant may or may not display an altered pH activity profile relative to the parent. For example, the variant may not be active at the increased or decreased pH, but is able to maintain its three dimensional structure and then regain activity once it is returned to the pH activity range. Alternatively, the variant may have an improved ability to refold relative to the parent following incubation at increased or decreased pH.

In one aspect, the pH stability profile is altered such that a lysozyme variant has improved stability at acidic pH. As used herein, acidic pH means from pH 2 to 5.5, preferably from 2.5 to 5.25, more preferably from 3 to 5, even more preferably from 3.5 to 4. Preferably, the variant lysozyme maintains at least 40%, preferably at least 50%, 60%, 70% or 80%, more preferably at least 90%, even more preferably at least 95% residual activity after incubation at a given pH for 1 hour when compared to the variant which has been maintained at pH 6.5 for the same time. Preferably, the residual activity of the variant lysozyme is at least 1.1-fold, at least 1.3-fold, at least 1.5-fold, preferably at least 2-fold, more preferably at least 5-fold, most preferably at least 7-fold, and even most preferably at least 10-fold higher than the residual activity of the parent lysozyme or an identified reference sequence which has been treated under the same conditions. Preferably, the activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.

pH activity: The term "pH activity" is defined herein as a variant lysozyme displaying an alteration of the pH-dependent activity profile when compared to the pH activity profile of the parent lysozyme or an identified reference sequence. The pH activity profile provides a measure of the enzyme's efficiency in preventing microbial growth, eliminating microbial cells and/or performing catalysis of a hydrolysis reaction over a pH range at given conditions such as temperature and

solvent composition. A lysozyme has a specific pH range wherein the polypeptide is stable and retains its enzymatic activity, outside this range the lysozyme becomes less active and potentially also less stable. Within the pH range there generally is a pH optimum, where the lysozyme shows the highest activity.

5 A lysozyme variant with improved activity at alkaline pH (e.g. from pH 7.5 to 12, preferably from 8 to 11, more preferably from 8.5 to 10, even more preferably from 9 to 9.5) will be able to function in more alkaline environments such as detergents.

 A variant with improved activity at acidic pH (e.g. from pH 2 to 6.5, preferably from 2.5 to 6, more preferably from 3 to 5.5, even more preferably from 3.5 to 5) will be able to function under
10 more acidic conditions, such as preservative in certain foods.

 A variant with improved activity at neutral to weakly acidic pH (e.g. from pH 4 to 7.0, preferably from 4.5 to 6.5, more preferably from 5 to 6.5) will be able to function under weakly acidic or neutral conditions, such as for use a eubiotic molecule in feeds, to stabilize the healthy microflora of animals or by suppressing growth/intestinal colonization of viral, parasitic or bacterial
15 pathogens in the GI tracts of animals.

 In one aspect, the pH activity profile is altered such that a lysozyme variant has improved activity at a more alkaline pH. Preferably, the activity of the lysozyme variant at a pH at least 0.5 units higher, preferably at least 1.0 pH units higher, more preferably at least 1.5 pH units higher, even more preferably at least 2.0 pH units higher is at least 1.1-fold, preferably at least 1.5-fold,
20 more preferably at least 2-fold, even more preferably at least 5-fold and most preferably at least 10-fold higher than that of the parent enzyme or an identified reference sequence. Preferably, the lysozyme variant at the same time maintains at least 40%, preferably at least 50%, 60%, 70% or 80%, or 90%, more preferably at least 95%, even more preferably at least 100% of the activity that parent lysozyme or an identified reference sequence exhibits at its pH optimum. Preferably, the
25 activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.

 In another aspect, the pH activity profile is altered such that a lysozyme variant has improved activity at a more acidic pH. Preferably, the activity of the lysozyme variant at a pH at least 0.5 units lower, preferably at least 1.0 pH units lower, more preferably at least 1.5 pH units
30 lower, even more preferably at least 2.0 pH units lower is at least 1.1-fold, preferably at least 1.5-fold, more preferably at least 2-fold, even more preferably at least 5-fold and most preferably at least 10-fold higher than that of the parent enzyme or an identified reference sequence. Preferably, the lysozyme variant at the same time maintains at least 40%, preferably at least 50%, 60%, 70% or 80%, or 90%, more preferably at least 95%, even more preferably at least 100% of the activity
35 that parent lysozyme or an identified reference sequence exhibits at its pH optimum. Preferably, the

activity is tested using the lysozyme turbidity activity assay described in the "Materials and Methods" section.

Substrate specificity: The term "substrate specificity" refers to the specificity of the lysozyme in regard to the type of bacteria it can kill/inhibit and/or in relation to model lysozyme substrates (e.g. p-NP-(NAG-NAM)_n or p-NP-(NAG)_m oligomers). By modifying the substrate specificity of the lysozyme, the type of bacteria the lysozyme can kill and/or inhibit can be altered. In one aspect, the substrate specificity of the lysozyme is broadened, thereby allowing other types of bacteria to be killed and/or inhibited apart from the bacteria which the wild type lysozyme can kill and/or inhibit.

Glycation Susceptibility: Non-enzymatic glycation is a spontaneous posttranslational process where reducing sugars bind covalently to free amino groups in proteins primarily at Lysine (K) residues. Glycation may impact the activity of the lysozyme. In accordance with the present invention, the susceptibility of the lysozyme to non-enzymatic glycation may be reduced by specified amino acid changes.

Improved properties may also include thermal properties, such as pelleting stability, steam stability, broader temperature activity profile. Further improved properties may include protease-sensibility, and/or glycosylation pattern. Improvements are preferably assessed in relation to the desired application conditions.

Catalytic domain: The term "catalytic domain" means the region of an enzyme containing the catalytic machinery of the enzyme.

cDNA: The term "cDNA" means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.

Coding sequence: The term "coding sequence" means a polynucleotide, which directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG, or TTG and ends with a stop codon such as TAA, TAG, or TGA. The coding sequence may be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.

Control sequences: The term "control sequences" means nucleic acid sequences necessary for expression of a polynucleotide encoding a mature polypeptide of the present invention. Each control sequence may be native (*i.e.*, from the same gene) or foreign (*i.e.*, from a different gene) to the polynucleotide encoding the polypeptide or native or foreign to each other. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a

minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a polypeptide.

5 **Expression:** The term "expression" includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

10 **Expression vector:** The term "expression vector" means a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences that provide for its expression.

15 **Fragment:** The term "fragment" means a polypeptide or a catalytic domain having one or more (e.g., several) amino acids absent from the amino and/or carboxyl terminus of a mature polypeptide or domain; wherein the fragment has lysozyme activity. In one aspect, a fragment contains at least 184 amino acid residues (e.g., amino acids 25 to 208 of SEQ ID NO: 4), or at least 195 amino acid residues (e.g., amino acids 22 to 216 of SEQ ID NO: 4). In a further aspect, a fragment contains at least 184 amino acid residues (e.g., amino acids 10 to 193 of SEQ ID NO: 8), or at least 195 amino acid residues (e.g., amino acids 5 to 199 of SEQ ID NO: 8).

20 **Host cell:** The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.

25 **Isolated:** The term "isolated" means a substance in a form or environment that does not occur in nature. Non-limiting examples of isolated substances include (1) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). An isolated substance may be present in a fermentation broth sample.

35 **Mature polypeptide:** The term "mature polypeptide" means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc. In one aspect, the mature polypeptide is amino acids 20 to 227 of SEQ ID NO: 4 or amino acids 1 to 208 of SEQ ID NO: 8 based on the

SignalP program (Nielsen *et al.*, 1997, *Protein Engineering* 10: 1-6) that predicts amino acids 1 to 19 of SEQ ID NO: 4 and amino acids -40 to -18 of SEQ ID NO: 8 are signal peptides. It is known in the art that a host cell may produce a mixture of two or more different mature polypeptides (*i.e.*, with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide.

5 **Mature polypeptide coding sequence:** The term "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide having lysozyme activity. In one aspect, the mature polypeptide coding sequence is the joined sequence of nucleotides 58 to 147 and nucleotides 302 to 835 of SEQ ID NO: 3, and nucleotides 121 to 744 of SEQ ID NO: 7 based on the SignalP program (Nielsen *et al.*, 1997, *supra*) that predicts nucleotides 1 to 57 of SEQ ID NO: 3
10 and nucleotides 1 to 69 of SEQ ID NO: 7 encodes signal peptides.

Nucleic acid construct: The term "nucleic acid construct" means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.

15 **Operably linked:** The term "operably linked" means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.

Sequence identity: The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity".

20 For purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *J. Mol. Biol.* 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *Trends Genet.* 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10,
25 gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled "longest identity" (obtained using the *-nobrief* option) is used as the percent identity and is calculated as follows:

$$(\text{Identical Residues} \times 100) / (\text{Length of Alignment} - \text{Total Number of Gaps in Alignment})$$

30 For purposes of the present invention, the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *supra*) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *supra*), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution

matrix. The output of Needle labeled "longest identity" (obtained using the `-nobrief` option) is used as the percent identity and is calculated as follows:

$$(\text{Identical Deoxyribonucleotides} \times 100) / (\text{Length of Alignment} - \text{Total Number of Gaps in Alignment})$$

5 **Stringency conditions:** The different stringency conditions are defined as follows.

 The term "very low stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 25% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15
10 minutes using 2X SSC, 0.2% SDS at 45°C.

 The term "low stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 25% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15
15 minutes using 2X SSC, 0.2% SDS at 50°C.

 The term "medium stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 35% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15
20 minutes using 2X SSC, 0.2% SDS at 55°C.

 The term "medium-high stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 35% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15
25 minutes using 2X SSC, 0.2% SDS at 60°C.

 The term "high stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15
30 minutes using 2X SSC, 0.2% SDS at 65°C.

 The term "very high stringency conditions" means for probes of at least 100 nucleotides in length, prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, following standard Southern blotting procedures for 12 to 24 hours. The carrier material is finally washed three times each for 15
35 minutes using 2X SSC, 0.2% SDS at 70°C.

Subsequence: The term “subsequence” means a polynucleotide having one or more (e.g., several) nucleotides absent from the 5' and/or 3' end of a mature polypeptide coding sequence; wherein the subsequence encodes a fragment having lysozyme activity. In one aspect, a subsequence contains at least 552 nucleotides (e.g., the joint sequence of nucleotides 73 to 147 and nucleotides 302 to 778 of SEQ ID NO: 3), or at least 585 nucleotides (e.g., the joint sequence of nucleotides 64 to 147 and nucleotides 302 to 802 of SEQ ID NO: 3). In a further aspect, a subsequence contains at least 552 nucleotides (e.g., the sequence of nucleotides 148 to 699 of SEQ ID NO: 7), or at least 585 nucleotides (e.g., the sequence of nucleotides 133 to 717 of SEQ ID NO: 7).

10 **Substantially pure polynucleotide:** The term “substantially pure polynucleotide” means a polynucleotide preparation free of other extraneous or unwanted nucleotides and in a form suitable for use within genetically engineered polypeptide production systems. Thus, a substantially pure polynucleotide contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1%, and at most 0.5% by weight of other polynucleotide material with which it is natively or recombinantly associated. A substantially pure polynucleotide may, however, include naturally occurring 5' and 3' untranslated regions, such as promoters and terminators. Preferably, the polynucleotide is at least 90% pure, e.g., at least 92% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, and at least 99.5% pure by weight. The polynucleotides of the present invention are preferably in a substantially pure form.

15 **Substantially pure polypeptide:** The term “substantially pure polypeptide” means a preparation that contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1%, and at most 0.5% by weight of other polypeptide material with which it is natively or recombinantly associated. Preferably, the polypeptide is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99%, at least 99.5% pure, and 100% pure by weight of the total polypeptide material present in the preparation. The polypeptides of the present invention are preferably in a substantially pure form. This can be accomplished, for example, by preparing the polypeptide by well known recombinant methods or by classical purification methods.

30 **Variant:** The term “variant” means a polypeptide having lysozyme activity comprising an alteration, i.e., a substitution, insertion, and/or deletion, of one or more (several) amino acid residues at one or more (e.g., several) positions. A substitution means replacement of the amino acid occupying a position with a different amino acid; a deletion means removal of the amino acid occupying a position; and an insertion means adding 1, 2, or 3 amino acids adjacent to and immediately following the amino acid occupying the position. A variant according to the invention

may comprise from 1 to 5; from 1 to 10; from 1 to 15; from 1 to 20; from 1 to 25; from 1 to 30; from 1 to 35; from 1 to 40; from 1 to 45; from , i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 alterations.

5 The variants of the present invention have at least one alteration/modification selected from the group consisting of position number 6, 10, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190 in which the position corresponds to the position in the mature sequence of SEQ ID NO: 8. The variant polypeptide sequence is preferably one which is not found in nature.

10 **Wild-type Lysozyme:** The term "wild-type" lysozyme means a lysozyme expressed by a naturally occurring microorganism, such as a bacterium, yeast, or filamentous fungus found in nature.

Conventions for Designation of Variants

For purposes of the present invention, the mature polypeptide disclosed in SEQ ID NO: 8 is
 15 used to determine the corresponding amino acid residue in another lysozyme. The amino acid sequence of another lysozyme is aligned with the mature polypeptide disclosed in SEQ ID NO: 8, and based on the alignment, the amino acid position number corresponding to any amino acid residue in the mature polypeptide disclosed in SEQ ID NO: 8 is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, *J. Mol. Biol.* 48: 443-453) as implemented in
 20 the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice *et al.*, 2000, *Trends Genet.* 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled "longest identity" (obtained using the *-nobrief* option) is used as the percent identity and is calculated as
 25 follows: (Identical Residues x 100)/(Length of Alignment – Total Number of Gaps in Alignment). The Needleman-Wunsch algorithm is used for sequence comparisons and for calculating sequence identities.

Identification of the corresponding amino acid residue in another lysozyme can be determined by an alignment of multiple polypeptide sequences using several computer programs
 30 including, but not limited to, MUSCLE (multiple sequence comparison by log-expectation; version 3.5 or later; Edgar, 2004, *Nucleic Acids Research* 32: 1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, *Nucleic Acids Research* 30: 3059-3066; Katoh *et al.*, 2005, *Nucleic Acids Research* 33: 511-518; Katoh and Toh, 2007, *Bioinformatics* 23: 372-374; Katoh *et al.*, 2009, *Methods in Molecular Biology* 537: 39-64; Katoh and Toh, 2010, *Bioinformatics* 26: 1899-1900),

and EMBOSS EMMA employing ClustalW (1.83 or later; Thompson *et al.*, 1994, *Nucleic Acids Research* 22: 4673-4680), using their respective default parameters.

When the other enzyme has diverged from the mature polypeptide of SEQ ID NO: 8 such that traditional sequence-based comparison fails to detect their relationship (Lindahl and Elofsson, 2000, *J. Mol. Biol.* 295: 613-615), other pairwise sequence comparison algorithms can be used. Greater sensitivity in sequence-based searching can be attained using search programs that utilize probabilistic representations of polypeptide families (profiles) to search databases. For example, the PSI-BLAST program generates profiles through an iterative database search process and is capable of detecting remote homologs (Atschul *et al.*, 1997, *Nucleic Acids Res.* 25: 3389-3402). Even greater sensitivity can be achieved if the family or superfamily for the polypeptide has one or more representatives in the protein structure databases. Programs such as GenTHREADER (Jones, 1999, *J. Mol. Biol.* 287: 797-815; McGuffin and Jones, 2003, *Bioinformatics* 19: 874-881) utilize information from a variety of sources (PSI-BLAST, secondary structure prediction, structural alignment profiles, and solvation potentials) as input to a neural network that predicts the structural fold for a query sequence. Similarly, the method of Gough *et al.*, 2000, *J. Mol. Biol.* 313: 903-919, can be used to align a sequence of unknown structure with the superfamily models present in the SCOP database. These alignments can in turn be used to generate homology models for the polypeptide, and such models can be assessed for accuracy using a variety of tools developed for that purpose.

For proteins of known structure, several tools and resources are available for retrieving and generating structural alignments. For example the SCOP superfamilies of proteins have been structurally aligned, and those alignments are accessible and downloadable. Two or more protein structures can be aligned using a variety of algorithms such as the distance alignment matrix (Holm and Sander, 1998, *Proteins* 33: 88-96) or combinatorial extension (Shindyalov and Bourne, 1998, *Protein Engineering* 11: 739-747), and implementation of these algorithms can additionally be utilized to query structure databases with a structure of interest in order to discover possible structural homologs (e.g., Holm and Park, 2000, *Bioinformatics* 16: 566-567).

In describing the variants of the present invention, the nomenclature described below is adapted for ease of reference. The accepted IUPAC single letter or three letter amino acid abbreviation is employed.

Substitutions: For an amino acid substitution, the following nomenclature is used: Original amino acid, position, substituted amino acid. Accordingly, the substitution of threonine at position 226 with alanine is designated as "Thr226Ala" or "T226A". Multiple mutations are separated by addition marks ("+"), e.g., "Gly205Arg + Ser411Phe" or "G205R + S411F", representing

substitutions at positions 205 and 411 of glycine (G) with arginine (R) and serine (S) with phenylalanine (F), respectively.

Deletions: For an amino acid deletion, the following nomenclature is used: Original amino acid, position, *. Accordingly, the deletion of glycine at position 195 is designated as "Gly195*" or "G195*". Multiple deletions are separated by addition marks ("+"), e.g., "Gly195* + Ser411*" or "G195* + S411*".

Insertions: For an amino acid insertion, the following nomenclature is used: Original amino acid, position, original amino acid, inserted amino acid. Accordingly the insertion of lysine after glycine at position 195 is designated "Gly195GlyLys" or "G195GK". An insertion of multiple amino acids is designated [Original amino acid, position, original amino acid, inserted amino acid #1, inserted amino acid #2; etc.]. For example, the insertion of lysine and alanine after glycine at position 195 is indicated as "Gly195GlyLysAla" or "G195GKA".

In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s). In the above example, the sequence would thus be:

Parent	Variant
195	195 195a 195b
G	G - K - A

Multiple alterations: Variants comprising multiple alterations are separated by addition marks ("+"), e.g., "Arg170Tyr+Gly195Glu" or "R170Y+G195E" representing a substitution of arginine and glycine at positions 170 and 195 with tyrosine and glutamic acid, respectively.

Different alterations: Where different alterations can be introduced at a position, the different alterations are separated by a comma, e.g., "Arg170Tyr,Glu" represents a substitution of arginine at position 170 with tyrosine or glutamic acid. Thus, "Tyr167Gly,Ala + Arg170Gly,Ala" designates the following variants: "Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala", "Tyr167Ala+Arg170Gly", and "Tyr167Ala+Arg170Ala".

DETAILED DESCRIPTION OF THE INVENTION

Polypeptides Having Lysozyme Activity

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 80% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 85% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 90% which have lysozyme activity.

5 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 91% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 92% which have lysozyme activity.

10 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 93% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 94% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 95% which have lysozyme activity.

15 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 96% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 97% which have lysozyme activity.

20 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 98% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 4 of at least 99% which have lysozyme activity.

25 In one aspect, the polypeptides differ by no more than 45 amino acids, *e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44, from the mature polypeptide of SEQ ID NO: 4.

30 A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 4 or an allelic variant thereof; or is a fragment thereof having lysozyme activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 4. In another aspect, the polypeptide comprises or consists of amino acids 20 to 227 of SEQ ID NO: 4.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 80% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 85% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 90% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 91% which have lysozyme activity.

5 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 92% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 93% which have lysozyme activity.

10 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 94% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 95% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 96% which have lysozyme activity.

15 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 97% which have lysozyme activity.

In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 98% which have lysozyme activity.

20 In an embodiment, the present invention relates to isolated polypeptides having a sequence identity to the mature polypeptide of SEQ ID NO: 8 of at least 99% which have lysozyme activity.

In one aspect, the polypeptides differ by no more than 45 amino acids, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44, from the mature polypeptide of SEQ ID NO: 8.

25 A polypeptide of the present invention preferably comprises or consists of the amino acid sequence of SEQ ID NO: 8 or an allelic variant thereof; or is a fragment thereof having lysozyme activity. In another aspect, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 8. In another aspect, the polypeptide comprises or consists of amino acids 20 to 227 of SEQ ID NO: 8.

30 In another embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide that hybridizes under medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions with the mature polypeptide coding sequence of (i) SEQ ID NO: 3 or SEQ ID NO: 7, (ii) the cDNA sequence thereof, or (iii) the full-length complement of (i) or (ii) (Sambrook *et al.*, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, New York).

The polynucleotide of SEQ ID NO: 3 or SEQ ID NO: 7 or a subsequence thereof, as well as the polypeptide of SEQ ID NO: 4 or SEQ ID NO: 8 or a fragment thereof, may be used to design nucleic acid probes to identify and clone DNA encoding polypeptides having lysozyme activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic DNA or cDNA of a cell of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, *e.g.*, at least 25, at least 35, or at least 70 nucleotides in length. Preferably, the nucleic acid probe is at least 100 nucleotides in length, *e.g.*, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, or at least 900 nucleotides in length. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with ^{32}P , ^3H , ^{35}S , biotin, or avidin). Such probes are encompassed by the present invention.

A genomic DNA or cDNA library prepared from such other strains may be screened for DNA that hybridizes with the probes described above and encodes a polypeptide having lysozyme activity. Genomic or other DNA from such other strains may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA that hybridizes with SEQ ID NO: 3 or SEQ ID NO: 7 or a subsequence thereof, the carrier material is used in a Southern blot.

For purposes of the present invention, hybridization indicates that the polynucleotide hybridizes to a labeled nucleic acid probe corresponding to (i) SEQ ID NO: 3 or SEQ ID NO: 7; (ii) the mature polypeptide coding sequence of SEQ ID NO: 3 or SEQ ID NO: 7; (iii) the cDNA sequence thereof; (iv) the full-length complement thereof; or (v) a subsequence thereof; under medium to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions can be detected using, for example, X-ray film or any other detection means known in the art.

In one aspect, the nucleic acid probe is nucleotides 58 to 147 or nucleotides 302 to 835 of SEQ ID NO: 3 or nucleotides 121 to 744 of SEQ ID NO: 7. In another aspect, the nucleic acid probe is a polynucleotide that encodes the polypeptide of SEQ ID NO: 4 or SEQ ID NO: 8; the mature polypeptide thereof; or a fragment thereof. In another aspect, the nucleic acid probe is SEQ ID NO: 3 or SEQ ID NO: 7 or the cDNA sequence thereof.

In another embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide having a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3 or the cDNA sequence thereof of at least 80%, at

least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.

In a further embodiment, the present invention relates to an isolated polypeptide having lysozyme activity encoded by a polynucleotide having a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 7 or the cDNA sequence thereof of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%.

In a preferred embodiment, the present invention relates to variants of the mature polypeptide of SEQ ID NO: 4 comprising a substitution, deletion, and/or insertion at one or more (e.g., several) positions. In an embodiment, the number of amino acid substitutions, deletions and/or insertions introduced into the mature polypeptide of SEQ ID NO: 4 is not more than 45, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45.

In a preferred embodiment, the present invention relates to variants of the mature polypeptide of SEQ ID NO: 8 comprising a substitution, deletion, and/or insertion at one or more (e.g., several) positions. In an embodiment, the number of amino acid substitutions, deletions and/or insertions introduced into the mature polypeptide of SEQ ID NO: 8 is not more than 45, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45.

The amino acid changes may be of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of 1-30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

Examples of conservative substitutions are within the groups of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions that do not generally alter specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. Common substitutions are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.

Alternatively, the amino acid changes are of such a nature that the physico-chemical properties of the polypeptides are altered. For example, amino acid changes may improve the thermal stability of the polypeptide, alter the substrate specificity, change the pH optimum, and the like.

5 Essential amino acids in a polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for lysozyme activity to identify amino acid residues that are critical to the activity of the molecule. See
10 also, Hilton *et al.*, 1996, *J. Biol. Chem.* 271: 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos *et al.*, 1992, *Science* 255: 306-312; Smith *et al.*, 1992, *J. Mol. Biol.* 224: 899-904;
15 Wlodaver *et al.*, 1992, *FEBS Lett.* 309: 59-64. The identity of essential amino acids can also be inferred from an alignment with a related polypeptide.

Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988,
20 *Science* 241: 53-57; Bowie and Sauer, 1989, *Proc. Natl. Acad. Sci. USA* 86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (e.g., Lowman *et al.*, 1991, *Biochemistry* 30: 10832-10837; U.S. Patent No. 5,223,409; WO 92/06204), and region-directed mutagenesis (Derbyshire *et al.*, 1986, *Gene* 46: 145; Ner *et al.*, 1988, *DNA* 7: 127).

25 Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness *et al.*, 1999, *Nature Biotechnology* 17: 893-896). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual
30 amino acid residues in a polypeptide.

The polypeptide may be a hybrid polypeptide in which a region of one polypeptide is fused at the N-terminus or the C-terminus of a region of another polypeptide.

The polypeptide may be a fusion polypeptide or cleavable fusion polypeptide in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide of the present
35 invention. A fusion polypeptide is produced by fusing a polynucleotide encoding another

polypeptide to a polynucleotide of the present invention. Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fusion polypeptide is under control of the same promoter(s) and terminator. Fusion polypeptides may also be constructed using intein
5 technology in which fusion polypeptides are created post-translationally (Cooper *et al.*, 1993, *EMBO J.* 12: 2575-2583; Dawson *et al.*, 1994, *Science* 266: 776-779).

A fusion polypeptide can further comprise a cleavage site between the two polypeptides. Upon secretion of the fusion protein, the site is cleaved releasing the two polypeptides. Examples of cleavage sites include, but are not limited to, the sites disclosed in Martin *et al.*, 2003, *J. Ind.*
10 *Microbiol. Biotechnol.* 3: 568-576; Svetina *et al.*, 2000, *J. Biotechnol.* 76: 245-251; Rasmussen-Wilson *et al.*, 1997, *Appl. Environ. Microbiol.* 63: 3488-3493; Ward *et al.*, 1995, *Biotechnology* 13: 498-503; and Contreras *et al.*, 1991, *Biotechnology* 9: 378-381; Eaton *et al.*, 1986, *Biochemistry* 25: 505-512; Collins-Racie *et al.*, 1995, *Biotechnology* 13: 982-987; Carter *et al.*, 1989, *Proteins: Structure, Function, and Genetics* 6: 240-248; and Stevens, 2003, *Drug Discovery World* 4: 35-48.

15 The crystal structure of the *Acremonium alkalophilum* CBS114.92 lysozyme was solved at a resolution of 1.3 Å. The atomic coordinates of this structure are shown in Figure 6. These atomic coordinates can be used to generate a three dimensional model depicting the structure of the *Acremonium alkalophilum* CBS114.92 lysozyme or homologous structures (such as the variants of the present invention).

20 The *Acremonium alkalophilum* CBS114.92 lysozyme belongs to the GH25 hydrolase family assigned E.C: number 3.2.1.17. The catalytic mechanism is believed to be the classical Koshland retaining mechanism, with net retention configuration of the confirmation around the anomeric carbon. This is often achieved by a two-step, double displacement mechanism involving a covalent glycosyl-enzyme intermediate. The reaction occurs with acid/base and nucleophilic assistance
25 provided by two amino acids side chains. In the first step (often called the glycosylation step), one amino acid residue (D95) plays the role of a nucleophile attacking the anomeric centre to displace the aglycon and form a glycosyl enzyme intermediate. At the same time, the second amino acid residue (E97) functions as an acid catalyst and protonates the glycosidic oxygen as the bond cleaves. In the second step (often called the deglycosylation step), the glycosyl-enzyme
30 intermediate is hydrolyzed by water, with the second amino acid residue (E97) now acting as a base catalyst deprotonating, the incoming water molecule. The pK_a value of the acid/base group is believed to cycle between high and low values during catalysis to optimize for its role at each step of the catalysis.

Using the x-ray structure, amino acid residues D95 and E97 (using SEQ ID NO: 8 for
35 numbering) have been identified as catalytic residues. In embodiments of the invention (in addition

to one or more of the alterations recited herein), no alteration is made to amino acid corresponding to E97 and D95, using SEQ ID NO: 8 for numbering, of the lysozyme variants of the present invention. From several lysozyme molecules it is known that mutation of the nucleophile can lead to an enzyme that retains some catalytic activity supposedly because water (perhaps in the form of OH⁻) can function as a nucleophile in this first step of the catalytic mechanism (Malcolm, B.A. *et al*, (1989), "Site-directed mutagenesis of the catalytic residues Asp-52 and Glu-35 of chicken egg white lysozyme", *Proc. Natl. Acad. Sci.* 86(1), 133-137).

Variants Having Lysozyme Activity

The lysozyme variants of the present invention comprise or consist of an alteration at one or more (e.g., several) positions corresponding to positions 6, 10, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190 of the mature polypeptide of SEQ ID NO: 8 wherein each alteration is independently a substitution, insertion or deletion and the variant has antimicrobial and/or lysozyme activity.

In an embodiment, the alteration is a substitution. In another embodiment, the alteration is an insertion. In a further embodiment, the alteration is a deletion.

The lysozyme variants of the present invention comprises or consists of a polypeptide comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with the mature polypeptide of SEQ ID NO: 4.

The lysozyme variants of the present invention comprises or consists of a polypeptide comprising an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity with the mature polypeptide of SEQ ID NO: 8.

The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 85% identity with the mature polypeptide of SEQ ID NO: 8.

The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 90% identity with the mature polypeptide of SEQ ID NO: 8.

The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 93% identity with the mature polypeptide of SEQ ID NO: 8.

The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 95% identity with the mature polypeptide of SEQ ID NO: 8.

5 The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 96% identity with the mature polypeptide of SEQ ID NO: 8.

The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 97% identity with the mature polypeptide of SEQ ID NO: 8.

10 The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 98% identity with the mature polypeptide of SEQ ID NO: 8.

The lysozyme variants of the present invention comprise or consist of a polypeptide comprising an amino acid sequence having at least 99% identity with the mature polypeptide of
15 SEQ ID NO: 8.

In one aspect, the number of alterations in the variants of the present invention is 1-45, e.g., 1-40, 1-35, 1-30, 1-25, 1-20, 1-15, 1-10 and 1-5, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 alterations.

20 In another aspect, a variant comprises an alteration, such as a substitution, insertion or deletion, at one or more (e.g., several) positions corresponding to positions 6, 10, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and 190 of the mature polypeptide of SEQ ID NO: 8. In another aspect, a variant comprises an alteration at two positions corresponding to any of positions 6, 10,
25 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and 190 of the mature polypeptide of SEQ ID NO: 8. In another aspect, a variant comprises an alteration at three positions corresponding to any of positions 6, 10, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and 190 of the mature polypeptide of
30 of SEQ ID NO: 8. In another aspect, a variant comprises an alteration at each position corresponding to positions 6, 10, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and 190 of the mature polypeptide of SEQ ID NO: 8.

An embodiment of the invention is to alter the pH activity profile of the lysozyme whilst
35 retaining lysozyme activity and/or antimicrobial activity. A preferred embodiment of the invention is

that the lysozyme has improved activity at a more alkaline pH; *i.e.* the pH of peak antimicrobial or lysozyme activity increases/becomes more alkaline.

In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 10 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration
5 comprises or consists of a substitution of an amino acid at position 10 (using SEQ ID NO: 8 for numbering) which alters the pH activity profile of the lysozyme. In another embodiment, the alteration comprises or consists of the substitution W10H which increases the pH of peak antimicrobial activity.

10 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 39 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 39 (using SEQ ID NO: 8 for numbering) which alters the pH activity profile of the lysozyme. In another embodiment, the alteration comprises or consists of the substitution S39D which increases the pH of peak antimicrobial activity.

15 In another embodiment, the isolated variant of the present invention consists of an alteration at position 10 (using SEQ ID NO: 8 for numbering) together with an alteration in one or more of the following positions: 6, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190. A preferred
20 embodiment is the substitution W10H together with an alteration in one or more of the following positions: 6, 11, 28, 30, 33, 37, 39, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190.

In another embodiment, the isolated variant of the present invention consists of an alteration at position 39 (using SEQ ID NO: 8 for numbering) together with an alteration in one or more of the following positions: 6, 10, 11, 28, 30, 33, 37, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101,
25 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190. A preferred embodiment is the substitution S39D together with an alteration in one or more of the following positions: 6, 10, 11, 28, 30, 33, 37, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190.

In a further embodiment, the isolated variant of the present invention consists of an
30 alteration at position 10 and 39 (using SEQ ID NO: 8 for numbering). A preferred embodiment consists of the substitutions W10H and S39D.

In a further embodiment, the isolated variant of the present invention consists of an alteration at position 10 and 39 (using SEQ ID NO: 8 for numbering) together with an alteration in one or more of the following positions: 6, 11, 28, 30, 33, 37, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98,
35 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or

190. A preferred embodiment are the substitutions W10H and S39D together with an alteration in one or more of the following positions: 6, 11, 28, 30, 33, 37, 59, 60, 61, 62, 63, 92, 93, 94, 96, 98, 99, 100, 101, 106, 133, 134, 135, 136, 137, 139, 140, 142, 143, 158, 161, 162, 178, 183 and/or 190.

5 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 6 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 6 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

10 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 11 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 11 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

15 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 30 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 30 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

20 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 33 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 33 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

25 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 37 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 37 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

30 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 101 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 101 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

35 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 139 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration comprises or consists of a substitution of an amino acid at position 139 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

40 In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 161 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration

comprises or consists of a substitution of an amino acid at position 161 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 162 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration
5 comprises or consists of a substitution of an amino acid at position 162 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 183 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration
10 comprises or consists of a substitution of an amino acid at position 183 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

In one embodiment, the isolated variant of the present invention comprises or consists of an alteration at position 190 (using SEQ ID NO: 8 for numbering). In an embodiment, the alteration
comprises or consists of a substitution of an amino acid at position 190 (using SEQ ID NO: 8 for numbering) which alters the substrate specificity of the lysozyme.

15 **Sources of Polypeptides Having lysozyme Activity**

A polypeptide having lysozyme activity of the present invention may be obtained from microorganisms of any genus. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source
20 has been inserted. In one aspect, the polypeptide obtained from a given source is secreted extracellularly.

The polypeptide may be a fungal polypeptide. For example, the polypeptide may be a filamentous fungal polypeptide such as an *Acremonium*, *Aspergillus*, *Chrysosporium*, *Fusarium*, *Humicola*, *Penicillium*, *Thielavia* or a *Trichoderma* polypeptide.

25 In another aspect, the polypeptide is an *Acremonium* cellulolyticus, *Aspergillus* aculeatus, *Aspergillus* awamori, *Aspergillus* foetidus, *Aspergillus* fumigatus, *Aspergillus* japonicus, *Aspergillus* nidulans, *Aspergillus* niger, *Aspergillus* oryzae, *Chrysosporium* inops, *Chrysosporium* keratinophilum, *Chrysosporium* lucknowense, *Chrysosporium* merdarium, *Chrysosporium* pannicola, *Chrysosporium* queenslandicum, *Chrysosporium* tropicum, *Chrysosporium* zonatum,
30 *Fusarium* bactridioides, *Fusarium* cerealis, *Fusarium* crookwellense, *Fusarium* culmorum, *Fusarium* graminearum, *Fusarium* graminum, *Fusarium* heterosporum, *Fusarium* negundi, *Fusarium* oxysporum, *Fusarium* reticulatum, *Fusarium* roseum, *Fusarium* sambucinum, *Fusarium* sarcochroum, *Fusarium* sporotrichioides, *Fusarium* sulphureum, *Fusarium* torulosum, *Fusarium* trichothecioides, *Fusarium* venenatum, *Humicola* grisea, *Humicola* insolens, *Humicola* lanuginosa,

Irpex lacteus, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium
 funiculosum, Penicillium purpurogenum, Phanerochaete chrysosporium, Thielavia achromatica,
 Thielavia albomyces, Thielavia albopilosa, Thielavia australeinsis, Thielavia fimeti, Thielavia
 microspora, Thielavia ovispora, Thielavia peruviana, Thielavia setosa, Thielavia spededonium,
 5 Thielavia subthermophila, Thielavia terrestris, Trichoderma harzianum, Trichoderma koningii,
 Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma viride polypeptide.

In another aspect, the polypeptide is an *Acremonium alcalophilum* polypeptide, e.g., a
 polypeptide obtained from *Acremonium alcalophilum* CBS 114.92.

It will be understood that for the aforementioned species, the invention encompasses both
 10 the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of
 the species name by which they are known. Those skilled in the art will readily recognize the
 identity of appropriate equivalents.

Strains of these species are readily accessible to the public in a number of culture
 collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von
 15 Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS),
 and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center
 (NRRL).

The polypeptide may be identified and obtained from other sources including
 microorganisms isolated from nature (e.g., soil, composts, water, etc.) or DNA samples obtained
 20 directly from natural materials (e.g., soil, composts, water, etc.) using the above-mentioned probes.
 Techniques for isolating microorganisms and DNA directly from natural habitats are well known in
 the art. A polynucleotide encoding the polypeptide may then be obtained by similarly screening a
 genomic DNA or cDNA library of another microorganism or mixed DNA sample. Once a
 polynucleotide encoding a polypeptide has been detected with the probe(s), the polynucleotide can
 25 be isolated or cloned by utilizing techniques that are known to those of ordinary skill in the art (see,
 e.g., Sambrook *et al.*, 1989, *supra*).

Polynucleotides

The present invention also relates to isolated polynucleotides encoding a polypeptide of the
 present invention, as described herein.

30 The techniques used to isolate or clone a polynucleotide are known in the art and include
 isolation from genomic DNA or cDNA, or a combination thereof. The cloning of the polynucleotides
 from genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR)
 or antibody screening of expression libraries to detect cloned DNA fragments with shared structural
 features. See, e.g., Innis *et al.*, 1990, *PCR: A Guide to Methods and Application*, Academic Press,

New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligation activated transcription (LAT) and polynucleotide-based amplification (NASBA) may be used. The polynucleotides may be cloned from a strain of *Aspergillus* or *Acremonium*, or a related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the polynucleotide.

Modification of a polynucleotide encoding a polypeptide of the present invention may be necessary for synthesizing polypeptides substantially similar to the polypeptide. The term "substantially similar" to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source, e.g., variants that differ in specific activity, thermostability, pH optimum, or the like. The variants may be constructed on the basis of the polynucleotide presented as the mature polypeptide coding sequence of SEQ ID NO: 3, SEQ ID NO: 7 or the cDNA sequences thereof, e.g., a subsequence thereof, and/or by introduction of nucleotide substitutions that do not result in a change in the amino acid sequence of the polypeptide, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions that may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, e.g., Ford *et al.*, 1991, *Protein Expression and Purification* 2: 95-107.

Nucleic Acid Constructs

The present invention also relates to nucleic acid constructs comprising a polynucleotide of the present invention operably linked to one or more control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.

A polynucleotide may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides utilizing recombinant DNA methods are well known in the art.

The control sequence may be a promoter, a polynucleotide that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention. The promoter contains transcriptional control sequences that mediate the expression of the polypeptide. The promoter may be any polynucleotide that shows transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), *Bacillus licheniformis* alpha-amylase gene (*amyL*),

Bacillus licheniformis penicillinase gene (*penP*), *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), *Bacillus subtilis* levansucrase gene (*sacB*), *Bacillus subtilis* *xylA* and *xylB* genes, *Bacillus thuringiensis cryIIIA* gene (Agaisse and Lereclus, 1994, *Molecular Microbiology* 13: 97-107), *E. coli lac* operon, *E. coli trc* promoter (Egon et al., 1988, *Gene* 69: 301-315), *Streptomyces coelicolor* agarase gene (*dagA*), and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, *Proc. Natl. Acad. Sci. USA* 75: 3727-3731), as well as the *tac* promoter (DeBoer et al., 1983, *Proc. Natl. Acad. Sci. USA* 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Gilbert et al., 1980, *Scientific American* 242: 74-94; and in Sambrook et al., 1989, *supra*. Examples of tandem promoters are disclosed in WO 99/43835.

Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for *Aspergillus nidulans* acetamidase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Aspergillus oryzae* TKA amylase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Fusarium oxysporum* trypsin-like protease (WO 96/00787), *Fusarium venenatum* amyloglucosidase (WO 00/56900), *Fusarium venenatum* Daria (WO 00/56900), *Fusarium venenatum* Quinn (WO 00/56900), *Rhizomucor miehei* lipase, *Rhizomucor miehei* aspartic proteinase, *Trichoderma reesei* beta-glucosidase, *Trichoderma reesei* cellobiohydrolase I, *Trichoderma reesei* cellobiohydrolase II, *Trichoderma reesei* endoglucanase I, *Trichoderma reesei* endoglucanase II, *Trichoderma reesei* endoglucanase III, *Trichoderma reesei* endoglucanase IV, *Trichoderma reesei* endoglucanase V, *Trichoderma reesei* xylanase I, *Trichoderma reesei* xylanase II, *Trichoderma reesei* beta-xylosidase, as well as the NA2-tpi promoter (a modified promoter from an *Aspergillus* neutral alpha-amylase gene in which the untranslated leader has been replaced by an untranslated leader from an *Aspergillus* triose phosphate isomerase gene; non-limiting examples include modified promoters from an *Aspergillus niger* neutral alpha-amylase gene in which the untranslated leader has been replaced by an untranslated leader from an *Aspergillus nidulans* or *Aspergillus oryzae* triose phosphate isomerase gene); and mutant, truncated, and hybrid promoters thereof.

In a yeast host, useful promoters are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP), *Saccharomyces cerevisiae* triose phosphate isomerase (TPI), *Saccharomyces cerevisiae* metallothionein (CUP1), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, *Yeast* 8: 423-488.

The control sequence may also be a transcription terminator, which is recognized by a host cell to terminate transcription. The terminator is operably linked to the 3'-terminus of the polynucleotide encoding the polypeptide. Any terminator that is functional in the host cell may be used in the present invention.

5 Preferred terminators for bacterial host cells are obtained from the genes for *Bacillus clausii* alkaline protease (*aprH*), *Bacillus licheniformis* alpha-amylase (*amyL*), and *Escherichia coli* ribosomal RNA (*rmB*).

Preferred terminators for filamentous fungal host cells are obtained from the genes for *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* glucoamylase, *Aspergillus niger* alpha-glucosidase, *Aspergillus oryzae* TAKA amylase, and *Fusarium oxysporum* trypsin-like protease.

Preferred terminators for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos *et al.*, 1992, *supra*.

15 The control sequence may also be an mRNA stabilizer region downstream of a promoter and upstream of the coding sequence of a gene which increases expression of the gene.

Examples of suitable mRNA stabilizer regions are obtained from a *Bacillus thuringiensis* *cryIIIA* gene (WO 94/25612) and a *Bacillus subtilis* SP82 gene (Hue *et al.*, 1995, *Journal of Bacteriology* 177: 3465-3471).

20 The control sequence may also be a leader, a nontranslated region of an mRNA that is important for translation by the host cell. The leader is operably linked to the 5'-terminus of the polynucleotide encoding the polypeptide. Any leader that is functional in the host cell may be used.

Preferred leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

25 Suitable leaders for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

30 The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3'-terminus of the polynucleotide and, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence that is functional in the host cell may be used.

Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* glucoamylase, *Aspergillus*

niger alpha-glucosidase *Aspergillus oryzae* TAKA amylase, and *Fusarium oxysporum* trypsin-like protease.

Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Mol. Cellular Biol.* 15: 5983-5990.

5 The control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a polypeptide and directs the polypeptide into the cell's secretory pathway. The 5'-end of the coding sequence of the polynucleotide may inherently contain a signal peptide coding sequence naturally linked in translation reading frame with the segment of the coding sequence that encodes the polypeptide. Alternatively, the 5'-end of the coding sequence
10 may contain a signal peptide coding sequence that is foreign to the coding sequence. A foreign signal peptide coding sequence may be required where the coding sequence does not naturally contain a signal peptide coding sequence. Alternatively, a foreign signal peptide coding sequence may simply replace the natural signal peptide coding sequence in order to enhance secretion of the polypeptide. However, any signal peptide coding sequence that directs the expressed polypeptide
15 into the secretory pathway of a host cell may be used.

Effective signal peptide coding sequences for bacterial host cells are the signal peptide coding sequences obtained from the genes for *Bacillus* NCIB 11837 maltogenic amylase, *Bacillus licheniformis* subtilisin, *Bacillus licheniformis* beta-lactamase, *Bacillus stearothermophilus* alpha-amylase, *Bacillus stearothermophilus* neutral proteases (*nprT*, *nprS*, *nprM*), and *Bacillus subtilis*
20 *prsA*. Further signal peptides are described by Simonen and Palva, 1993, *Microbiological Reviews* 57: 109-137.

Effective signal peptide coding sequences for filamentous fungal host cells are the signal peptide coding sequences obtained from the genes for *Aspergillus niger* neutral amylase, *Aspergillus niger* glucoamylase, *Aspergillus oryzae* TAKA amylase, *Humicola insolens* cellulase,
25 *Humicola insolens* endoglucanase V, *Humicola lanuginosa* lipase, and *Rhizomucor miehei* aspartic proteinase.

Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding sequences are described by Romanos *et al.*, 1992, *supra*.

30 The control sequence may also be a propeptide coding sequence that encodes a propeptide positioned at the N-terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding sequence may be obtained from the
35 genes for *Bacillus subtilis* alkaline protease (*aprE*), *Bacillus subtilis* neutral protease (*nprT*),

Myceliophthora thermophila laccase (WO 95/33836), *Rhizomucor miehei* aspartic proteinase, and *Saccharomyces cerevisiae* alpha-factor.

Where both signal peptide and propeptide sequences are present, the propeptide sequence is positioned next to the N-terminus of a polypeptide and the signal peptide sequence is positioned
5 next to the N-terminus of the propeptide sequence.

It may also be desirable to add regulatory sequences that regulate expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those that cause expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems
10 include the *lac*, *tac*, and *trp* operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the *Aspergillus niger* glucoamylase promoter, *Aspergillus oryzae* TKA alpha-amylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used. Other examples of regulatory sequences are those that allow for gene amplification. In eukaryotic systems, these regulatory sequences include the dihydrofolate reductase gene that is amplified in
15 the presence of methotrexate, and the metallothionein genes that are amplified with heavy metals. In these cases, the polynucleotide encoding the polypeptide would be operably linked with the regulatory sequence.

Expression Vectors

The present invention also relates to recombinant expression vectors comprising a
20 polynucleotide of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleotide and control sequences may be joined together to produce a recombinant expression vector that may include one or more convenient restriction sites to allow for insertion or substitution of the polynucleotide encoding the polypeptide at such sites. Alternatively, the polynucleotide may be expressed by inserting the polynucleotide or a nucleic acid construct
25 comprising the polynucleotide into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

The recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the
30 polynucleotide. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may be a linear or closed circular plasmid.

The vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a

plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one that, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or
 5 two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon, may be used.

The vector preferably contains one or more selectable markers that permit easy selection of transformed, transfected, transduced, or the like cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to
 10 auxotrophs, and the like.

Examples of bacterial selectable markers are *Bacillus licheniformis* or *Bacillus subtilis* *dal* genes, or markers that confer antibiotic resistance such as ampicillin, chloramphenicol, kanamycin, neomycin, spectinomycin, or tetracycline resistance. Suitable markers for yeast host cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for
 15 use in a filamentous fungal host cell include, but are not limited to, *amdS* (acetamidase), *argB* (ornithine carbamoyltransferase), *bar* (phosphinothricin acetyltransferase), *hph* (hygromycin phosphotransferase), *niaD* (nitrate reductase), *pyrG* (orotidine-5'-phosphate decarboxylase), *sC* (sulfate adenylyltransferase), and *trpC* (anthranilate synthase), as well as equivalents thereof. Preferred for use in an *Aspergillus* cell are *Aspergillus nidulans* or *Aspergillus oryzae* *amdS* and
 20 *pyrG* genes and a *Streptomyces hygroscopicus* *bar* gene.

The vector preferably contains an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.

For integration into the host cell genome, the vector may rely on the polynucleotide's sequence encoding the polypeptide or any other element of the vector for integration into the
 25 genome by homologous or non-homologous recombination. Alternatively, the vector may contain additional polynucleotides for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to 10,000 base
 30 pairs, which have a high degree of sequence identity to the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding polynucleotides. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. The origin of replication may be any plasmid replicator mediating autonomous replication that functions in a cell. The term "origin of replication" or "plasmid replicator" means a polynucleotide that enables a plasmid or
 5 vector to replicate *in vivo*.

Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAM β 1 permitting replication in *Bacillus*.

Examples of origins of replication for use in a yeast host cell are the 2 micron origin of
 10 replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.

Examples of origins of replication useful in a filamentous fungal cell are AMA1 and ANS1 (Gems *et al.*, 1991, *Gene* 98: 61-67; Cullen *et al.*, 1987, *Nucleic Acids Res.* 15: 9163-9175; WO 00/24883). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the
 15 gene can be accomplished according to the methods disclosed in WO 00/24883.

More than one copy of a polynucleotide of the present invention may be inserted into a host cell to increase production of a polypeptide. An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the polynucleotide where cells
 20 containing amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g.,
 25 Sambrook *et al.*, 1989, *supra*).

Signal Peptide

The present invention also relates to an isolated polynucleotide encoding a signal peptide comprising or consisting of amino acids amino acids 1 to 19 of SEQ ID NO: 4, or amino acids -40 to -18 of SEQ ID NO: 4. The polynucleotides may further comprise a gene encoding a protein, which
 30 is operably linked to the signal peptide. The protein is preferably foreign to the signal peptide. In one aspect, the polynucleotide encoding the signal peptide is nucleotides 1 to 57 of SEQ ID NO: 3 or nucleotides 1 to 69 of SEQ ID NO: 7.

The present invention also relates to nucleic acid constructs, expression vectors and recombinant host cells comprising such polynucleotides.

The present invention also relates to methods of producing a protein, comprising (a) cultivating a recombinant host cell comprising such polynucleotide; and (b) recovering the protein.

The protein may be native or heterologous to a host cell. The term "protein" is not meant herein to refer to a specific length of the encoded product and, therefore, encompasses peptides, oligopeptides, and polypeptides. The term "protein" also encompasses two or more polypeptides combined to form the encoded product. The proteins also include hybrid polypeptides and fused polypeptides.

Preferably, the protein is a hormone, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter. For example, the protein may be a hydrolase, isomerase, ligase, lyase, oxidoreductase, or transferase, e.g., an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellobiohydrolase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, endoglucanase, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, or beta-xylosidase.

The gene may be obtained from any prokaryotic, eukaryotic, or other source.

Host Cells

The present invention also relates to recombinant host cells, comprising a polynucleotide of the present invention operably linked to one or more control sequences that direct the production of a polypeptide of the present invention. A construct or vector comprising a polynucleotide is introduced into a host cell so that the construct or vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

The host cell may be any cell useful in the recombinant production of a polypeptide of the present invention, e.g., a prokaryote or a eukaryote.

The prokaryotic host cell may be any Gram-positive or Gram-negative bacterium. Gram-positive bacteria include, but are not limited to, *Bacillus*, *Clostridium*, *Enterococcus*, *Geobacillus*, *Lactobacillus*, *Lactococcus*, *Oceanobacillus*, *Staphylococcus*, *Streptococcus*, and *Streptomyces*. Gram-negative bacteria include, but are not limited to, *Campylobacter*, *E. coli*, *Flavobacterium*, *Fusobacterium*, *Helicobacter*, *Ilyobacter*, *Neisseria*, *Pseudomonas*, *Salmonella*, and *Ureaplasma*.

The bacterial host cell may be any *Bacillus* cell including, but not limited to, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus*

coagulans, *Bacillus firmus*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis* cells.

The bacterial host cell may also be any *Streptococcus* cell including, but not limited to,
 5 *Streptococcus equisimilis*, *Streptococcus pyogenes*, *Streptococcus uberis*, and *Streptococcus equi* subsp. *Zooepidemicus* cells.

The bacterial host cell may also be any *Streptomyces* cell including, but not limited to, *Streptomyces achromogenes*, *Streptomyces avermitilis*, *Streptomyces coelicolor*, *Streptomyces griseus*, and *Streptomyces lividans* cells.

10 The introduction of DNA into a *Bacillus* cell may be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Mol. Gen. Genet.* 168: 111-115), competent cell transformation (see, e.g., Young and Spizizen, 1961, *J. Bacteriol.* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *J. Mol. Biol.* 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, *J. Bacteriol.* 169:
 15 5271-5278). The introduction of DNA into an *E. coli* cell may be effected by protoplast transformation (see, e.g., Hanahan, 1983, *J. Mol. Biol.* 166: 557-580) or electroporation (see, e.g., Dower *et al.*, 1988, *Nucleic Acids Res.* 16: 6127-6145). The introduction of DNA into a *Streptomyces* cell may be effected by protoplast transformation, electroporation (see, e.g., Gong *et al.*, 2004, *Folia Microbiol. (Praha)* 49: 399-405), conjugation (see, e.g., Mazodier *et al.*, 1989, *J.*
 20 *Bacteriol.* 171: 3583-3585), or transduction (see, e.g., Burke *et al.*, 2001, *Proc. Natl. Acad. Sci. USA* 98: 6289-6294). The introduction of DNA into a *Pseudomonas* cell may be effected by electroporation (see, e.g., Choi *et al.*, 2006, *J. Microbiol. Methods* 64: 391-397) or conjugation (see, e.g., Pinedo and Smets, 2005, *Appl. Environ. Microbiol.* 71: 51-57). The introduction of DNA into a *Streptococcus* cell may be effected by natural competence (see, e.g., Perry and Kuramitsu, 1981,
 25 *Infect. Immun.* 32: 1295-1297), protoplast transformation (see, e.g., Catt and Jollick, 1991, *Microbios* 68: 189-207), electroporation (see, e.g., Buckley *et al.*, 1999, *Appl. Environ. Microbiol.* 65: 3800-3804), or conjugation (see, e.g., Clewell, 1981, *Microbiol. Rev.* 45: 409-436). However, any method known in the art for introducing DNA into a host cell can be used.

The host cell may also be a eukaryote, such as a mammalian, insect, plant, or fungal cell.

30 The host cell may be a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota as well as the Oomycota and all mitosporic fungi (as defined by Hawksworth *et al.*, In, *Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK).

The fungal host cell may be a yeast cell. "Yeast" as used herein includes ascosporeogenous
 35 yeast (Endomycetales), basidiosporeogenous yeast, and yeast belonging to the Fungi Imperfecti

(Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, Passmore, and Davenport, editors, *Soc. App. Bacteriol. Symposium Series No. 9*, 1980).

The yeast host cell may be a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*,
 5 *Schizosaccharomyces*, or *Yarrowia* cell, such as a *Kluyveromyces lactis*, *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis*, *Saccharomyces oviformis*, or *Yarrowia lipolytica* cell.

The fungal host cell may be a filamentous fungal cell. "Filamentous fungi" include all
 10 filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth *et al.*, 1995, *supra*). The filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon
 15 catabolism may be fermentative.

The filamentous fungal host cell may be an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Bjerkandera*, *Ceriporiopsis*, *Chrysosporium*, *Coprinus*, *Coriolus*, *Cryptococcus*, *Filibasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Phanerochaete*, *Phlebia*, *Piromyces*, *Pleurotus*, *Schizophyllum*,
 20 *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, *Trametes*, or *Trichoderma* cell.

For example, the filamentous fungal host cell may be an *Aspergillus awamori*, *Aspergillus foetidus*, *Aspergillus fumigatus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, *Aspergillus oryzae*, *Bjerkandera adusta*, *Ceriporiopsis aneirina*, *Ceriporiopsis caregiea*, *Ceriporiopsis gilvescens*, *Ceriporiopsis pannocinta*, *Ceriporiopsis rivulosa*, *Ceriporiopsis subrufa*,
 25 *Ceriporiopsis subvermispora*, *Chrysosporium inops*, *Chrysosporium keratinophilum*, *Chrysosporium lucknowense*, *Chrysosporium merdarium*, *Chrysosporium pannicola*, *Chrysosporium queenslandicum*, *Chrysosporium tropicum*, *Chrysosporium zonatum*, *Coprinus cinereus*, *Coriolus hirsutus*, *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*,
 30 *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, *Fusarium venenatum*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Phanerochaete chrysosporium*, *Phlebia radiata*, *Pleurotus eryngii*, *Thielavia terrestris*, *Trametes villosa*, *Trametes*

versicolor, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* cell.

Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known *per se*. Suitable procedures
5 for transformation of *Aspergillus* and *Trichoderma* host cells are described in EP 238023, Yelton *et al.*, 1984, *Proc. Natl. Acad. Sci. USA* 81: 1470-1474, and Christensen *et al.*, 1988, *Bio/Technology* 6: 1419-1422. Suitable methods for transforming *Fusarium* species are described by Malardier *et al.*, 1989, *Gene* 78: 147-156, and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, *In* Abelson, J.N. and Simon, M.I., editors, *Guide to Yeast*
10 *Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito *et al.*, 1983, *J. Bacteriol.* 153: 163; and Hinnen *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75: 1920.

Methods of Production

The present invention also relates to methods of producing a polypeptide of the present
15 invention, comprising (a) cultivating a cell, which in its wild-type form produces the polypeptide, under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide. In a preferred aspect, the cell is an *Acremonium* cell. In a more preferred aspect, the cell is an *Acremonium alcalophilum* cell. In a most preferred aspect, the cell is an *Acremonium alcalophilum* CBS114.92.

20 The present invention also relates to methods of producing a polypeptide of the present invention, comprising (a) cultivating a recombinant host cell of the present invention under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

The host cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation,
25 or small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be
30 prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

The polypeptide may be detected using methods known in the art that are specific for the polypeptides for example the lysozyme spot assay as described below. These detection methods include, but are not limited to, use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide.

The polypeptide may be recovered using methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

The polypeptide may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., *Protein Purification*, Janson and Ryden, editors, VCH Publishers, New York, 1989) to obtain substantially pure polypeptides.

In an alternative aspect, the polypeptide is not recovered, but rather a host cell of the present invention expressing the polypeptide is used as a source of the polypeptide.

Plants

The present invention also relates to isolated plants, e.g., a transgenic plant, plant part, or plant cell, comprising a polynucleotide of the present invention so as to express and produce a polypeptide or domain in recoverable quantities. The polypeptide or domain may be recovered from the plant or plant part. Alternatively, the plant or plant part containing the polypeptide or domain may be used as such for improving the quality of a food or feed, e.g., improving nutritional value, palatability, and rheological properties, or to destroy an antinutritive factor.

The transgenic plant can be dicotyledonous (a dicot) or monocotyledonous (a monocot). Examples of monocot plants are grasses, such as meadow grass (blue grass, *Poa*), forage grass such as *Festuca*, *Lolium*, temperate grass, such as *Agrostis*, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and maize (corn).

Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, rape seed, and the closely related model organism *Arabidopsis thaliana*.

Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers as well as the individual tissues comprising these parts, e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems. Specific plant cell compartments, such as chloroplasts, apoplasts,

mitochondria, vacuoles, peroxisomes and cytoplasm are also considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part. Likewise, plant parts such as specific tissues and cells isolated to facilitate the utilization of the invention are also considered plant parts, e.g., embryos, endosperms, aleurone and seed coats.

5 Also included within the scope of the present invention are the progeny of such plants, plant parts, and plant cells.

The transgenic plant or plant cell expressing the polypeptide or domain may be constructed in accordance with methods known in the art. In short, the plant or plant cell is constructed by incorporating one or more expression constructs encoding the polypeptide or domain into the plant
10 host genome or chloroplast genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.

The expression construct is conveniently a nucleic acid construct that comprises a polynucleotide encoding a polypeptide or domain operably linked with appropriate regulatory sequences required for expression of the polynucleotide in the plant or plant part of choice.
15 Furthermore, the expression construct may comprise a selectable marker useful for identifying plant cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).

The choice of regulatory sequences, such as promoter and terminator sequences and
20 optionally signal or transit sequences, is determined, for example, on the basis of when, where, and how the polypeptide or domain is desired to be expressed. For instance, the expression of the gene encoding a polypeptide or domain may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific tissue or plant part such as seeds or leaves. Regulatory sequences are, for example, described by Tague *et al.*, 1988, *Plant*
25 *Physiology* 86: 506.

For constitutive expression, the 35S-CaMV, the maize ubiquitin 1, or the rice actin 1 promoter may be used (Franck *et al.*, 1980, *Cell* 21: 285-294; Christensen *et al.*, 1992, *Plant Mol. Biol.* 18: 675-689; Zhang *et al.*, 1991, *Plant Cell* 3: 1155-1165). Organ-specific promoters may be, for example, a promoter from storage sink tissues such as seeds, potato tubers, and fruits
30 (Edwards and Coruzzi, 1990, *Ann. Rev. Genet.* 24: 275-303), or from metabolic sink tissues such as meristems (Ito *et al.*, 1994, *Plant Mol. Biol.* 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin, or albumin promoter from rice (Wu *et al.*, 1998, *Plant Cell Physiol.* 39: 885-889), a *Vicia faba* promoter from the legumin B4 and the unknown seed protein gene from *Vicia faba* (Conrad *et al.*, 1998, *J. Plant Physiol.* 152: 708-711), a promoter from a seed oil body
35 protein (Chen *et al.*, 1998, *Plant Cell Physiol.* 39: 935-941), the storage protein *napA* promoter from

Brassica napus, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the *rbcs* promoter from rice or tomato (Kyoizuka *et al.*, 1993, *Plant Physiol.* 102: 991-1000), the chloroplast virus adenine methyltransferase gene promoter (Mitra and Higgins, 1994, *Plant Mol. Biol.* 26: 85-93), the *aldP* gene promoter from rice (Kagaya *et al.*, 1995, *Mol. Gen. Genet.* 248: 668-674), or a wound inducible promoter such as the potato *pin2* promoter (Xu *et al.*, 1993, *Plant Mol. Biol.* 22: 573-588). Likewise, the promoter may be induced by abiotic treatments such as temperature, drought, or alterations in salinity or induced by exogenously applied substances that activate the promoter, e.g., ethanol, oestrogens, plant hormones such as ethylene, abscisic acid, and gibberellic acid, and heavy metals.

A promoter enhancer element may also be used to achieve higher expression of a polypeptide or domain in the plant. For instance, the promoter enhancer element may be an intron that is placed between the promoter and the polynucleotide encoding a polypeptide or domain. For instance, Xu *et al.*, 1993, *supra*, disclose the use of the first intron of the rice actin 1 gene to enhance expression.

The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.

The nucleic acid construct is incorporated into the plant genome according to conventional techniques known in the art, including *Agrobacterium*-mediated transformation, virus-mediated transformation, microinjection, particle bombardment, biolistic transformation, and electroporation (Gasser *et al.*, 1990, *Science* 244: 1293; Potrykus, 1990, *Bio/Technology* 8: 535; Shimamoto *et al.*, 1989, *Nature* 338: 274).

Agrobacterium tumefaciens-mediated gene transfer is a method for generating transgenic dicots (for a review, see Hooykas and Schilperoort, 1992, *Plant Mol. Biol.* 19: 15-38) and for transforming monocots, although other transformation methods may be used for these plants. A method for generating transgenic monocots is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, *Plant J.* 2: 275-281; Shimamoto, 1994, *Curr. Opin. Biotechnol.* 5: 158-162; Vasil *et al.*, 1992, *Bio/Technology* 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh *et al.*, 1993, *Plant Mol. Biol.* 21: 415-428. Additional transformation methods include those described in U.S. Patent Nos. 6,395,966 and 7,151,204 (both of which are herein incorporated by reference in their entirety).

Following transformation, the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well known in the art. Often the transformation procedure is designed for the selective elimination of selection genes either

during regeneration or in the following generations by using, for example, co-transformation with two separate T-DNA constructs or site specific excision of the selection gene by a specific recombinase.

5 In addition to direct transformation of a particular plant genotype with a construct of the present invention, transgenic plants may be made by crossing a plant having the construct to a second plant lacking the construct. For example, a construct encoding a polypeptide or domain can be introduced into a particular plant variety by crossing, without the need for ever directly transforming a plant of that given variety. Therefore, the present invention encompasses not only a plant directly regenerated from cells which have been transformed in accordance with the present
10 invention, but also the progeny of such plants. As used herein, progeny may refer to the offspring of any generation of a parent plant prepared in accordance with the present invention. Such progeny may include a DNA construct prepared in accordance with the present invention. Crossing results in the introduction of a transgene into a plant line by cross pollinating a starting line with a donor plant line. Non-limiting examples of such steps are described in U.S. Patent No. 7,151,204.

15 Plants may be generated through a process of backcross conversion. For example, plants include plants referred to as a backcross converted genotype, line, inbred, or hybrid.

Genetic markers may be used to assist in the introgression of one or more transgenes of the invention from one genetic background into another. Marker assisted selection offers advantages relative to conventional breeding in that it can be used to avoid errors caused by
20 phenotypic variations. Further, genetic markers may provide data regarding the relative degree of elite germplasm in the individual progeny of a particular cross. For example, when a plant with a desired trait which otherwise has a non-agronomically desirable genetic background is crossed to an elite parent, genetic markers may be used to select progeny which not only possess the trait of interest, but also have a relatively large proportion of the desired germplasm. In this way, the
25 number of generations required to introgress one or more traits into a particular genetic background is minimized.

The present invention also relates to methods of producing a polypeptide or domain of the present invention comprising (a) cultivating a transgenic plant or a plant cell comprising a polynucleotide encoding the polypeptide or domain under conditions conducive for production of
30 the polypeptide or domain; and (b) recovering the polypeptide or domain.

Uses

Examples of preferred uses of the lysozyme or compositions thereof of the present invention are given below. The dosage of the lysozyme and other conditions under which the lysozyme is used may be determined on the basis of methods known in the art.

The polypeptides of the invention are typically useful at any locus subject to contamination by bacteria, fungi, yeast or algae. Typically, loci are in aqueous systems such as cooling water systems, laundry rinse water, oil systems such as cutting oils, lubricants, oil fields and the like, where it is desired to kill the microorganisms or at least to control their growth. However, the present invention may also be used in all applications for which known lysozymes compositions are useful, such as protection of wood, latex, adhesive, glue, paper, cardboard, textile, leather, plastics, caulking, and feed.

A lysozyme, or a composition thereof, of the present invention may be used in several applications to degrade a material comprising a peptidoglycan or a chitodextrin by treating the material with the lysozyme or composition thereof (see for example Proctor and Cunningham, (1988) *Critical Reviews in Food Science and Nutrition* 26:359-395; Carini et al. (1985) *Microbiol. Alimen. Nutr.* 3:299-320; Hughey and Johnson (1987) *Appl. Environ. Microbiol.* 53:2165-2170; Cunningham et al. (1991) *World's Poultry Science Journal* 47:141-163).

Uses of Lysozymes of the Invention for Cleaning and/or Detergents

A lysozyme of the present invention is preferably incorporated into and/or used together with detergent compositions as described below. When washing is performed repeatedly at temperatures below 60°C there is an increased risk of malodour in the washing machine (laundry as well as dishwashing) and on the textiles or items washed in the machine. This malodour is likely to be caused by microbial organisms such as bacteria, fungi, algae or other unicellular organisms growing in the washing machine.

Furthermore, the invention relates to a process for laundering of fabrics comprising treating fabrics with a washing solution containing a detergent composition and a lysozyme or a lysozyme composition of the invention. The laundering treatment can for example be carried out in a machine washing process or in a manual washing process. The washing solution can for example be an aqueous washing solution containing the detergent composition and with a pH between 3 and 12.

The fabrics subjected to the methods of the present invention may be conventional washable laundry, for example household laundry. Preferably, the major part of the laundry is garments and fabrics, including knits, wovens, denims, yarns, and towelling, made from cotton, cotton blends or natural or manmade cellulose (e.g. originating from wood pulp) or blends thereof. Examples of blends are blends of cotton or rayon/viscose with one or more companion material such as wool, synthetic fibers (e.g. polyamide fibers, acrylic fibers, polyester fibers, polyvinyl alcohol fibers, polyvinyl chloride fibers, polyurethane fibers, polyurea fibers, aramid fibers), and cellulose-containing fibers (e.g. rayon/viscose, ramie, flax/linen, jute, cellulose acetate fibers, lyocell).

The present invention provides a method of reducing microbial contamination on a surface, such as a textile garment or hard surface such as metal, plastic or rubber parts in a washing machine or dish washing machine, bathroom tiles, floors, table tops, drains, sinks and washbasin, by treating the microbially contaminated surface with a lysozyme or lysozyme composition of the present invention. Such a treatment is also expected to reduce the malodour on textiles and hard surfaces containing microbial contamination.

The reduction of microbial contamination can be assessed in several ways, for example by letting a panel assess whether the smell has been decreased, alternatively a sample may be taken from the surface and cultivated to assess whether the microbial count has been reduced as a result of the treatment compared to a treatment without lysozyme.

Uses of Lysozymes of the Invention in Animal Feed

A lysozyme of the invention may also be used in animal feed. In an embodiment, the present invention provides a method for preparing an animal feed composition comprising adding a lysozyme of the present invention to one or more animal feed ingredients.

A lysozyme of the present invention may for example be used to stabilize the healthy microflora of animals, in particular livestock such as, but not limited to, sheep, goats, cattle (including, but not limited to, beef cattle, cows, and young calves), deer, pigs or swine (including, but not limited to, piglets, growing pigs, and sows), poultry (including, but not limited to, geese, turkeys, ducks and chicken such as broilers, chicks and layers); horses, moose and rabbits but also in fish (including but not limited to salmon, trout, tilapia, catfish and carps; and crustaceans (including but not limited to shrimps and prawns)) by suppressing growth/intestinal colonization of viral (such as *Coronaviridae*, Porcine reproductive and respiratory syndrome virus (PRRSV), *Persivirus* coursing Bovin virus diarrhoe and likewise), parasitic pathogens (coccidian protozoa, *Eimeria maxima*, *Eimeria mitis*) or bacterial pathogens such as *Clostridium perfringens*, *Escherichia coli*, *Campylobacter coli*, *C. hyointestinalis* and *C. jejuni*, *Yersinia* ssp., *Treponema suis*, *Brachyspira hyodysenteriae*, *Lawsonia intracellularis* and *Salmonella*, such as *Salmonella enterica*, *Salmonella* Typhimurium and *Salmonella* Mbandaka.. In a preferred embodiment a lysozyme is applied to chicken and has anti-microbial activity against *Clostridium perfringens*. In a further embodiment a lysozyme of the present invention is used as a feed additive, where it may provide a positive effect on the microbial balance of the chicken digestive tract and in this way improve animal performance.

A lysozyme of the present invention may also be used in animal feed as feed enhancing enzymes that improve feed digestibility to increase the efficiency of its utilization according to WO 00/21381 and WO 04/026334.

In a further embodiment a lysozyme of the present invention may be used as a feed additive, where it may provide a positive effect on the animals digestive tract and in this way improve animal performance in accordance to weight gain, feed conversion ratio (FCR), or improved animal health such as decreased mortality rate. FCR is calculated as the feed intake in g/animal relative to the weight gain in g/animal.

Uses of Lysozymes of the Invention as Antimicrobial Agents

A lysozyme of the present invention may be used as antimicrobial agents. One aspect of the present invention is a method for reducing microbial contamination, comprising treating a microbial contaminated surface with a lysozyme of the present invention.

To assess whether a lysozyme of the present invention is capable of acting as an antimicrobial agent it can be tested in a turbidity assay. In this assay it is tested whether the lysozyme is capable of degrading microbial cells e.g. a dried substrate of *Exiguobacterium undae* cells (isolated from a smelly sock) or *Micrococcus luteus* cells dissolved in buffer or detergent, and thereby reducing the optical density (OD) at for example 540 nm, when compared to a microbial suspension only treated with buffer.

Uses of Lysozymes of the Invention for Disinfection or as a Disinfectant

A lysozyme of the present invention may be useful as a disinfectant or used for disinfection, e.g. for the treatment of infections in the eye or the mouth, or for cleaning and disinfection of contact lenses, and for preventing or removing biofilm on a surface according to U.S. Patent No. 6,777,223.

A lysozyme of the present invention may also be used in oral care. For example, lysozyme can be used alone or in combination with other enzymes or even antimicrobial peptides in toothpaste or other oral care products. The polypeptides may be introduced into the oral cavity or applied to an article that is to be introduced into the oral cavity. See for example WO 08/124764.

In general it is contemplated that the polypeptides of the present invention are useful for cleaning, disinfecting or inhibiting microbial growth on any surface. Examples of surfaces, which may advantageously be contacted with the polypeptides of the invention are surfaces of process equipment used e.g. dairies, chemical or pharmaceutical process plants, water sanitation systems, oil processing plants, paper pulp processing plants, water treatment plants, and cooling towers. The polypeptides of the invention should be used in an amount, which is effective for cleaning, disinfecting or inhibiting microbial growth on the surface in question.

The polypeptides of the invention may additionally be used for cleaning surfaces and cooking utensils in food processing plants and in any area in which food is prepared or served such as hospitals, nursing homes and restaurants.

Uses of Lysozymes of the Invention in Food Applications

5 A lysozyme of the present invention may also be used to selectively inhibit the uncontrolled growth of *Clostridium tyrobutyricum* during the maturation of cheeses, in particular those made from pressed and cooked curds, e.g. Swiss Cheese, Parmesan, Edam, Gouda, Cheddar, and many others.

10 A lysozyme of the present invention may also be used in wine making, to control or inhibit microbial contamination.

Uses of Lysozymes of the Invention as treatments

A lysozyme of the present invention may also be used in topical treatment of dystrophic and inflammatory lesions of the skin and soft tissues. See for example Palmieri and Boral di (1977) *Arch. Sci. Med.* (Torino) 134:481-485.

15 A lysozyme of the present invention may also be used in skin care. For example, the polypeptide is applied to the skin of a patient suffering from a skin infection, such as acne. The lysozyme may also be used in a wound dressing, which is applied to wounded skin, for example, to aid in healing of the wound. See, for example, U.S. Application No. 20080254079.

20 A lysozyme of the present invention may also be used in lipstick, lip balm, lip gel, or lip gloss. For example, such products can be used for treatment of a localized lip infection, for example, a cold sore. See, for example, U.S. Application No. 20080254079.

A lysozyme of the present invention may also be used in the treatment of bronchopulmonary diseases.

25 A lysozyme of the present invention may also be used as digestive enzymes or digestive aids. A lysozyme of the present invention may also be used to improve the use of dead/live bacteria as a food source, e.g., by controlling undesirable microbial contaminants.

A lysozyme of the present invention may also be used as a therapeutic in a human or other animal, e.g., to control or inhibit bacterial overgrowth in the intestines of a human suffering from a disease, e.g., pancreatic disease or an immuno compromised patient.

30 Uses of Lysozymes of the Invention for Extracting Bacterial Genomic DNA

A lysozyme of the present invention may also be used to aid in the extraction of bacterial genomic DNA from both pure cultures and environmental samples containing multiple bacterial species. In order to be able to sequence bacterial DNA, the bacterial cell wall needs to be broken

down to isolate the DNA inside it. Hen egg white lysozyme is the standard enzyme used for DNA isolation from gram positive bacteria and works by hydrolyzing the peptidoglycan chains present in the cell wall thereby aiding in the degradation of the cell walls. However some gram positive cell walls are not degraded by hen egg white lysozymes. For example, it is recommended that cells from e.g. *Staphylococcus aureus* are lysed with lysostaphin as described by Pitcher and Saunders (1989), App. Environ. Microbiol. 56(3): 782-787. However, these methods do not work for all types of gram positive bacteria and novel lysozymes thus potentially offer access to novel genomes that cannot be isolated with commercial lysozyme solutions

Addition of one or more lysozymes of the present invention, optionally together with lysostaphin or hen egg white lysozyme, affords the breakdown of cell walls from bacteria, preferably gram positive bacteria, which is not possible using current commercial solutions. In an embodiment the lysozyme is a GH25 lysozyme having SEQ ID NO: 4, SEQ ID NO: 8 or a variant thereof. In a further embodiment, the lysozyme is effective in breaking down the cell walls of bacteria from bacteria such as *Bacillus*, *Micrococcus*, *Zobellia*, *Cellulophaga* and *Streptomyces*. An additional embodiment is bacteria such as *Bacillus subtilis*, *Micrococcus luteus*, *Zobellia uliginosa*, *Cellulophaga lytica* and *Streptomyces mobaraensis*. In another embodiment, the lysozyme is effective in combination with hen egg white lysozyme in breaking down the cell walls of bacteria such as *Bacillus*, *Micrococcus*, *Zobellia*, *Cellulophaga* and *Streptomyces*, such as *Bacillus subtilis*, *Micrococcus luteus*, *Zobellia uliginosa*, *Cellulophaga lytica* and *Streptomyces mobaraensis*. A particular embodiment is breaking down the cell walls from the bacteria *Streptomyces mobaraensis*.

The lysozyme of the present invention may be used in a composition or kit to breakdown the cell walls from bacteria, optionally together with lysostaphin or hen egg white lysozyme. The lysozyme component may be a GH25 lysozyme of the present invention or a GH25 lysozyme having SEQ ID NO: 4, SEQ ID NO: 8 or a variant thereof.

Other Uses of Lysozymes of the Invention

A lysozyme of the present invention may also be used to control microbial growth in a fermentation process, such as, in making ethanol or other products from biomass. See, for example, WO 2007/109750. Accordingly, the lysozyme may be used, e.g., in a process for producing a fermentation product comprising (a) liquefying and/or saccharifying a carbohydrate material and (b) fermenting using a fermentation organism, wherein a lysozyme of the present invention is applied to the fermentation process before, during and/or after fermentation concentrations sufficient to kill and/or inhibit growth of bacterial cells.

A lysozyme of the present invention may also be used in controlling microbial growth in a fish or shrimp farm.

Other uses include preservation of foods, beverages, cosmetics such as lotions, creams, gels, ointments, soaps, shampoos, conditioners, antiperspirants, deodorants, enzyme formulations,
5 or food ingredients.

Compositions

In a still further aspect, the present invention relates to compositions comprising a polypeptide of the present invention having antimicrobial and/or lysozyme activity.

The composition may comprise a polypeptide of the invention as the major enzymatic
10 component, e.g., a mono-component composition. Alternatively, the composition may comprise multiple enzymatic activities, such as an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase,
15 pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.

The compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, the polypeptide composition may be in the form of a granulate or a microgranulate. The polypeptide to be included in the composition may
20 be stabilized in accordance with methods known in the art.

Examples are given below of preferred uses of the polypeptide compositions of the invention. The dosage of the polypeptide composition of the invention and other conditions under which the composition is used may be determined on the basis of methods known in the art.

Bacterial Genomic DNA Extraction Composition

The lysozyme of the invention may be added to and thus become a component of a
25 composition to extract genomic DNA from bacteria. The lysozyme may additionally be used in combination with one or more further lysozymes, such as but not limited to lysostaphin, mutanolysin or hen egg white lysozyme. The composition may form part of a kit which can be mixed together according to a set of instructions to extract the genomic DNA from bacteria. The kit may contain a
30 buffer, one or more metal ion binders such as EDTA, a protease such as proteinases K, a detergent such as SDS or Triton X and one or more lysozymes, such as the GH25 lysozyme of the invention, lysostaphin, mutanolysin or hen egg white lysozyme. The bacterial genomic DNA may be extracted from both pure cultures and environmental samples containing multiple bacterial species.

A preferred embodiment is a GH25 lysozyme having SEQ ID NO: 4, SEQ ID NO: 8 or a variant thereof.

Animal Feed Compositions

The present invention is also directed to methods for using the polypeptides of the present invention having lysozyme activity in animal feed, as well as to feed compositions and feed additives comprising the lysozymes of the invention.

The term animal includes all animals, including human beings. Examples of animals are non-ruminants, and ruminants. Ruminant animals include, for example, animals such as sheep, goats, and cattle, e.g. beef cattle and cows. In a particular embodiment, the animal is a non-ruminant animal. Non-ruminant animals include mono-gastric animals, e.g. pigs or swine (including, but not limited to, piglets, growing pigs, and sows); poultry such as turkeys, geese, ducks and chicken (including but not limited to broiler chicks, layers); horses (including but not limited to hotbloods, coldbloods and warm bloods), young calves; and fish (including but not limited to salmon, trout, tilapia, catfish and carps; and crustaceans (including but not limited to shrimps and prawns).

The term feed or feed composition means any compound, preparation, mixture, or composition suitable for, or intended for intake by an animal. In the use according to the invention the lysozyme can be fed to the animal before, after, or simultaneously with the diet. The latter is preferred. Such lysozyme compositions may of course be mixed with other enzymes.

The lysozyme can be added to the feed in any form, be it as a relatively pure lysozyme or in admixture with other components intended for addition to animal feed, i.e. in the form of animal feed additives, such as the so-called pre-mixes for animal feed. In a further aspect the present invention relates to compositions for use in animal feed, such as animal feed, and animal feed additives, e.g. premixes.

Apart from the lysozyme of the invention, the animal feed additives of the invention contain at least one fat-soluble vitamin, and/or at least one water soluble vitamin, and/or at least one trace mineral, and/or at least one macro mineral.

Further, optional, feed-additive ingredients are colouring agents, e.g. carotenoids such as beta-carotene, astaxanthin, and lutein; stabilisers; growth improving additives and aroma compounds/flavorings, e.g. creosol, anethol, deca-, undeca-and/or dodeca-lactones, ionones, irone, gingerol, piperidine, propylidene phthalide, butylidene phthalide, capsaicin and/or tannin; polyunsaturated fatty acids (PUFAs); reactive oxygen generating species; also, a support may be used that may contain, for example, 40-50% by weight of wood fibres, 8-10% by weight of stearine, 4-5% by weight of curcuma powder, 4-58% by weight of rosemary powder, 22-28% by weight of

limestone, 1-3% by weight of a gum, such as gum arabic, 5-50% by weight of sugar and/or starch and 5-15% by weight of water.

A feed or a feed additive of the invention may also comprise at least one other enzyme selected from amongst phytase (EC 3.1.3.8 or 3.1.3.26); xylanase (EC 3.2.1.8); galactanase (EC
5 3.2.1.89); alpha-galactosidase (EC 3.2.1.22); protease (EC 3.4), phospholipase A1 (EC 3.1.1.32); phospholipase A2 (EC 3.1.1.4); lysophospholipase (EC 3.1.1.5); phospholipase C (3.1.4.3); phospholipase D (EC 3.1.4.4); amylase such as, for example, alpha-amylase (EC 3.2.1.1); and/or beta-glucanase (EC 3.2.1.4 or EC 3.2.1.6).

Examples of polyunsaturated fatty acids are C18, C20 and C22 polyunsaturated fatty acids,
10 such as arachidonic acid, docosohexaenoic acid, eicosapentaenoic acid and gamma-linoleic acid.

Examples of reactive oxygen generating species are chemicals such as perborate, persulphate, or percarbonate; and enzymes such as an oxidase, an oxygenase or a syntethase.

Usually fat- and water-soluble vitamins, as well as trace minerals form part of a so-called premix intended for addition to the feed, whereas macro minerals are usually separately added to
15 the feed. Either of these composition types, when enriched with a protease of the invention, is an animal feed additive of the invention.

In a particular embodiment, the animal feed additive of the invention is intended for being included (or prescribed as having to be included) in animal diets or animal feed at levels of 0.1 ppm to 1000 ppm, preferably 0.5 ppm to 200 ppm and more preferably 1 ppm to 100 ppm. The
20 aforementioned dosing levels can also be used for premixes.

The animal feed composition of the invention may contain at least one vegetable protein, such as that derived from or originating from a vegetable, including modified proteins and protein-derivatives. Vegetable proteins may be derived from vegetable protein sources, such as legumes and cereals, for example materials from plants of the families *Fabaceae* (*Leguminosae*),
25 *Cruciferaeae*, *Chenopodiaceae*, and *Poaceae*, such as soy bean meal, lupin meal and rapeseed meal, Alternatively, the vegetable protein source is material from one or more plants of the family *Chenopodiaceae*, e.g. beet, sugar beet, spinach or quinoa. Other examples of vegetable protein sources are rapeseed, sunflower seed, cotton seed, and cabbage and cereals such as barley, wheat, rye, oat, maize (corn), rice, tritcale, and sorghum.

30 The animal feed composition of the invention may also contain animal protein, such as Meat and Bone Meal, Feather meal, and/or Fish Meal, typically in an amount of 0-25%. The animal feed composition of the invention may also comprise Dried Distillers Grains with Solubles (DDGS), typically in amounts of 0-30%.

In still further particular embodiments, the animal feed composition of the invention contains
35 0-80% maize; and/or 0-80% sorghum; and/or 0-70% wheat; and/or 0-70% Barley; and/or 0-30%

oats; and/or 0-40% soybean meal; and/or 0-25% fish meal; and/or 0-25% meat and bone meal; and/or 0-20% whey.

Animal diets can e.g. be manufactured as mash feed (non pelleted) or pelleted feed. Typically, the milled feed-stuffs are mixed and sufficient amounts of essential vitamins and minerals are added according to the specifications for the species in question. Enzymes can be added as solid or liquid enzyme formulations. For example, for mash feed a solid or liquid enzyme formulation may be added before or during the ingredient mixing step. For pelleted feed the (liquid or solid) lysozyme/enzyme preparation may also be added before or during the feed ingredient step. Typically a liquid lysozyme/enzyme preparation is added after the pelleting step. The enzyme may also be incorporated in a feed additive or premix.

The final enzyme concentration in the diet is within the range of 0.01-200 mg enzyme protein per kg diet, for example in the range of 0.5-25 mg enzyme protein per kg animal diet.

Cleaning or Detergent Compositions

The lysozyme of the invention may be added to and thus become a component of a detergent composition, particularly in a liquid detergent having a pH of 7 or lower.

The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.

In a specific aspect, the invention provides a detergent additive comprising the lysozyme of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.

In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

In one embodiment, the invention is directed to cleaning or detergent compositions comprising of an enzyme of the present invention in combination with one or more additional cleaning components. The choice of additional cleaning components is within the skill of the artisan and includes conventional ingredients, including the exemplary non-limiting components set forth below.

The choice of components may include, for textile care, the consideration of the type of textile to be cleaned, the type and/or degree of soiling, the temperature at which cleaning is to take place, and the formulation of the detergent product. Although the components mentioned below are categorized according to a particular function, this should not be construed as a limitation since the component may have one or more additional functionalities which the skilled artisan will appreciate.

The cleaning or detergent composition may be suitable for the laundering of textiles such as e.g. fabrics, cloths or linen, or for cleaning hard surfaces such as e.g. floors, tables, or dish wash.

The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Surfactants

The detergent composition may comprise one or more surfactants, which may be anionic and/or cationic and/or non-ionic and/or semi-polar and/or zwitterionic, or a mixture thereof. In a particular embodiment, the detergent composition includes a mixture of one or more nonionic surfactants and one or more anionic surfactants. The surfactant(s) is typically present at a level of from about 0.1% to 60% by weight, such as about 1% to about 40%, or about 3% to about 20%, or about 3% to about 10%. The surfactant(s) is chosen based on the desired cleaning application, and includes any conventional surfactant(s) known in the art. Any surfactant known in the art for use in detergents may be utilized.

When included therein the detergent will usually contain from about 1% to about 40% by weight, such as from about 5% to about 30%, including from about 5% to about 15%, or from about 20% to about 25% of an anionic surfactant. Non-limiting examples of anionic surfactants include sulfates and sulfonates, in particular, linear alkylbenzenesulfonates (LAS), isomers of LAS, branched alkylbenzenesulfonates (BABS), phenylalkanesulfonates, alpha-olefinsulfonates (AOS), olefin sulfonates, alkene sulfonates, alkane-2,3-diylbis(sulfates), hydroxyalkanesulfonates and disulfonates, alkyl sulfates (AS) such as sodium dodecyl sulfate (SDS), fatty alcohol sulfates (FAS), primary alcohol sulfates (PAS), alcohol ethersulfates (AES or AEOS or FES, also known as alcohol ethoxysulfates or fatty alcohol ether sulfates), secondary alkanesulfonates (SAS), paraffin sulfonates (PS), ester sulfonates, sulfonated fatty acid glycerol esters, alpha-sulfo fatty acid methyl esters (alpha-SFMe or SES) including methyl ester sulfonate (MES), alkyl- or alkenylsuccinic acid, dodecenyl/tetradecenyl succinic acid (DTSA), fatty acid derivatives of amino acids, diesters and monoesters of sulfo-succinic acid or soap, and combinations thereof.

When included therein the detergent will usually contain from about 0% to about 10% by weight of a cationic surfactant. Non-limiting examples of cationic surfactants include alkyltrimethylammonium bromide (CTAB),

dimethyldistearylammonium chloride (DSDMAC), and alkylbenzyltrimethylammonium, alkyl quaternary ammonium compounds, alkoxylated quaternary ammonium (AQA) compounds, and combinations thereof.

When included therein the detergent will usually contain from about 0.2% to about 40% by weight of a non-ionic surfactant, for example from about 0.5% to about 30%, in particular from about 1% to about 20%, from about 3% to about 10%, such as from about 3% to about 5%, or from about 8% to about 12%. Non-limiting examples of non-ionic surfactants include alcohol ethoxylates (AE or AEO), alcohol propoxylates, propoxylated fatty alcohols (PFA), alkoxylated fatty acid alkyl esters, such as ethoxylated and/or propoxylated fatty acid alkyl esters, alkylphenol ethoxylates (APE), nonylphenol ethoxylates (NPE), alkylpolyglycosides (APG), alkoxylated amines, fatty acid monoethanolamides (FAM), fatty acid diethanolamides (FADA), ethoxylated fatty acid monoethanolamides (EFAM), propoxylated fatty acid monoethanolamides (PFAM), polyhydroxy alkyl fatty acid amides, or *N*-acyl *N*-alkyl derivatives of glucosamine (glucamides, GA, or fatty acid glucamide, FAGA), as well as products available under the trade names SPAN and TWEEN, and combinations thereof.

When included therein the detergent will usually contain from about 0% to about 10% by weight of a semipolar surfactant. Non-limiting examples of semipolar surfactants include amine oxides (AO) such as alkyldimethylamineoxide, *N*-(coco alkyl)-*N,N*-dimethylamine oxide and *N*-(tallow-alkyl)-*N,N*-bis(2-hydroxyethyl)amine oxide, fatty acid alkanolamides and ethoxylated fatty acid alkanolamides, and combinations thereof.

When included therein the detergent will usually contain from about 0% to about 10% by weight of a zwitterionic surfactant. Non-limiting examples of zwitterionic surfactants include betaine, alkyldimethylbetaine, sulfobetaine, and combinations thereof.

Hydrotropes

A hydrotrope is a compound that solubilises hydrophobic compounds in aqueous solutions (or oppositely, polar substances in a non-polar environment). Typically, hydrotropes have both hydrophilic and a hydrophobic character (so-called amphiphilic properties as known from surfactants); however the molecular structure of hydrotropes generally do not favor spontaneous self-aggregation, see e.g. review by Hodgdon and Kaler (2007), Current Opinion in Colloid & Interface Science 12: 121-128. Hydrotropes do not display a critical concentration above which self-aggregation occurs as found for surfactants and lipids forming micellar, lamellar or other well defined meso-phases. Instead, many hydrotropes show a continuous-type aggregation process where the sizes of aggregates grow as concentration increases. However, many hydrotropes alter the phase behavior, stability, and colloidal properties of systems containing substances of polar and non-polar character, including mixtures of water, oil, surfactants, and polymers. Hydrotropes are

classically used across industries from pharma, personal care, food, to technical applications. Use of hydrotropes in detergent compositions allow for example more concentrated formulations of surfactants (as in the process of compacting liquid detergents by removing water) without inducing undesired phenomena such as phase separation or high viscosity.

5 The detergent may contain 0-5% by weight, such as about 0.5 to about 5%, or about 3% to about 5%, of a hydrotrope. Any hydrotrope known in the art for use in detergents may be utilized. Non-limiting examples of hydrotropes include sodium benzene sulfonate, sodium p-toluene sulfonate (STS), sodium xylene sulfonate (SXS), sodium cumene sulfonate (SCS), sodium cymene sulfonate, amine oxides, alcohols and polyglycolethers, sodium hydroxynaphthoate, sodium
10 hydroxynaphthalene sulfonate, sodium ethylhexyl sulfate, and combinations thereof.

Builders and Co-Builders

The detergent composition may contain about 0-65% by weight, such as about 5% to about 45% of a detergent builder or co-builder, or a mixture thereof. In a dish wash detergent, the level of builder is typically 40-65%, particularly 50-65%. The builder and/or co-builder may particularly be
15 a chelating agent that forms water-soluble complexes with Ca and Mg. Any builder and/or co-builder known in the art for use in laundry detergents may be utilized. Non-limiting examples of builders include zeolites, diphosphates (pyrophosphates), triphosphates such as sodium triphosphate (STP or STPP), carbonates such as sodium carbonate, soluble silicates such as sodium metasilicate, layered silicates (e.g., SKS-6 from Hoechst), ethanolamines such as 2-
20 aminoethan-1-ol (MEA), diethanolamine (DEA, also known as iminodiethanol), triethanolamine (TEA, also known as 2,2',2''-nitrilotriethanol), and carboxymethyl inulin (CMI), and combinations thereof.


The detergent composition may also contain 0-20% by weight, such as about 5% to about 10%, of a detergent co-builder, or a mixture thereof. The detergent composition may include
25 include a co-builder alone, or in combination with a builder, for example a zeolite builder. Non-limiting examples of co-builders include homopolymers of polyacrylates or copolymers thereof, such as poly(acrylic acid) (PAA) or copoly(acrylic acid/maleic acid) (PAA/PMA). Further non-limiting examples include citrate, chelators such as aminocarboxylates, aminopolycarboxylates and phosphonates, and alkyl- or alkenylsuccinic acid. Additional specific examples include 2,2',2''-
30 nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), iminodisuccinic acid (IDS), ethylenediamine-*N,N'*-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), glutamic acid-*N,N*-diacetic acid (GLDA), 1-hydroxyethane-1,1-diphosphonic acid (HEDP), ethylenediaminetetra-(methylenephosphonic acid) (EDTMPA), diethylenetriaminepentakis(methylenephosphonic acid) (DTPMPA or DTPMPA), *N*-(2-
35 hydroxyethyl)iminodiacetic acid (EDG), aspartic acid-*N*-monoacetic acid (ASMA), aspartic acid-

N,N-diacetic acid (ASDA), aspartic acid-*N*-monopropionic acid (ASMP), iminodisuccinic acid (IDA),
N-(2-sulfomethyl)-aspartic acid (SMAS), *N*-(2-sulfoethyl)-aspartic acid (SEAS), *N*-(2-sulfomethyl)-
 glutamic acid (SMGL), *N*-(2-sulfoethyl)-glutamic acid (SEGL), *N*-methyliminodiacetic acid (MIDA),
 α -alanine-*N*, *N*-diacetic acid (α -ALDA), serine-*N*, *N*-diacetic acid (SEDA), isoserine-*N*, *N*-diacetic
 5 acid (ISDA), phenylalanine-*N*, *N*-diacetic acid (PHDA), anthranilic acid-*N*, *N*-diacetic acid (ANDA),
 sulfanilic acid-*N*, *N*-diacetic acid (SLDA), taurine-*N*, *N*-diacetic acid (TUDA) and sulfomethyl-*N*, *N*-
 diacetic acid (SMDA), *N*-(2-hydroxyethyl)-ethylidenediamine-*N*, *N'*, *N'*-triacetate (HEDTA),
 diethanolglycine (DEG), diethylenetriamine penta(methylenephosphonic acid) (DTPMP),
 aminotris(methylenephosphonic acid) (ATMP), and combinations and salts thereof. Further
 10 exemplary builders and/or co-builders are described in, e.g., WO 09/102854, US 5977053

Bleaching Systems

The detergent may contain 0-50% by weight, such as about 0.1% to about 25%, of a
 bleaching system. Any bleaching system known in the art for use in laundry detergents may be
 utilized. Suitable bleaching system components include bleaching catalysts, photobleaches, bleach
 15 activators, sources of hydrogen peroxide such as sodium percarbonate and sodium perborates,
 preformed peracids and mixtures thereof. Suitable preformed peracids include, but are not limited
 to, peroxydicarboxylic acids and salts, percarbonic acids and salts, perimidic acids and salts,
 peroxymonosulfuric acids and salts, for example, Oxone (R), and mixtures thereof. Non-limiting
 examples of bleaching systems include peroxide-based bleaching systems, which may comprise,
 20 for example, an inorganic salt, including alkali metal salts such as sodium salts of perborate
 (usually mono- or tetra-hydrate), percarbonate, persulfate, perphosphate, persulfate salts, in
 combination with a peracid-forming bleach activator. The term bleach activator is meant herein as a
 compound which reacts with peroxygen bleach like hydrogen peroxide to form a peracid. The
 peracid thus formed constitutes the activated bleach. Suitable bleach activators to be used herein
 25 include those belonging to the class of esters amides, imides or anhydrides. Suitable examples are
 tetracetylene diamine (TAED), sodium 4-[(3,5,5-trimethylhexanoyl)oxy]benzene sulfonate
 (ISONOBS), diperoxy dodecanoic acid, 4-(dodecanoyloxy)benzenesulfonate (LOBS), 4-
 (decanoyloxy)benzenesulfonate, 4-(decanoyloxy)benzoate (DOBS), 4-(nonanoyloxy)-
 benzenesulfonate (NOBS), and/or those disclosed in WO98/17767. A particular family of bleach
 30 activators of interest was disclosed in EP624154 and particularly preferred in that family is acetyl
 triethyl citrate (ATC). ATC or a short chain triglyceride like triacetin has the advantage that it is
 environmental friendly as it eventually degrades into citric acid and alcohol. Furthermore acetyl
 triethyl citrate and triacetin has a good hydrolytical stability in the product upon storage and it is an
 efficient bleach activator. Finally ATC provides a good building capacity to the laundry additive.
 35 Alternatively, the bleaching system may comprise peroxyacids of, for example, the amide, imide, or

sulfone type. The bleaching system may also comprise peracids such as 6-(phthalimido)peroxyhexanoic acid (PAP). The bleaching system may also include a bleach catalyst. In some embodiments the bleach component may be an organic catalyst selected from the group consisting of organic catalysts having the following formulae:



10 (iii) and mixtures thereof; wherein each R^1 is independently a branched alkyl group containing from 9 to 24 carbons or linear alkyl group containing from 11 to 24 carbons, preferably each R^1 is independently a branched alkyl group containing from 9 to 18 carbons or linear alkyl group containing from 11 to 18 carbons, more preferably each R^1 is independently selected from the group consisting of 2-propylheptyl, 2-butyloctyl, 2-pentylononyl, 2-hexyldecyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, iso-nonyl, iso-decyl, iso-tridecyl and iso-pentadecyl. Other
15 exemplary bleaching systems are described, e.g. in WO2007/087258, WO2007/087244, WO2007/087259 and WO2007/087242. Suitable photobleaches may for example be sulfonated zinc phthalocyanine

Polymers

20 The detergent may contain 0-10% by weight, such as 0.5-5%, 2-5%, 0.5-2% or 0.2-1% of a polymer. Any polymer known in the art for use in detergents may be utilized. The polymer may function as a co-builder as mentioned above, or may provide antiredeposition, fiber protection, soil release, dye transfer inhibition, grease cleaning and/or anti-foaming properties. Some polymers may have more than one of the above-mentioned properties and/or more than one of the below-
25 mentioned motifs. Exemplary polymers include (carboxymethyl)cellulose (CMC), poly(vinyl alcohol) (PVA), poly(vinylpyrrolidone) (PVP), poly(ethyleneglycol) or poly(ethylene oxide) (PEG), ethoxylated poly(ethyleneimine), carboxymethyl inulin (CMI), and polycarboxylates such as PAA, PAA/PMA, poly-aspartic acid, and lauryl methacrylate/acrylic acid copolymers, hydrophobically modified CMC (HM-CMC) and silicones, copolymers of terephthalic acid and oligomeric glycols, copolymers of poly(ethylene terephthalate) and poly(oxyethylene terephthalate) (PET-POET), PVP,
30 poly(vinylimidazole) (PVI), poly(vinylpyridine-N-oxide) (PVPO or PVPNO) and polyvinylpyrrolidone-vinylimidazole (PVPVI). Further exemplary polymers include sulfonated polycarboxylates, polyethylene oxide and polypropylene oxide (PEO-PPO) and diquaternium ethoxy sulfate. Other exemplary polymers are disclosed in, e.g., WO 2006/130575. Salts of the above-mentioned
35 polymers are also contemplated.

Fabric hueing agents

The detergent compositions of the present invention may also include fabric hueing agents such as dyes or pigments, which when formulated in detergent compositions can deposit onto a fabric when said fabric is contacted with a wash liquor comprising said detergent compositions and thus altering the tint of said fabric through absorption/reflection of visible light. Fluorescent whitening agents emit at least some visible light. In contrast, fabric hueing agents alter the tint of a surface as they absorb at least a portion of the visible light spectrum. Suitable fabric hueing agents include dyes and dye-clay conjugates, and may also include pigments. Suitable dyes include small molecule dyes and polymeric dyes. Suitable small molecule dyes include small molecule dyes selected from the group consisting of dyes falling into the Colour Index (C.I.) classifications of Direct Blue, Direct Red, Direct Violet, Acid Blue, Acid Red, Acid Violet, Basic Blue, Basic Violet and Basic Red, or mixtures thereof, for example as described in WO2005/03274, WO2005/03275, WO2005/03276 and EP1876226 (hereby incorporated by reference). The detergent composition preferably comprises from about 0.00003 wt% to about 0.2 wt%, from about 0.00008 wt% to about 0.05 wt%, or even from about 0.0001 wt% to about 0.04 wt% fabric hueing agent. The composition may comprise from 0.0001 wt% to 0.2 wt% fabric hueing agent, this may be especially preferred when the composition is in the form of a unit dose pouch. Suitable hueing agents are also disclosed in, e.g. WO 2007/087257 and WO2007/087243.

Additional Enzymes

In one aspect, the present invention provides a detergent additive comprising a lysozyme of the present invention. The detergent additive as well as the detergent composition may comprise one or more [additional] enzymes such as a protease, lipase, cutinase, an amylase, carbohydrase, cellulase, pectinase, mannanase, arabinase, galactanase, xylanase, oxidase, e.g., a laccase, and/or peroxidase.

In general the properties of the selected enzyme(s) should be compatible with the selected detergent, (i.e., pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

Cellulases: Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g., the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in US 4,435,307, US 5,648,263, US 5,691,178, US 5,776,757 and WO 89/09259.

Especially suitable cellulases are the alkaline or neutral cellulases having color care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those

described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471, WO 98/12307 and PCT/DK98/00299.

Commercially available cellulases include Celluzyme™, and Carezyme™ (Novozymes A/S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation).

Proteases: Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. The protease may be a serine protease or a metalloprotease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus*, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g., of porcine or bovine origin) and the *Fusarium* protease described in WO 89/06270 and WO 94/25583.

Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235, and 274.

Preferred commercially available protease enzymes include Alcalase™, Savinase™, Primase™, Duralase™, Esperase™, and Kannase™ (Novozymes A/S), Maxatase™, Maxacal™, Maxapem™, Properase™, Purafect™, Purafect OxP™, FN2™, and FN3™ (Genencor International Inc.).

Lipases and Cutinases: Suitable lipases and cutinases include those of bacterial or fungal origin. Chemically modified or protein engineered mutant enzymes are included. Examples include lipase from *Thermomyces*, e.g. from *T. lanuginosus* (previously named *Humicola lanuginosa*) as described in EP258068 and EP305216, cutinase from *Humicola*, e.g. *H. insolens* (WO96/13580), lipase from strains of *Pseudomonas* (some of these now renamed to *Burkholderia*), e.g. *P. alcaligenes* or *P. pseudoalcaligenes* (EP218272), *P. cepacia* (EP331376), *P. sp.* strain SD705 (WO95/06720 & WO96/27002), *P. wisconsinensis* (WO96/12012), GDSSL-type *Streptomyces* lipases (WO10/065455), cutinase from *Magnaporthe grisea* (WO10/107560), cutinase from *Pseudomonas mendocina* (US5,389,536), lipase from *Thermobifida fusca* (WO11/084412), *Geobacillus stearothermophilus* lipase (WO11/084417), lipase from *Bacillus subtilis* (WO11/084599), and lipase from *Streptomyces griseus* (WO11/150157) and *S. pristinaespiralis* (WO12/137147).

Other examples are lipase variants such as those described in EP407225, WO92/05249, WO94/01541, WO94/25578, WO95/14783, WO95/30744, WO95/35381, WO95/22615,

WO96/00292, WO97/04079, WO97/07202, WO00/34450, WO00/60063, WO01/92502, WO07/87508 and WO09/109500.

Preferred commercial lipase products include include LipolaseTM, LipexTM; LipolexTM and LipocleanTM (Novozymes A/S), Lumafast (originally from Genencor) and Lipomax (originally from
5 Gist-Brocades).

Still other examples are lipases sometimes referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to *Candida antarctica* lipase A (WO10/111143), acyltransferase from *Mycobacterium smegmatis* (WO05/56782), perhydrolases from the CE 7 family (WO09/67279), and variants of the *M. smegmatis* perhydrolase in particular the S54V variant
10 used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd (WO10/100028).

Amylases: Suitable amylases (α and/or β) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, α -amylases obtained from *Bacillus*, e.g., a special strain of *Bacillus licheniformis*, described in more
15 detail in GB 1,296,839.

Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444.

Commercially available amylases are DuramylTM, TermamylTM, FungamylTM, StainzymeTM, NatalaseTM and BANTM (Novozymes A/S), RapidaseTM and PurastarTM (from Genencor International Inc.).
20

Peroxidases/Oxidases: Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful
25 peroxidases include peroxidases from *Coprinus*, e.g., from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include GuardzymeTM (Novozymes A/S).

The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of
30 these enzymes. A detergent additive of the invention, i.e., a separate additive or a combined additive, can be formulated, for example, as a granulate, liquid, slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty
5 alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established
10 methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

Adjunct materials

Any detergent components known in the art for use in laundry detergents may also be utilized. Other optional detergent components include anti-corrosion agents, anti-shrink agents, anti-soil redeposition agents, anti-wrinkling agents, bactericides, binders, corrosion inhibitors,
15 disintegrants/disintegration agents, dyes, enzyme stabilizers (including boric acid, borates, CMC, and/or polyols such as propylene glycol), fabric conditioners including clays, fillers/processing aids, fluorescent whitening agents/optical brighteners, foam boosters, foam (suds) regulators, perfumes, soil-suspending agents, softeners, suds suppressors, tarnish inhibitors, and wicking agents, either alone or in combination. Any ingredient known in the art for use in laundry detergents may be
20 utilized. The choice of such ingredients is well within the skill of the artisan.

Dispersants: The detergent compositions of the present invention can also contain dispersants. In particular powdered detergents may comprise dispersants. Suitable water-soluble organic materials include the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two
25 carbon atoms. Suitable dispersants are for example described in Powdered Detergents, Surfactant science series volume 71, Marcel Dekker, Inc.

Dye Transfer Inhibiting Agents: The detergent compositions of the present invention may also include one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N-oxide polymers,
30 copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinylloxazolidones and polyvinylimidazoles or mixtures thereof. When present in a subject composition, the dye transfer inhibiting agents may be present at levels from about 0.0001 % to about 10%, from about 0.01% to about 5% or even from about 0.1% to about 3% by weight of the composition.

Fluorescent whitening agent: The detergent compositions of the present invention will
35 preferably also contain additional components that may tint articles being cleaned, such as

fluorescent whitening agent or optical brighteners. Where present the brightener is preferably at a level of about 0,01% to about 0,5%.. Any fluorescent whitening agent suitable for use in a laundry detergent composition may be used in the composition of the present invention. The most commonly used fluorescent whitening agents are those belonging to the classes of

5 diaminostilbene-sulphonic acid derivatives, diarylpyrazoline derivatives and bisphenyl-distyryl derivatives. Examples of the diaminostilbene-sulphonic acid derivative type of fluorescent whitening agents include the sodium salts of: 4,4'-bis-(2-diethanolamino-4-anilino-s-triazin-6-ylamino) stilbene-2,2'-disulphonate; 4,4'-bis-(2,4-dianilino-s-triazin-6-ylamino) stilbene-2,2'-disulphonate; 4,4'-bis-(2-anilino-4(N-methyl-N-2-hydroxy-ethylamino)-s-triazin-6-ylamino) stilbene-2,2'-

10 disulphonate, 4,4'-bis-(4-phenyl-2,1,3-triazol-2-yl)stilbene-2,2'-disulphonate; 4,4'-bis-(2-anilino-4(1-methyl-2-hydroxy-ethylamino)-s-triazin-6-ylamino) stilbene-2,2'-disulphonate and 2-(stilbyl-4"-naphtho-1.,2':4,5)-1,2,3-triazole-2"-sulphonate. Preferred fluorescent whitening agents are Tinopal DMS and Tinopal CBS available from Ciba-Geigy AG, Basel, Switzerland. Tinopal DMS is the disodium salt of 4,4'-bis-(2-morpholino-4 anilino-s-triazin-6-ylamino) stilbene disulphonate. Tinopal

15 CBS is the disodium salt of 2,2'-bis-(phenyl-styryl) disulphonate. Also preferred are fluorescent whitening agents is the commercially available Parawhite KX, supplied by Paramount Minerals and Chemicals, Mumbai, India. Other fluorescers suitable for use in the invention include the 1-3-diaryl pyrazolines and the 7-alkylaminocoumarins. Suitable fluorescent brightener levels include lower levels of from about 0.01, from 0.05, from about 0.1 or even from about 0.2 wt % to upper levels of

20 0.5 or even 0.75 wt%.

Soil release polymers: The detergent compositions of the present invention may also include one or more soil release polymers which aid the removal of soils from fabrics such as cotton and polyester based fabrics, in particular the removal of hydrophobic soils from polyester based fabrics. The soil release polymers may for example be nonionic or anionic terephthalate

25 based polymers, polyvinyl caprolactam and related copolymers, vinyl graft copolymers, polyester polyamides see for example Chapter 7 in Powdered Detergents, Surfactant science series volume 71, Marcel Dekker, Inc. Another type of soil release polymers are amphiphilic alkoxylated grease cleaning polymers comprising a core structure and a plurality of alkoxylate groups attached to that core structure. The core structure may comprise a polyalkylenimine structure or a polyalkanolamine

30 structure as described in detail in WO 2009/087523 (hereby incorporated by reference). Furthermore random graft co-polymers are suitable soil release polymers Suitable graft co-polymers are described in more detail in WO 2007/138054, WO 2006/108856 and WO 2006/113314 (hereby incorporated by reference). Other soil release polymers are substituted polysaccharide structures especially substituted cellulosic structures such as modified cellulose

35 derivatives such as those described in EP 1867808 or WO 2003/040279 (both are hereby

incorporated by reference). Suitable cellulosic polymers include cellulose, cellulose ethers, cellulose esters, cellulose amides and mixtures thereof. Suitable cellulosic polymers include anionically modified cellulose, nonionically modified cellulose, cationically modified cellulose, zwitterionically modified cellulose, and mixtures thereof. Suitable cellulosic polymers include methyl cellulose, carboxy methyl cellulose, ethyl cellulose, hydroxyl ethyl cellulose, hydroxyl propyl methyl cellulose, ester carboxy methyl cellulose, and mixtures thereof.

Anti-redeposition agents: The detergent compositions of the present invention may also include one or more anti-redeposition agents such as carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyoxyethylene and/or polyethyleneglycol (PEG), homopolymers of acrylic acid, copolymers of acrylic acid and maleic acid, and ethoxylated polyethyleneimines. The cellulose based polymers described under soil release polymers above may also function as anti-redeposition agents.

Other suitable adjunct materials include, but are not limited to, anti-shrink agents, anti-wrinkling agents, bactericides, binders, carriers, dyes, enzyme stabilizers, fabric softeners, fillers, foam regulators, hydrotropes, perfumes, pigments, sod suppressors, solvents, and structurants for liquid detergents and/or structure elasticizing agents.

Biofilms

Microorganisms growing in biofilms are less susceptible to all types of antimicrobial agents than the same microorganisms when grown in conventional suspension cultures.

It is well known that starved bacteria can be much less susceptible to a variety of antimicrobial challenges. For example, a number of classical antibiotics such as penicillin, perform poorly in slow or non dividing bacteria. Because lysozyme attacks and destroys the peptidoglycan layer regardless of the growth state of the bacteria, it remains effective.

Biofilm control; example dental water lines:

Biofilm buildup within a dental water line can contain biofilms consisting of *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Legionella* sp. to name but a few. There is also the possibility of colonisation of species generally found within the oral cavity as a result of the failure of anti retraction valves within the system. The risk of cross infection becomes even more of a potential risk of course when immuno – compromised patients are involved and in this day and age the numbers of patients within this category continues to steadily increase. The need exists for effective control of bacterial biofilm accumulation in dental water lines. A review of biofilms can be found: Watnick P and Kolter R (2000), "Biofilm, city of microbes", *J Bacteriol.*;182(10):2675-9.

WO 2013/076253

PCT/EP2012/073483

63

A typical example of a commercial throat lozenge product is Lysopaine produced by:
BOEHRINGER INGELHEIM FRANCE

Active ingredients:

BACITRACIN 200 U.I.

5 (to 65 iu/mg)

PAPAIN 2 mg

to 30 NK / mg

LYSOZYME CHLORHYDRATE 5 mg

10 to 26000 U FIP / mg : units determined by measuring OD kinetics of lysis of bacteria
suspended in buffer. The unit determination was measured by lysis induced change in turbidity of a
bacterial culture suspended in buffer.

Non active ingredients:

SACCHARIN excipient

15 MAGNESIUM STEARATE excipient

Menthol aromatisant

SORBITOL excipient

For local treatment of point infections limited to the buccal membranes of the oropharynx.
Caution, if clinical indications of a general bacterial infection are evident, antibiotic therapy is
20 advised.

Toothpaste:

Lysozyme can be used alone or in combination with other enzymes or even antimicrobial
peptides. Examples of other enzymes are glucose oxidase and lactoperoxidase.

25 A typical toothpaste composition including lysozyme is "Biotene" by Laclede, Inc., 2030 East
University Drive, Rancho Dominguez, CA 90220, USA.

Active Ingredients

30 Contains: Lactoperoxidase (100gm)

Inactive Ingredients

Glucose Oxidase, Lysozyme, Sodium Monofluorophosphate, Sorbitol, Glycerin, Calcium Pyrophosphate, Hydrated Silica, Zylitol, Cellulose Gum, Flavor, Sodium Benzoate, Beta-d-glucose, Potassium Thiocyanate

- 5 The present invention is further described by the following examples that should not be construed as limiting the scope of the invention.

EXAMPLES

Strains

- 10 *Aspergillus oryzae* MT3568 strain was used for expression of the *Acremonium alkalophilum* gene encoding the GH25 enzyme. *A. oryzae* MT3568 is an amdS (acetamidase) disrupted gene derivative of *Aspergillus oryzae* JaL355 (WO 2002/40694) in which pyrG auxotrophy was restored by disrupting the *A. oryzae* acetamidase (amdS) gene with the pyrG gene. According to Central Bureau vor Schnimmelkulture, *Acremonium alkalophilum* CBS 114.92 was isolated by A. Yoneda in 1984 from the sludge of pig faeces compost near Tsukui Lake, Japan. *Aspergillus oryzae* Toc1512
15 was used for expression *Acremonium alkalophilum* gene encoding GH25 enzyme (SEQ ID: 7) and variants. *A. oryzae* is and pyrG deficient strain that can be transformed with an pyrG gene and transformants selected by their ability to grow in the absence of uridine.

Media and Solutions

- 20 YP medium was composed of 10 g of yeast extract, 20 g of Bactopeptone, and deionized water to 1 liter.

LB medium was composed of 10 g of tryptone, 5 g of yeast extract, 5 g of sodium chloride, and deionized water to 1 liter.

MDU-2 Bp medium was composed of per liter 45 g maltose-1H₂O, 7 g yeast extract, 12 g KH₂PO₄, 1 g MgSO₄·7H₂O, 2 g K₂SO₄, 5 g Urea, 1 g NaCl, 0.5 ml AMG trace metal solution pH 5.0.

- 25 G2-Gly media was composed of 18 g of yeast extract, 24 g of glycerol (86-88%), 1 ml Dowfax 63N10 and deionized water to 1 liter.

Horikoshi agar medium was composed of: 1% (w/v) Dextrose, 1% soluble starch, 0.5% (w/v) peptone, 0.5% (w/v) yeast extract, 0.02% (w/v) MgSO₄·7H₂O, 0.1% (w/v) K₂HPO₄, and 15 g (w/v) of Bacto-agar. 1% (w/v) Na₂CO₃ was added separately after sterilization.

30

Bacto agar plates were composed of LB medium and 15 g of Bacto agar per liter.

PDA agar plates were composed of potato infusion (potato infusion was made by boiling 300 g of sliced (washed but unpeeled) potatoes in water for 30 minutes and then decanting or straining the broth through cheesecloth. Distilled water was then added until the total volume of the suspension was one liter, followed by 20 g (w/v) of dextrose and 20 g (w/v) of agar powder. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998).

COVE sucrose plates were composed of 342 g of sucrose, 20 g of agar powder, 20 ml of COVE salt solution, and deionized water to 1 liter. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998). The medium was cooled to 60°C and 10 mM acetamide, 15 mM CsCl and Triton X-100 (50 µl/500 ml) were added.

NaNO₃ Sucrose plates were composed of 20ml COVE salt solution, 20 g of agar powder, 342 g sucrose and deionized water to 1 liter. The medium was sterilized by autoclaving at 15 psi for 15 minutes (Bacteriological Analytical Manual, 8th Edition, Revision A, 1998). The medium was cooled to 60°C and 10 mM NaNO₃ and Triton X-100 (50 µl/500 ml) were added.

LB agar plates were composed of 37 g of LB agar and deionized water to 1 liter.

COVE salt solution was composed of 26 g of MgSO₄•7H₂O, 26 g of KCL, 26 g of KH₂PO₄, 50 ml of COVE trace metal solution, and deionized water to 1 liter.

COVE trace metal solution was composed of 0.04 g of Na₂B₄O₇•10H₂O, 0.4 g of CuSO₄•5H₂O, 1.2 g of FeSO₄•7H₂O, 0.7 g of MnSO₄•H₂O, 0.8 g of Na₂MoO₄•2H₂O, 10 g of ZnSO₄•7H₂O, and deionized water to 1 liter.

AMG trace metals were composed of per liter 14.3 g ZnSO₄•7H₂O, 2.5 g CuSO₄•5H₂O, 0.5 g NiCl₂, 13.8 g FeSO₄, 8.5 g MnSO₄, 3.0 g citric acid.

COVE N-gly slants were composed of 10 g of 100% glycerol, 50 ml of COVE salt solution, 218 g sorbitol, 2.02 g KNO₃, 25 g agar, and deionized water to 1 liter.

Example 1: Lysozyme assay

Xanthomonas campestris is the production organism for all xanthan gum production. The separation of *Xanthomonas* cells from the highly viscous xanthan solution is a cost-intensive process in the industrial production (Homma *et al.*, EP690072, Murofushi *et al.*, EP718311, US5702927). Nowadays, the favoured method for recovering xanthan from the fermentation liquid is precipitation with alcohol, mainly isopropanol, after pasteurization to destroy bacterial cells and enzymes (Cottrell, W. I.; Kang, S. K. Dev. (1978), "Xanthan gum: A unique bacterial polysaccharide for food applications", *Ind. Microbiol*, 19:177). Subsequently the xanthan/cell debris precipitate is

spray dried and milled to a powder. The alcohol is recovered by distillation. Because of the significant amounts of Xanthomonas cell wall debris in some commercial preparations of xanthan gum, and this debris is peptidoglycan rich Xanthomonas cell wall material, the gum can be used as a convenient assay for peptidoglycan degrading activity.

5 Solid Plate Assay:

Commercially prepared Xanthan gum (Sigma #G-1253) is dissolved in a buffered solution or bacterial growth media to 0.5% w/v in the presence of 0.7% agarose and then autoclaved. Enzyme preparations, supernatants or whole organisms are either deposited in wells cut out of the Bacto agar plates or deposited directly on the surface of the media. The preparations are able to form
10 clearing zones in the plates. These clearing zones can indicate degradation of bacterial cell wall material.

Liquid clearing assay:

Commercially prepared xanthan gum is dissolved in a buffered solution in the presence or absence of sodium chloride. The solution is autoclaved and used for studies of xanthan gum
15 clearing. Enzyme preparations, supernatants or whole organisms are added to the assay medium and incubated. Resulting treatments are measured in a spectrophotometer to determine the OD of the solution. Typically a wavelength of 600nm is used.

Example 2: Cloning and characterization of the lysozyme encoding gene from *Acremonium alkalophilum* (SEQ ID NO: 4)

20 Genomic sequence information was generated by the U.S. Department of Energy Joint Genome Institute (JGI). According to Central Bureau vor Schnimmelkulture, *Acremonium alkalophilum* CBS 114.92 was isolated by A. Yoneda in 1984 from the sludge of pig faeces compost near Tsukui Lake, Japan. A preliminary assembly of the genome was downloaded from JGI and analyzed using the Pedant-Pro™ Sequence Analysis Suite (Biomax Informatics AG, Martinsried,
25 Germany). Gene models constructed by the software were used as a starting point for detecting GH25 homologues in the genome. More precise gene models were constructed manually using multiple known GH25 protein sequences as a guide.

Acremonium alkalophilum CBS 114.92 was propagated on Horikoshi agar, pH9 for 7 days at 30 C. Mycelia was harvested directly from the plate and DNA was isolated according to the
30 FastDNA SPIN Kit for Soil (www.mpbio.com). The DNA was eluted in 100 ul 10mM TRIS buffer, 0.1mM EDTA, pH 7, 5 and stored at 4 C until use.

The pair of synthetic oligonucleotide primers shown in table 1 below were designed to PCR amplify the *A. alkalophilum* CBS114.92 P242M9 GH25 gene, from the *A. alkalophilum* genomic DNA. An IN-FUSION™ Cloning Kit (Clontech, Mountain View, CA, USA) was used to clone the fragment directly into the expression vector pDau109 (WO 2005/042735).

5 Table 1: Primers used for GH25 PCR Amplification

GH25 gene	Specific forward primer	Specific reverse primer
<i>A. alkalophilum</i> CBS114.92 GH25 P242M9	F-P242M9 <u>5'-ACACAACTGGGGATCCACCAT</u> GAAGCTTCTTCCCTCCTTGA-3' (SEQ ID NO: 5)	R-P242M9 <u>5'-AGATCTCGAGAAGCTTATTAGTCTC</u> CGTTAGCGAGAGC-3' (SEQ ID NO: 6)

Bold letters represent coding sequence. The underlined sequence is homologous to the insertion sites of pDau109.

10 The PCR reaction (25 µl) was composed of 12.5 µl of 2X IPROOF™ HF Master Mix, 0,5 µl of primer F- P242M9 (100 µM), 0,5 µl of primer R- P242M9 (100 µM), 0,5 µl of genomic (100 ng/µl), and 11 µl of deionized water.

15 The PCR reaction (25 µl) was composed of Phusion High-Fidelity DNA Polymerase (Cat. No. F-530S, Thermoscientific, USA), 5 uls 5X Pfusion buffer, 0,5ul 10mM dNTP, 0,5 µl of primer F- P242M9 (100 µM), 0,5 µl of primer R- P242M9 (100 µM), 0,5 µl of genomic (100 ng/µl), and 18 µl of deionized water. The PCR reaction was incubated in a DYAD® Dual-Block Thermal Cycler (MJ Research Inc., Waltham, MA, USA) programmed for 1 cycle at 95°C for 2 minutes; 35 cycles each at 98°C for 10 seconds, 72°C for 2 minutes and 30 seconds, 1 cycle at 72°C for 10 minutes. Samples were cooled to 12°C before removal and further processing.

20 Five µl of the PCR reaction were analyzed by 1% agarose gel electrophoresis using TAE buffer where an approximately 874 bp product band was observed. The remaining PCR reaction was purified using an ILLUSTRATE™ GFX™ PCR DNA and Gel Band Purification Kit according to the manufacturer's instructions.

25 The fragment was then cloned into Hind III and Bam HI digested pDau109 using an IN-FUSION™ Cloning Kit resulting in plasmid pP242M9. Cloning of the P242M9 gene into Hind III-Bam HI digested pDau109 resulted in the transcription of the *Aspergillus aculeatus* P242M9 gene under the control of a NA2-tpi double promoter. NA2-tpi is a modified promoter from the gene encoding the *Aspergillus niger* neutral alpha-amylase in which the untranslated leader has been replaced by an untranslated leader from the gene encoding the *Aspergillus nidulans* triose phosphate isomerase.

The cloning protocol was performed according to the IN-FUSION™ Cloning Kit instructions generating a P242M9 GH25 construct. The treated plasmid and insert were transformed into Fusion Blue™ E. coli cells (Clontech, Mountain View, CA, USA) according to the manufacturer's protocol and plated onto LB plates supplemented with 50 µg of ampicillin per ml. After incubating at 37°C overnight, colonies were seen growing under selection on the LB ampicillin plates. Ten colonies transformed with the P242M9 GH25 construct were cultivated in LB medium supplemented with 50 µg of ampicillin per ml and plasmid was isolated using a FASTPlasmid mini kit from 5Prime (5 PRIME GmbH, Königstrasse 4a, 22767 Hamburg, Germany) according to the manufacturer's instructions.

Isolated plasmids were sequenced with vector primers and in order to determine a representative plasmid expression clone that was free of PCR errors. The DNA sequencing of the *Acremonium alkalophilum* CBS114.92 GH25 genomic clones were performed with an Applied Biosystems Model 3730xl Automated DNA Sequencer using version 3.1 BIG-DYE™ terminator chemistry (Applied Biosystems, Inc., Foster City, CA, USA) and primer walking strategy. Nucleotide sequence data were scrutinized for quality and all sequences were compared to each other with assistance of PHRED/PHRAP software (University of Washington, Seattle, WA, USA). The sequences obtained were identical to the sequences from the JGI.

The nucleotide sequence and deduced amino acid sequence of the *Acremonium alkalophilum* P242M9 GH25 gene are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively. The coding sequence is 838 bp including the stop codon and is interrupted by one intron of 154 bp (nucleotides 148 to 301). The encoded predicted protein is 227 amino acids. Using the SignalP program (Nielsen et al., 1997, Protein Engineering 10: 1-6), a signal peptide of 19 residues was predicted. The predicted mature protein contains 207 amino acids.

The *Aspergillus oryzae* strain MT3568 was used for all experiments. *Aspergillus oryzae* MT3568 is an amdS (acetamidase) disrupted derivative of *A. oryzae* JaL355 (WO 2002/40694) in which pyrG auxotrophy was restored in the process of knocking out the *A. oryzae* amdS gene. *A. oryzae* MT3568 protoplasts were prepared according to the method of European Patent, EP0238023, pages 14-15. Fresh protoplasts of *A. oryzae* MT3568 were prepared and transformed with the pP242M9 GH25 plasmid. Plasmid DNA from the above mini prep procedure was used to transform *A. oryzae* MT3568.

Six µl containing about 3.0 µg total DNA was used for the transformation. The DNA was gently added to 100 µl of *A. oryzae* MT3568 protoplasts and 250 µl of 60% PEG 4000 (Sigma-Aldrich cat. No. 95904). The 60% (W/V) PEG 4000 was prepared in the following manner: PEG 4000 powder was dissolved in double distilled H₂O and then heated for 10-20 seconds in a microwave oven at 800 watt until dissolved. The dissolved solution was cooled down to room

temperature and then then adjusted with CaCl₂ solution and Tris-HCl solution (pH 7.5) for a final concentration of 10mM of each. After adding the 60% PEG 4000 solution, the tube was gently mixed and incubated at 37°C for 30 minutes. The mix was added to 6 ml of top agar with 10 mM acetamide and plated onto COVE-sorbitol plates with 10 mM acetamide.

- 5 The plates were incubated at 37°C for 3 or more days and then moved to 26°C for two days. Spores from 4 individual colonies were picked by first dipping a white 10 µl inoculation pin (Nunc A/S, Denmark) in a 0.1% TWEEN® 80 solution, contacting the sporulating colony on the selection plate, and restreaking with the pin onto fresh COVE sorbitol plates containing 10 mM acetamide. After 5 days at 26°C, spores from the restreaked colonies were used to inoculate a 96
10 well deep dish plate (NUNC, cat. no. 260251, Thermoscientific, USA). The wells of the deep dish plate contained 500µls of either YP + 2% glucose or YP + 2% maltodextrin media. The inoculated plate was sealed with gas permeable tape (89009-656, VWR.com). Plates were incubated stationary at 30 C for 5 days. Expression was verified by analysis of 20 uls of harvested culture
15 Coomassie blue staining. One transformant was selected for further work and designated A. oryzae EXP03864.

Spores of EXP03864 were inoculated into DAP-4C-1 medium (100mls in 500ml Erlenmeyer shake flask with baffles). The cultures were incubated at 26°C and 150 rpm, 3 days and if necessary 4 days. An SDS gel was run as above to test protein amount.

20 Plate test for lysozyme activity

A Spot assay was performed with Xanthan gum, at pH 5, 7 and 8 as described in the section lysozyme plate assay.

A 1.5% Agarose (Invitrogen cat. 15510-027, electrophoresis grade) solution was prepared in the following buffers:

- 25 pH ~5 – in water
pH ~7 - in 0.02M potassium phosphate pH 7
pH ~8 - in 0.02M potassium phosphate pH 8

- The agarose was autoclaved for 20 minutes at 121°C. 0.5% Xanthan gum (Sigma G1253) was dissolved in the melted 1.5 % agarose and the mixture poured into petri plates. When the
30 plates were set, sample application wells were made with a P-1000 pippette tip (cut off to a 3 mm diameter) attached to a vacuum line.

20ul of the culture fluid of EXP03899 was deposited in the application wells and incubated at 37°C overnight . Samples with lysozyme activity were observed by clearing zones where the cell debris in the xanthan gum was observed. Culture fluids from EXP03864 displayed such a clearing

zone while the *Aspergillus oryzae* untransformed transformation host MT3568 did not produce a noticeable clearing zone. The remaining culture EXP03899 fluid was filtered through a Fast PES Bottle top filter with a 0.22 µm cut-off and stored in aliquots at -20°C until further use.

Example 3: RDA (Radial diffusion assays)

Initially, the antimicrobial activity of the culture supernatants and purified fractions containing the recombinantly expressed lysozymes was confirmed using an RDA's as described previously by Lehrer et al. (Lehrer RI, Rosenman M, Harwig SS et al. (1991), "Ultrasensitive assays for endogenous antimicrobial polypeptides", *J Immunol Methods*, 137:167–73), with several modifications. Briefly, 30 mL of melted 1/10 Mueller–Hinton broth (MHB) (Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989) with 1% agarose was cooled to 42°C, supplemented to 5.0×10^5 cfu/mL with *S. carnosus* ATCC 51365 or *E. coli* DSM682 (ATCC 10536) and was poured into a single-well omnitray (Nunc) plate. The omnitray plate was overlayed with a TSP plate (Nunc) and left to solidify. After 1 h, the TSP plate was removed; leaving 96 1-mm wells in which 10 µL of the compound of interest could be tested.

10 µl of the test solution is spotted pr. well and the plates are incubated O/N at 37°C. The following day clearing zones indicated no growth of test bacteria and thereby antimicrobial activity. The clearing zones were visualized by colouring with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole), that is reduced to purple formazan in living cells (Mosmann, Tim (1983), "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays", *Journal of Immunological Methods* **65** (1–2): 55–63). This colouring provides for a dark colouring of living cells and no colouring of the clearing zones without living cells.

The *Aspergillus fumigatus* GH25 lysozyme (prepared as disclosed in Korczynska et al, *Acta Cryst.* (2010) F66, 973-977) was included in the test as a reference. The purified samples shown in table 2 below have been tested in the RDA assay.

Table 2: Radial Diffusion Assay of GH24 and GH25 Lysozymes

Lysozyme	Stock conc.	Dilution 0.7 ug/ul	Dilution 0.35 ug/ul
<i>A.alcalophilum</i> GH24 SEQ ID NO: 2	1.4 µg/ul	37.5 µl enz. + 37.5 µl water	18.8 µl enz. + 56.2 µl water
<i>A. alcalophilum</i> GH25 SEQ ID NO: 4	0.77 µg/ul	68.2 µl enz. + 6.8 µl water	34.1 µl enz. + 40.9 µl water

<i>A.fumigatus</i> GH25 (reference)	12.2 µg/ul	4.3 µl enz. + 70.6 µl water	2.2 µl enz. + 72.8 µl water
--	------------	-----------------------------	-----------------------------

Measurement of clearing zones

The experiment was performed in triplicate with all resulting in same measured clearing zones /zones of inhibition, see Figure 1. Table 3 below shows the clearing zones in mm.

Table 3: Antimicrobial Clearing Zones of the GH25 Lysozymes Against *Staphylococcus carnosus* and *Escherichia coli*.

	0.7 µg/µl <i>S. carnosus</i>	0.35 µg/µl <i>S. carnosus</i>	0.7 µg/µl <i>E. coli</i>	0.35 µg/µl <i>E. coli</i>
<i>A.alcalophilum</i> GH24 SEQ ID NO: 2	12	10	16	14
<i>A. alcalophilum</i> GH25 SEQ ID NO: 4	faint	faint	8 (cloudy)	6 (cloudy)
<i>A.fumigatus</i> GH25 (reference)	11	10	10	8

The purified lysozyme *A. alcalophilum* GH24 (SEQ ID NO: 4) showed antimicrobial activity against viable cells of the gram positive bacteria *Staphylococcus carnosus* and the Gram negative bacteria *Escherichia coli*.

10 The antimicrobial activity is not present in culture supernatants from the untransformed *Aspergillus* production host (results not shown).

Large clearing zones with non defined borders were observed surrounding the application zone for *A. alcalophilum* GH24 (SEQ ID NO: 2). The experiment indicates that the *A. alcalophilum* lysozyme (SEQ ID NO: 2) and the *Aspergillus fumigatus* GH25 reference lysozyme have different
15 activity and specificity against the two bacteria tested in this example.

Example 4: Turbidity assay

The activity of lysozyme was determined by measuring the decrease (drop) in absorbance/optical density of a solution of resuspended *Micrococcus lysodeikticus* ATTC No. 4698 (Sigma-Aldrich M3770) or *Exiguobacterium undea* (DSM14481) measured in a spectrophotometer
20 at 540 nm.

Preparation of Micrococcus lysodeikticus substrate

Before use the cells were resuspended in citric acid – phosphate buffer pH 6.5 to a concentration of 0.5 mg cells/mL and the optical density (OD) at 540 nm was measured. The cell suspension was then adjusted so that the cell concentration equalled an OD₅₄₀ = 1.0. The adjusted cell suspension was then stored cold before use. Resuspended cells were used within 4 hours.

Preparation of citric acid – phosphate buffer pH 6.5

29 mL 0.1 M citric acid was mixed with 61 mL 0.2 M Na₂HPO₄, and the pH was adjusted with HCl or NaOH to pH 6.5.

10 Preparation of dried cells of Exiguobacterium undae (the substrate)

A culture of *E. undae* (DSM14481) was grown in 100 mL LB medium (Fluka 51208, 25 g/L) in a 500 mL shake-flask at 30°C, 250 rpm overnight. The overnight culture was then centrifuged at 20°C and 5000g for 10 minutes, and the pellet was washed two times in sterile milliQ water, and resuspended in Milli-Q water. The washed cells were centrifuged for 1 minute at 13000 rpm and as much as possible of the supernatant was decanted. The washed cells were dried in a vacuum centrifuge for 1 hour. The cell pellet was resuspended in citric acid – phosphate buffer pH 6.5 so that the optical density (OD) at 540nm = 1.

Measurement of lysozyme antimicrobial activity in the turbidity assay

The lysozyme sample to be measured was diluted to a concentration of 100-200 mg enzyme protein/L in citric acid – phosphate buffer pH 6.5, and kept on ice until use. In a 96 well microtiterplate (Nunc) 200µL of the substrate was added to each well, and the plate was incubated at 25°C or 37°C for 5 minutes in a VERSAmax microplate reader (Molecular Devices). Following incubation, the absorbance of each well was measured at 540 nm (start value). To start the activity measurement, 20 µL of the diluted lysozyme sample was added to each substrate (200 µL) and kinetic measurement of absorbance at 540 nm was initiated for minimum 30 minutes up to 24 hours at 25°C or 37°C. The measured absorbance at 540 nm was monitored for each well and over time a drop in absorbance is seen if the lysozyme has lysozyme activity.

The *Aspergillus fumigatus* GH25 lysozyme (Korczynska et al (2010) *supra.*) was included in the test as a reference and the results are shown in table 4 below.

30 Table 4: Lysozyme Activity of GH25 Lysozymes against *Micrococcus lysodeikticus* and *Exiguobacterium undae* as measured by Optical Density Drop

	<i>Micrococcus lysodeikticus</i>	<i>Exiguobacterium undae</i>	
Temperature	37°C	25°C	37°C
<i>A. alcalophilum</i> GH25 (SEQ ID NO: 4)	NT	++	+++
<i>A. fumigatus</i> GH25 (reference)	+	+++	+++

NT means not tested

- Means no effect

+ means small effect

++ means medium effect

+++ means large effect

5

Example 5: Purification of P242M9 GH25 protein in *Aspergillus oryzae*

The fermentation supernatant with the lysozyme was filtered through a Fast PES Bottle top filter with a 0.22 µm cut-off. pH was adjusted to 4.5 with 10% acetic acid. After the pH-adjustment the solution became a little cloudy and this was removed by filtration through a Fast PES Bottle top filter with a 0.22 µm cut-off.

After pretreatment about 650 ml of the lysozyme containing solution was purified by chromatography on SP Sepharose, approximately 50 ml in a XK26 column, using as buffer A 50 mM Na-acetate pH 4.5, and as buffer B 50 mM Na-acetate + 1 M NaCl pH 4.5. The fractions from the column were pooled based on the chromatogram (absorption at 280 and 254 nm) and SDS-PAGE analysis. The pooled fractions were buffer-changed into 50 mM Na-acetate, pH 5.5 and concentrated using Amicon spin filters with a 10 kDa cut-off.

15

The molecular weight, as estimated from SDS-PAGE, was approximately 22 kDa and the purity was > 95%.

Example 6: Temperature Stability of P242M9 GH25

Temperature stability was determined for *Acremonium alcalophilum* P242M9 GH25 lysozyme (SEQ ID NO: 4). The purpose of this study is to determine residual activity of *Acremonium alcalophilum* GH25 lysozyme after heat treatment at 60°C - 85°C.

20

Samples were incubated at different temperature for a short period of time (30s and 60s) after which the residual activity was measured for 1h at 37°C in a citric acid – phosphate buffer

using gram positive bacteria *Micrococcus luteus* as substrate. OD drop turbidity assay at 540nm was used to determine lysozyme activity.

Heat treatment

The heat treatment was performed in a buffered solution of *Acremonium alcalophilum* GH25 lysozyme (SEQ ID NO: 4) in a preheated PCR Thermocycler (GeneAmp PCR system 9700) for 30/60 sec at different temperatures. 60, 65, 70, 75, 80 and 85°C were used for either 30 or 60 seconds after which the tubes were placed on an ice bath for instant cooling of the samples.

Turbidity assay

The activity of lysozyme was determined by measuring the decrease (drop) in absorbance/optical density of a solution of re-suspended *Micrococcus luteus* (also named *Micrococcus lysodeikticus*) ATTC No. 4698 (Sigma-Aldrich M3770) measured in a spectrophotometer at 540 nm.

Preparation of *Micrococcus luteus* substrate

Before use the cells were re-suspended in citric acid – phosphate buffer (prepared by mixing 29 mL 0.1 M citric acid with 61 mL 0.2 M Na₂HPO₄ and adjusting to pH 6.5 with HCl or NaOH) to a concentration of 0.5 mg cells/mL and the optical density (OD) at 540 nm was measured. The cell suspension was then adjusted so the cell concentration equaled an OD₅₄₀ = 1.0. The adjusted cell suspension was then stored cold before use. Suspended cells were used within 4 hours.

Measurement of lysozyme antimicrobial activity in the turbidity assay

The lysozyme sample was diluted to a concentration of 100-200 mg enzyme protein/L in citric acid – phosphate buffer, and kept on ice until use. In a 96 well microtiterplate (Nunc), the *Micrococcus luteus* substrate (200µL) was added to each well, and the plate was incubated at 37°C for 5 minutes in a VERSAmax microplate reader (Molecular Devices). Following the incubation the absorbance of each well was measured at 540 nm (start value). To start the activity measurement, the diluted lysozyme sample (20 µL) was added to the pH adjusted diluted substrate (200 µL) in each well and kinetic measurement of absorbance at 540 nm was initiated for minimum 30 minutes up to 24 hours at 37°C.

The measured absorbance at 540 nm was monitored for each well and over time a drop in absorbance is seen if the lysozyme has antimicrobial activity. The difference between the absorbance at T=0 and the time points was calculated as the ΔOD and compared between test substances (table 5 and figure 2). The percentage remaining activity was calculated by comparing

the ΔOD of the heat treated sample with the ΔOD of the sample which was not heat treated. The experiment described above was performed in triplicate.

Table 5: Temperature Stability of the P242M9 GH25 Lysozyme as measured by OD Drop

Time (Sec)	Temperature (°C)						
	60	65	70	75	80	85	No heat
30	0.2320	0.2263	0.1958	0.2416	0.2300	0.2322	0.2210
60	0.2464	0.2181	0.2109	0.2031	0.1888	0.1858	0.2268

Table 6: Percentage Remaining Activity of the P242M9 GH25 Lysozyme

Time (Sec)	Temperature (°C)						
	60	65	70	75	80	85	No heat
30	105%	102%	89%	109%	104%	105%	100%
60	109%	96%	93%	90%	83%	82%	100%

5

The results show that the P242M9 GH25 lysozyme is stable after 30 seconds even at 85°C and that the GH25 lysozyme retains over 80% activity even after 60 seconds at 85°C.

Example 7: Thermostability of P242M9 GH25 determined using DSC

10 An aliquot of the protein sample of lysozyme (P242M9 GH25), purified as described in Example 7, was buffer-changed (see buffer in table below) using a prepacked PD-10 column. The sample was 0.45 μ m filtered and diluted with buffer to approx. 2 A280 units. The buffer was used as reference solution. The thermostability of the lysozyme in different pH values was determined by Differential Scanning Calorimetry (DSC) using a VP-capillary DSC instrument (MicroCal Inc., Piscataway, NJ, USA) equipped with an auto sampler. The thermal denaturation temperature, Td
15 (°C), was taken as the top of denaturation peak (major endothermic peak) in thermograms (Cp vs. T) obtained after heating the lysozyme solutions in the buffer at a constant programmed heating rate.

Sample and reference solutions (approx. 0.5 ml) were thermally pre-equilibrated for 10 minutes at 20 °C and the DSC scan was performed from 20 to 110 °C at a scan rate of 200 K/hour.
20 Data-handling is performed using the MicroCal Origin software (version 7.0383). Denaturation

temperatures were determined at an accuracy of approximately $\pm 0.5^{\circ}\text{C}$. The results of the DSC measurements are summarized in table 7 and figure 3.

Table 7: Denaturation Temperature of the P242M9 GH25 Lysozyme

Buffer	Td ($^{\circ}\text{C}$)
50 mM Na-acetate, pH 4.5	71.2
50 mM Na-acetate, pH 5.5	67.3
50 mM MES (2-(<i>N</i> -morpholino)ethanesulfonic acid), pH 6.5	65.8

Example 8: Cloning and expression of lysozyme encoding genes from *Acremonium alkalophilum* (SEQ ID NO: 8)

Based on the nucleotide sequence identified as SEQ ID NO: 3, a synthetic gene having SEQ ID NO: 7, was synthesized by Gene Art (GENEART AG BioPark, Josef-Engert-Str. 11, 93053, Regensburg, Germany). The PCR primer set listed below in table 8 was used to PCR amplify the synthetic GH25 gene. For cloning purposes the restriction sites *Bam*HI and *Eco*RI were introduced in the end of the PCR fragment (restriction sites are underlined in the primer sequences listed below and bold letters represent coding sequence).

Table 8: Primers used for PCR amplification of the GH25

GH25 gene	Specific forward primer	Specific reverse primer
Synthetic gene	Fwd. <i>Bam</i>HI 5'TACACAACTGGGGATCCAGCGGCCG CACCATGAAGTTCTTCACCAC-3' SEQ ID NO: 9	Rev. <i>Eco</i>RI 5'-ATACTTGTCCGAATTCCT AATCGCCGTTCGCCAATGC-3' SEQ ID NO: 10

The PCR fragment was spin purified, digested with *Bam*HI and *Eco*RI (New England Biolabs) and ligated using the Rapid DNA Ligation kit (Roche) into the dual *A. Oryzae*/*E.coli* plasmid expression vector pENI1898 that first had been digested with *Bam*HI and *Eco*RI. pENI1898 is modified from vector pENI1861 (WO 03/070956) as the AMA sequence (Clutterbuck A. J., et al. (1991) Gene 98 (1): 61-67) has been removed by digestion of the vector with *Hind*III followed by re-ligation of the agarose gel-purified vector. Further, pENI1861 carries the *pyrG* gene and is able to complement a *pyrG* deficient *Aspergillus* strain.

Following 5 minutes incubation at room temperature the ligation reaction was transformed into competent *E.coli* TOP10 cells (Invitrogen) which were plated onto LB agar plates containing

150µg/ml ampicillin. Plates were incubated for 16 hours at 37°C. Plasmid DNA were purified from selected transformants, and sequenced for verification of cloning procedure.

The encoded predicted protein is 248 amino acids and contains a signal peptide of 23 residues and a mature protein of 207 amino acids. The mature sequence of SEQ ID NO: 4 is
5 identical to the mature sequence of SEQ ID NO: 8.

Example 9: Cloning and expression of lysozyme GH25 variants

Variants of GH25 gene

10 variants containing a single amino acid changes in the synthetic GH25 lysozyme gene were cloned and expressed. The variants of the GH25 lysozyme consist of the single substitution
10 as follows: W10H, Y28M, S39D, G92P, A93M, E97A, V133M, T142N, F178I or D190A.

Cloning of variants of GH25

To generate the GH25 variants as described above, PCR-based site-directed mutagenesis was done with mutagenic primers that introduced the desired sequence change (substitutions). Primers were designed so that the mutation lies in the middle of the oligonucleotide with sufficient
15 flanking nucleotides (15-25). The plasmid DNA containing GH25 was used as template and PCR was setup with a proofreading DNA polymerase (Phusion DNA polymerase (New England Biolabs)). The PCR products were used to transform competent *E.coli* TOP 10 cells (Invitrogen) according to the instructions from the manufacturer. Plasmid DNA was isolated from monoclonal transformed *E.coli* strains, and sequenced to verify the presence of the desired substitution.

20 Transformation and expression of GH25 and variants

The plasmid DNA pENI1898 encoding the lysozyme gene was used for transformation into *A. oryzae* ToC1512 protoplasts (WO 2005/070962) as described in example 2 and plated onto NaNO₃ sucrose plates without uridine for selection of transformants carrying correct constructs. Plates were incubated 72 hours at 37°C.

25 Single colonies were isolated by restreaking colonies on NaNO₃ sucrose plates for 72 hours at 37°C and grown in YP media at 34°C for 72 hours. Colonies expressing lysozyme were selected after examination of broths by the turbidity assay in 50 mM 3,3 dimethylglutaric acid at pH 6.4 with *Micrococcus lysodeikticus* cell walls as substrates. Further, expression of lysozyme was confirmed by visual inspection of a band of approximately 23 KDa by SDS-PAGE analysis.

30 Transformants expressing lysozyme were restreaked and grown on COVE N-gly slants at 37° C. for another 5 days and inoculated to 200 ml of G2-Gly shaking flask. After the cultivation with vigorous agitation at 30°C for 1 day, 3 ml of each culture was transferred to 200 ml of MDU-2Bp in

shaking flask to cultivate at 30°C for 3 days. Culture broths were purified in a similar manor to the purification of the P242M9 GH25 lysozyme in example 6 above.

Example 10: Antimicrobial Activity

The antimicrobial activity of the P242M9 GH25 lysozyme, the synthetic GH25 lysozyme and
5 11 variants of the synthetic GH25 lysozyme were tested against two *Clostridium perfringens* strains.

Method and materials

The activity was determined by both measuring the optical density and the number of colony forming units of *Cl. perfringens* cultures before and after exposure to lysozyme. Exposure of *Cl.*
10 *perfringens* to active lysozymes will result in a kill of the bacteria and a corresponding decrease in both optical density (OD-drop) and the number of colony forming units.

Briefly, lysozyme stock solutions were diluted in PBS (pH 6) to concentrations of 50 µg/ml. Two-fold dilution series of these 50 µg/ml solutions were performed in PBS (pH 6) to end concentrations of 0.4 µg/ml.

15 Then overnight cultures of *Cl. perfringens* were re-suspended in PBS (pH 6). OD₅₄₆ was measured and adjusted to 1. Cultures (75 µl) were mixed in micro-titre plates (Nunc) 1:1 with prepared lysozyme-solutions (75 µl), which resulted in exposure of *Cl. perfringens* to end concentrations of lysozymes ranging from 0.4-25 µg/ml (7 concentrations in total pr. lysozyme). Cultures were exposed to lysozymes for 4 hours under anaerobic conditions at 42°C. OD₅₄₆ and
20 CFU/ml were measured at time points 0 and 4 hours post-exposure.

Results

The results of the activity testing are shown in tables 9, 10 and 11 and figures 4 and 5. Table 9 shows the decrease in colony forming units of two strains of *Clostridium perfringens* per mL (CFU/mL) of GH25 lysozyme or variant. Exposure to active lysozymes resulted typically in 1-2 log
25 reductions in CFU/mL. Lysozyme activity was evaluated as significant if reduction in CFU/ml was ≥1 log.

Table 10 shows the optical density drop (delta OD) of *Clostridium perfringens* NN01260 upon exposure to the GH25 lysozyme P242M9 (SEQ ID NO: 4), the synthetic GH25 lysozyme (SEQ ID NO: 8) or 11 variants of SEQ ID NO: 8. Table 11 shows the optical density drop (delta OD)
30 of *Clostridium perfringens* clinical isolate upon exposure to the GH25 lysozyme P242M9 (SEQ ID NO: 4), the synthetic GH25 lysozyme (SEQ ID NO: 8) or 11 variants of SEQ ID NO: 8.

Table 9: Decrease in CFU/mL of *Clostridium perfringens* when treated with Wild Type and Variant GH25 Lysozymes

GH25 Wild Type or Variant	Decrease in CFU/mL	
	<i>Cl. perfringens</i> (NNO11260)	<i>Cl. perfringens</i> - clinical isolate from chickens
SEQ ID NO: 4	++	++
V133M	++	+
W10H	++	+
S39D	++	+
F178I	++	++
SEQ ID NO: 8	++	++
Y28M	++	++
D95A	++	+
G92P	+	+
E97A	-	-
D190A	(+)	(+)
A93M	+	(+)
T142N	+	(+)

++ significant activity within the whole range of lysozyme concentrations tested.

+ significant activity for a reduced number of lysozyme concentrations tested.

- no significant activity of the lysozyme.

5

Table 10: OD-Drop of *Clostridium perfringens* NN011260 when treated with Wild Type and Variant GH25 Lysozymes

GH25 Wild Type or Variant	Concentration of <i>Cl. Perfringens</i> NN011260 (µg/ml)*							
	25		6.25		1.56		0.39	
	Delta OD ₅₄₆	SD	Delta OD ₅₄₆	SD	Delta OD ₅₄₆	SD	Delta OD ₅₄₆	SD

WO 2013/076253

80

PCT/EP2012/073483

SEQ ID NO: 4	0,090	0,006	0,093	0,005	0,075	0,010	0,061	0,004
V133M	0,081	0,007	0,101	0,004	0,076	0,009	0,058	0,005
W10H	0,074	0,004	0,077	0,018	0,062	0,005	0,043	0,006
S39D	0,087	0,014	0,083	0,007	0,073	0,012	0,067	0,010
F178I	0,087	0,008	0,090	0,013	0,091	0,009	0,065	0,014
SEQ ID NO: 8	0,098	0,011	0,082	0,001	0,083	0,014	0,086	0,015
Y28M	0,086	0,013	0,081	0,004	0,080	0,017	0,075	0,014
D95A	0,066	0,007	0,088	0,008	0,082	0,007	0,073	0,010
G92P	0,069	0,004	0,062	0,004	0,043	0,009	0,047	0,009
E97A	0,019	0,005	0,030	0,008	0,013	0,005	0,024	0,012
D190A	0,077	0,004	0,089	0,007	0,059	0,007	0,055	0,005
A93M	0,069	0,003	0,077	0,004	0,063	0,004	0,043	0,005
T142N	0,064	0,008	0,073	0,008	0,051	0,004	0,020	0,003

*Average of three biological replicates

Table 11: OD-Drop of *Clostridium perfringens* clinical isolate when treated with Wild Type and Variant GH25 Lysozymes

GH25 Wild Type or Variant	Concentration of <i>Cl. Perfringens</i> clinical strain (µg/ml)*							
	25		6.25		1.56		0.39	
	Delta OD ₅₄₆	SD	Delta OD ₅₄₆	SD	Delta OD ₅₄₆	SD	Delta OD ₅₄₆	SD
SEQ ID NO: 4	0,068	0,014	0,062	0,012	0,028	0,021	0,009	0,003
V133M	0,060	0,010	0,050	0,009	0,016	0,009	-0,001	0,006
W10H	0,050	0,018	0,024	0,029	0,007	0,016	-0,005	0,011
S39D	0,058	0,016	0,047	0,006	0,025	0,015	0,003	0,006
F178I	0,070	0,015	0,068	0,018	0,033	0,010	0,008	0,005
SEQ ID NO: 8	0,073	0,015	0,060	0,013	0,042	0,018	0,011	0,008
Y28M	0,064	0,015	0,065	0,013	0,047	0,026	0,014	0,017
D95A	0,060	0,014	0,059	0,010	0,027	0,019	0,011	0,015
G92P	0,049	0,021	0,025	0,022	0,008	0,010	0,002	0,001
E97A	0,002	0,012	0,009	0,019	0,001	0,011	0,007	0,008
D190A	0,049	0,018	0,028	0,016	0,019	0,024	0,005	0,009
A93M	0,059	0,012	0,038	0,024	0,007	0,020	0,006	0,017

T142N	0,063	0,012	0,036	0,017	0,015	0,034	-0,002	0,024
-------	-------	-------	-------	-------	-------	-------	--------	-------

*Average of three biological replicates

The results show that the mutation of 9 positions did not result in the loss of lysozyme activity. However, mutation of position 97 resulted in loss of activity indicating that this position cannot be mutated.

Example 11: pH Activity Profile

The pH activity profile of the lysozyme of the invention was determined by measuring the decrease (drop) in absorbance/optical density of a solution of resuspended *Micrococcus luteus* ATTC No. 4698 (Sigma-Aldrich M3770) measured in a spectrophotometer at 540 nm for a range of pH values in order to determine at which pH the GH25 lysozyme or variant has peak lysozyme activity.

The *Micrococcus luteus* substrate was prepared as described in example 6. The lysozyme antimicrobial activity was measured as described in example 6 except that the citric acid – phosphate buffer was adjusted to one of the following pH values with HCl or NaOH prior to beginning the experiment: 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 and 7.0. The experiment described above was performed in duplicates or triplicates and the results are given in table 12 below.

Table 12: pH Activity Profile of Wild Type and Variant GH25 Lysozymes

GH25 Wild Type or Variant	pH of Peak Antimicrobial Activity
SEQ ID NO: 4	4.0
V133M	4.0
W10H	4.5
S39D	4.5
F178I	4.0
SEQ ID NO: 8	4.0
Y28M	4.0
D95A	4.0
G92P	4.0

E97A	no activity found
D190A	no activity found
A93M	4.0
T142N	4.0

The results show that GH25 lysozyme variants of the invention having the substitution Y28M, G92P, A93M, V133M, T142N or F178I retained antimicrobial activity without significant change in the pH activity profile compared to the wild type lysozyme. GH25 lysozyme variants of the invention having the substitution W10H or S39D resulted in an altered pH profile, such that the pH profile increased by 0.5 pH unit, whilst retaining antimicrobial activity.

Example 12: Gastric Stability

The activity of Hen egg white lysozyme, *A. alcalophilum* GH25 lysozyme (SEQ ID NO: 8) and two variants (W10H and S39D) were activity tested by the turbidity assay after incubation for up to 1 hour in artificial gastric juice (pH 2) containing pepsin. This activity was then compared to a standard curve made for each lysozyme under the same or equivalent conditions but without incubation with gastric juice containing pepsin.

The different lysozymes were incubated in artificial gastric juice for a time span of 0, 15, 30 or 60 minutes. After incubation, a stop buffer was added to raise pH and thereby prevent the low pH and pepsin from degrading peptide bonds of the lysozyme. After deactivation of pepsin, an activity turbidity assay was performed together with a standard curve of different concentrations of the lysozyme in question for comparison.

Artificial gastric juice: (HCl pH 2, 1 mg/ml pepsin, 0.1 M NaCl).

Solution A: 0.01 M HCl, 0.1 M NaCl (prepared by mixing 275 μ l 1M HCl with 2.5 ml 1M NaCl and adding 22.23 ml MQ water to a total volume of 25 ml).

Solution B: 0.01 M HCl, 0.1 M NaCl, 10 mg/ml pepsin (prepared by weighing out 50 mg pepsin and adding 5 ml solution A).

Preparation of standard curve

Artificial gastric juice (160 μ l) was added to each microtiter well followed by 20 μ l citric acid - phosphate buffer (pH 7 for hen egg white lysozyme, pH 4 for *A. alcalophilum* GH25 lysozyme and pH 4.5 for the variants W10H and S39D). The lysozyme solution (20 μ l) was added then *Micrococcus luteus* substrate (20 μ l, prepared as described in example 6) was added to each well

(standard curve as well as time series samples) and the OD 540 nm was measured each minute for one hour at 37°C.

The lysozyme antimicrobial activity was measured as described in example 6 except that the citric acid – phosphate buffer was adjusted to the optimal pH for the different lysozymes (as given in the previous paragraph) by addition of HCl or NaOH. The experiment described above was performed in duplicates and the results are given in table 13 below.

Table 13: Residual activity of lysozyme after incubation with artificial gastric juice

Lysozyme	Residual activity (minutes)			
	0 min	15 min	30 min	60 min
Hen egg white lysozyme	100%	56%	30%	7%
<i>Acremonium alcalophilum</i> GH25 lysozyme	100%	109%	109%	102%
<i>Acremonium alcalophilum</i> GH25 lysozyme variant W10H	100%	97%	97%	101%
<i>Acremonium alcalophilum</i> GH25 lysozyme variant S39D	100%	99%	93%	89%

The remaining lysozyme activity after incubation in artificial gastric juice was dramatically reduced for hen egg white lysozymes even after 15 minutes. In comparison, the GH25 lysozyme from *Acremonium alcalophilum* showed no reduction in activity. In addition, the two GH25 variants having the substitution W10H or S39D also retained lysozyme activity, showing similar residual activity as the GH25 lysozymes from *Acremonium alcalophilum*.

Example 13: Isolation of Genomic DNA

The yield of bacterial genomic DNA purifications with added *Acremonium alcalophilum* GH25 lysozyme (SEQ ID NO. 8) and a combination of hen egg white lysozyme and *Acremonium alcalophilum* GH25 lysozyme (SEQ ID NO. 8) were compared to DNA purification without lysozyme and with hen egg white lysozyme alone. Genomic DNA was isolated from five different bacteria.

Method

Bacterial mass was obtained either by scraping off cells from an agar plate with an inoculation loop or by centrifugation of a liquid culture (see table 14). DNA was isolated using a

modified version of the QIAamp DNA Blood Mini Kit (Cat. No 51106) and purified either using a Qiagen QIAcube or a manual process.

Table 14: Overview of bacterial strains tested, cell starting material and purification method.

Bacterial strain	DSMZ No.:	Cell starting material	Purification method
<i>Micrococcus luteus</i>	DSM20030	Colony scrape	QIAcube with Qiagen kit #51106
<i>Bacillus subtilis</i>	DSM3256	Colony scrape	QIAcube with Qiagen kit #51106
<i>Zobillia uliginosa</i>	DSM2061	Liquid culture	Qiagen kit #51106
<i>Streptomyces coelicolor</i>	DSM40233	Liquid culture	Qiagen kit #51106
<i>Cellulophaga lytica</i>	DSM2039	Colony scrape	Qiagen kit #51106
<i>Streptomyces mobaraensis</i>	DSM40847	Liquid culture	Qiagen kit #51106

DNA isolation using QIAcube:

- 5 A colony scrape fitting a 10 µL inoculation loop was resuspended in 3 mL M9 buffer (prepared by dissolving 8.77 g Na₂HPO₄·2H₂O, 3 g KH₂PO₄, 4 g NaCl and 0.2 g MgSO₄·7H₂O in 1000 mL H₂O and adjusting the pH to 7 with NaOH or HCl). The solution was centrifuged for 5 min at 3000 RPM and the pellet was resuspended in 3 mL P1 buffer (included in Qiagen kit# 51106). 200 µL aliquots were added to 12 2 mL tubes and 15 µL of water, *A. alcalophilum* GH25 lysozyme (10 mg/mL), Hen egg white lysozyme (10 mg/mL) or *A. alcalophilum* GH25 lysozyme (10 mg/mL) + hen egg white (10 mg/mL) 1:1 mix were added to tubes in triplicates. Tubes were placed in the QIAcube and processed according to Qiagens recommendations.

Manual DNA isolation:

- 15 Liquid culture pellets and colony scrape were resuspended in 3 mL M9 buffer. Bacterial M9 buffer suspensions were centrifuged for 5 min at 3000 RPM and pellets were resuspended in 3 mL P1 buffer. 200 µL aliquots were added to 12 2 mL tubes and 15 µL of water, *A. alcalophilum* GH25 lysozyme (10 mg/mL), Hen egg white lysozyme (10 mg/mL) or *A. alcalophilum* GH25 lysozyme (10 mg/mL) + hen egg white (10 mg/mL) 1:1 mix were added to tubes in triplicates. Tubes were incubated at 37°C for 30 min after which 25 µL Qiagen Protease and 200 µL Qiagen buffer AL were added. The tubes were then incubated at 56°C for 20 min. 210 µL 96% ethanol were next added to

each tube. The tubes were vortexed and liquids were transferred to Qiagen spin columns and centrifuged at 8000 rpm for 1 min. The columns were washed twice with 500 µl AW1 buffer (included in Qiagen kit# 51106). After the first wash, the columns were centrifuged for 1 min at 8000 RPM and after the second wash, the columns were centrifuged for 3 min at 15000 RPM.

- 5 Genomic DNA was eluted from column by addition by 100 µL milliQ water (heated to 70°C) to each column, incubated for 1 min at room temperature and centrifuged into Eppendorf tubes at 8000 RPM for 1 min. All incubations were repeated in triplicate.

Results

- 10 The yield of genomic DNA yield was estimated by running the isolated DNA on an agarose gel and visually inspecting the intensity of the DNA band (table 15). The relative DNA yield between the 4 different treatments of each bacterial strain was estimated by eye using 4 different scores.

Table 15: Comparison of the Genomic DNA yield between different combinations of *Acremonium alcalophilum* GH25 lysozyme (SEQ ID NO. 8) and hen egg white lysozyme

Bacterial strain	No lysozyme	<i>A. alcalophilum</i> GH25 lysozyme	Hen egg white	<i>A. alcalophilum</i> GH25 lysozyme and hen egg white
<i>Micrococcus luteus</i>	-	++	+++	+++
<i>Bacillus subtilis</i>	-	+	+++	++
<i>Zobillia uliginosa</i>	++	+++	+++	+++
<i>Streptomyces coelicolor</i>	-	-	+	+
<i>Cellulophaga lytica</i>	+++	+++	+++	+++
<i>Streptomyces mobaraensis</i>	-	++	+	+++

Yields were scored by eye using the following scale:

- 15 - no DNA band visible
- + weak band
- ++ medium band
- +++ strong band.

WO 2013/076253

PCT/EP2012/073483

86

The use of *A. alcalophilum* GH25 lysozyme gave as good as or better yield of genomic DNA in 3 out of 6 cases compared to hen egg lysozyme. The use of the combination of *A. alcalophilum* GH25 lysozyme and hen egg lysozyme gave as good as or better yield of genomic DNA in 5 out of 6 cases compared to either lysozyme alone.

CLAIMS

1. An isolated polypeptide having lysozyme activity, selected from the group consisting of:
 - (a) a polypeptide having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the mature polypeptide of SEQ ID NO: 4 or to the mature polypeptide of SEQ ID NO: 8;
 - (b) a polypeptide encoded by a polynucleotide having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 3 or to the mature polypeptide coding sequence of SEQ ID NO: 7;
 - (c) a polypeptide encoded by a polynucleotide that hybridizes under medium-high stringency conditions with the mature polypeptide coding sequence of SEQ ID NO: 3 or SEQ ID NO: 7, or the full-length complement thereof;
 - (d) a variant of the mature polypeptide of SEQ ID NO: 4 or SEQ ID NO: 8, comprising a substitution, deletion, and/or insertion at one or more (e.g., several) positions; and
 - (e) a fragment of the polypeptide of (a), (b), (c) or (d) that has lysozyme activity.
2. The polypeptide of claim 1, selected among polypeptides comprising or consisting of SEQ ID NO: 4 or SEQ ID NO: 8 or the mature polypeptide of SEQ ID NO: 4 or SEQ ID NO: 8.
3. The polypeptide of claim 2, wherein the mature polypeptide is selected among amino acids 20 to 227 of SEQ ID NO: 4 or amino acids 1 to 208 of SEQ ID NO: 8.
4. The polypeptide of any of claims 1-3, which is a variant of the mature polypeptide of SEQ ID NO: 4 or SEQ ID NO: 8 comprising a substitution, deletion, and/or insertion at one or more (several) positions.
5. A composition comprising the polypeptide of any of claims 1-4.
6. The composition of claim 5 being a detergent composition.
7. The detergent composition of claim 6 for laundry, dish wash or cleaning hard surfaces.

8. The detergent composition of any of claims 6 to 7, wherein the composition comprises one or more further enzymes selected from the group comprising proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidases, haloperoxygenases, catalases and mannanases, or any mixture thereof.
5
9. The detergent composition of any of claim 6 to 8 comprising one or more components selected from the group comprising surfactants, builders, hydrotopes, bleaching systems, polymers, fabric hueing agents, adjunct materials, dispersants, dye transfer inhibiting agents, fluorescent whitening agents, soil release polymers and anti-redeposition agents.
10
10. An animal feed composition comprising the polypeptide of any of claims 1-4.
11. The animal feed composition of claim 10, which further comprises of one or more amylases; phytases; xylanases; galactanases; alpha-galactosidases; proteases, phospholipases, beta-glucanases, or any mixture thereof.
15
12. An animal feed additive comprising
at least one polypeptide of any one of claims 1-4; and
20 at least one fat-soluble vitamin, and/or
at least one water-soluble vitamin, and/or
at least one trace mineral.
13. The animal feed additive of claim 12, which further comprises of one or more amylases; phytases; xylanases; galactanases; alpha-galactosidases; proteases, phospholipases, beta-glucanases, or any mixture thereof.
25
14. The composition of claim 5 being a bacterial genomic DNA extraction composition.
15. The bacterial genomic DNA extraction composition of claim 14 wherein the composition additionally comprises of one or more further lysozymes.
30
16. Use of a polypeptide according to any of claims 1-4 as an inhibitor of bio-film formation.
17. Use of a polypeptide according to any of claims 1-4 in a dental composition.
35

18. Use of a polypeptide according to any of claims 1-4 in a detergent composition.
19. Use of a polypeptide according to any of claims 1-4 in animal feed.
- 5 20. Use of a polypeptide according to any of claims 1-4 for breaking down the cell walls of bacteria.
- 10 21. The polypeptide of claim 20, wherein the polypeptide is used in a process for isolating DNA from bacteria.
22. A method of isolating DNA from bacteria, comprising:
 - (a) treating the isolated bacteria with the polypeptide of any of claims 1-4; and
 - (b) recovering the bacterial DNA.
- 15 23. An isolated polynucleotide encoding the polypeptide of any of claims 1-4.
24. A nucleic acid construct or expression vector comprising the polynucleotide of claim 23 operably linked to one or more control sequences that direct the production of the polypeptide in an expression host.
- 20 25. A recombinant host cell comprising the polynucleotide of claim 23 operably linked to one or more control sequences that direct the production of the polypeptide.
- 25 26. A method of producing the polypeptide of any of claims 1-4, comprising:
 - (a) cultivating a cell, which in its wild-type form produces the polypeptide, under conditions conducive for production of the polypeptide; and
 - (b) recovering the polypeptide.
- 30 27. A method of producing a polypeptide having lysozyme activity, comprising:
 - (a) cultivating the host cell of claim 25 under conditions conducive for production of the polypeptide; and
 - (b) recovering the polypeptide.

WO 2013/076253

PCT/EP2012/073483

90

28. A transgenic plant, plant part or plant cell transformed with a polynucleotide encoding the polypeptide of any of claims 1-4.


29. A method of producing a polypeptide having lysozyme activity, comprising:

- 5 (a) cultivating the transgenic plant or plant cell of claim 28 under conditions conducive for production of the polypeptide; and
- (b) recovering the polypeptide.

10

1/34

Figure 1



2/34

Figure 2





Figure 3



3/34

Figure 4





Figure 5



WO 2013/076253

PCT/EP2012/073483

4/34

Figure 6

ATOM	1	N	ARG	A	1	44.522	50.717	8.838	1.00	28.67	N
ATOM	2	CA	ARG	A	1	43.694	49.714	8.356	1.00	13.65	C
ATOM	3	C	ARG	A	1	42.875	50.460	7.316	1.00	11.82	C
ATOM	4	O	ARG	A	1	41.722	50.065	7.025	1.00	13.40	O
ATOM	5	CB	ARG	A	1	42.689	49.227	9.407	1.00	14.16	C
ATOM	6	CG	ARG	A	1	42.877	49.550	10.880	1.00	18.87	C
ATOM	7	CD	ARG	A	1	44.201	49.369	11.187	1.00	20.58	C
ATOM	8	NE	ARG	A	1	44.812	49.349	12.569	1.00	37.10	N
ATOM	9	CZ	ARG	A	1	44.332	49.709	13.792	1.00	32.66	C
ATOM	10	NH1	ARG	A	1	43.123	50.137	14.019	1.00	31.65	N
ATOM	11	NH2	ARG	A	1	45.164	49.607	14.845	1.00	47.10	N
ATOM	12	N	ILE	A	2	43.477	51.484	6.693	1.00	9.49	N
ATOM	13	CA	ILE	A	2	42.829	52.301	5.732	1.00	8.53	C
ATOM	14	C	ILE	A	2	43.510	52.136	4.370	1.00	7.94	C
ATOM	15	O	ILE	A	2	44.735	52.324	4.281	1.00	8.51	O
ATOM	16	CB	ILE	A	2	42.818	53.768	6.165	1.00	9.40	C
ATOM	17	CG1	ILE	A	2	42.070	53.960	7.542	1.00	10.36	C
ATOM	18	CG2	ILE	A	2	42.222	54.673	5.149	1.00	9.51	C
ATOM	19	CD1	ILE	A	2	40.610	53.674	7.510	1.00	13.29	C
ATOM	20	N	PRO	A	3	42.758	51.956	3.295	1.00	8.33	N
ATOM	21	CA	PRO	A	3	43.374	51.836	1.953	1.00	8.50	C
ATOM	22	C	PRO	A	3	43.590	53.176	1.294	1.00	7.67	C
ATOM	23	O	PRO	A	3	42.848	54.166	1.486	1.00	9.16	O
ATOM	24	CB	PRO	A	3	42.353	51.019	1.148	1.00	9.95	C
ATOM	25	CG	PRO	A	3	41.022	51.355	1.829	1.00	10.42	C
ATOM	26	CD	PRO	A	3	41.290	51.706	3.246	1.00	9.80	C
ATOM	27	N	GLY	A	4	44.627	53.242	0.433	1.00	7.51	N
ATOM	28	CA	GLY	A	4	44.913	54.373	-0.398	1.00	7.59	C
ATOM	29	C	GLY	A	4	45.783	53.972	-1.586	1.00	7.28	C
ATOM	30	O	GLY	A	4	45.956	52.778	-1.853	1.00	7.83	O
ATOM	31	N	PHE	A	5	46.330	54.959	-2.269	1.00	7.08	N
ATOM	32	CA	PHE	A	5	47.028	54.702	-3.507	1.00	7.40	C
ATOM	33	C	PHE	A	5	48.018	55.802	-3.773	1.00	7.27	C
ATOM	34	O	PHE	A	5	48.047	56.820	-3.049	1.00	7.99	O
ATOM	35	CB	PHE	A	5	46.086	54.401	-4.647	1.00	7.75	C
ATOM	36	CG	PHE	A	5	45.207	55.534	-5.143	1.00	8.67	C
ATOM	37	CD1	PHE	A	5	44.137	55.975	-4.407	1.00	9.72	C
ATOM	38	CD2	PHE	A	5	45.401	56.042	-6.402	1.00	9.19	C
ATOM	39	CE1	PHE	A	5	43.305	57.031	-4.910	1.00	11.03	C
ATOM	40	CE2	PHE	A	5	44.560	57.028	-6.925	1.00	10.44	C
ATOM	41	CZ	PHE	A	5	43.538	57.527	-6.187	1.00	11.01	C
ATOM	42	N	ASP	A	6	48.820	55.681	-4.824	1.00	6.90	N
ATOM	43	CA	ASP	A	6	49.724	56.758	-5.243	1.00	6.79	C
ATOM	44	C	ASP	A	6	49.826	56.760	-6.775	1.00	6.82	C
ATOM	45	O	ASP	A	6	49.689	55.720	-7.408	1.00	7.49	O
ATOM	46	CB	ASP	A	6	51.101	56.692	-4.538	1.00	7.91	C
ATOM	47	CG	ASP	A	6	51.857	55.472	-4.847	1.00	9.00	C
ATOM	48	OD1	ASP	A	6	52.552	55.425	-5.913	1.00	9.22	O
ATOM	49	OD2	ASP	A	6	51.814	54.483	-4.007	1.00	8.80	O
ATOM	50	N	ILE	A	7	50.062	57.947	-7.278	1.00	6.73	N
ATOM	51	CA	ILE	A	7	50.053	58.210	-8.735	1.00	7.42	C

WO 2013/076253

PCT/EP2012/073483

5/34

ATOM	52	C	ILE	A	7	51.110	59.263	-9.051	1.00	8.07	C
ATOM	53	O	ILE	A	7	51.579	60.035	-8.239	1.00	7.60	O
ATOM	54	CB	ILE	A	7	48.654	58.697	-9.233	1.00	8.10	C
ATOM	55	CG1	ILE	A	7	48.225	60.003	-8.485	1.00	8.33	C
ATOM	56	CG2	ILE	A	7	47.643	57.575	-9.068	1.00	8.98	C
ATOM	57	CD1	ILE	A	7	46.836	60.482	-8.839	1.00	9.54	C
ATOM	58	N	SER	A	8	51.481	59.225	-10.348	1.00	8.89	N
ATOM	59	CA	SER	A	8	52.388	60.211	-10.988	1.00	8.79	C
ATOM	60	C	SER	A	8	51.797	60.578	-12.361	1.00	9.19	C
ATOM	61	O	SER	A	8	50.724	60.199	-12.750	1.00	10.07	O
ATOM	62	CB	SER	A	8	53.787	59.651	-11.138	1.00	10.12	C
ATOM	63	OG	SER	A	8	53.783	58.646	-12.164	1.00	10.96	O
ATOM	64	N	GLY	A	9	52.606	61.339	-13.106	1.00	10.94	N
ATOM	65	CA	GLY	A	9	52.279	61.698	-14.467	1.00	12.92	C
ATOM	66	C	GLY	A	9	52.156	60.479	-15.358	1.00	12.95	C
ATOM	67	O	GLY	A	9	51.550	60.572	-16.518	1.00	13.87	O
ATOM	68	N	TRP	A	10	52.661	59.336	-14.987	1.00	11.18	N
ATOM	69	CA	TRP	A	10	52.497	58.128	-15.730	1.00	12.59	C
ATOM	70	C	TRP	A	10	51.047	57.589	-15.762	1.00	12.34	C
ATOM	71	O	TRP	A	10	50.701	56.733	-16.578	1.00	13.98	O
ATOM	72	CB	TRP	A	10	53.400	57.012	-15.191	1.00	13.30	C
ATOM	73	CG	TRP	A	10	54.837	57.149	-15.585	1.00	14.62	C
ATOM	74	CD1	TRP	A	10	55.587	58.202	-15.409	1.00	15.09	C
ATOM	75	CD2	TRP	A	10	55.651	56.228	-16.335	1.00	17.86	C
ATOM	76	NE1	TRP	A	10	56.893	58.006	-15.862	1.00	17.04	N
ATOM	77	CE2	TRP	A	10	56.929	56.812	-16.457	1.00	18.57	C
ATOM	78	CE3	TRP	A	10	55.465	54.928	-16.825	1.00	21.59	C
ATOM	79	CZ2	TRP	A	10	58.003	56.182	-17.131	1.00	21.31	C
ATOM	80	CZ3	TRP	A	10	56.554	54.304	-17.515	1.00	25.45	C
ATOM	81	CH2	TRP	A	10	57.784	54.946	-17.620	1.00	24.61	C
ATOM	82	N	GLN	A	11	50.183	58.108	-14.889	1.00	11.59	N
ATOM	83	CA	GLN	A	11	48.729	57.778	-14.843	1.00	11.19	C
ATOM	84	C	GLN	A	11	47.962	58.913	-15.531	1.00	12.13	C
ATOM	85	O	GLN	A	11	47.742	59.940	-14.942	1.00	13.60	O
ATOM	86	CB	GLN	A	11	48.272	57.611	-13.408	1.00	11.93	C
ATOM	87	CG	GLN	A	11	48.604	56.274	-12.810	1.00	11.53	C
ATOM	88	CD	GLN	A	11	50.090	56.067	-12.586	1.00	11.82	C
ATOM	89	OE1	GLN	A	11	50.719	56.753	-11.777	1.00	11.76	O
ATOM	90	NE2	GLN	A	11	50.678	55.110	-13.245	1.00	12.98	N
ATOM	91	N	PRO	A	12	47.524	58.705	-16.789	1.00	13.98	N
ATOM	92	CA	PRO	A	12	46.797	59.805	-17.504	1.00	13.98	C
ATOM	93	C	PRO	A	12	45.446	60.165	-16.907	1.00	13.81	C
ATOM	94	O	PRO	A	12	44.979	61.272	-17.093	1.00	15.84	O
ATOM	95	CB	PRO	A	12	46.610	59.249	-18.948	1.00	17.78	C
ATOM	96	CG	PRO	A	12	46.878	57.852	-18.884	1.00	17.75	C
ATOM	97	CD	PRO	A	12	47.784	57.586	-17.682	1.00	15.28	C
ATOM	98	N	THR	A	13	44.836	59.161	-16.281	1.00	13.32	N
ATOM	99	CA	THR	A	13	43.458	59.221	-15.873	1.00	12.96	C
ATOM	100	C	THR	A	13	43.266	58.706	-14.449	1.00	12.59	C
ATOM	101	O	THR	A	13	43.712	57.628	-14.111	1.00	12.26	O
ATOM	102	CB	THR	A	13	42.513	58.504	-16.847	1.00	15.23	C
ATOM	103	OG1	THR	A	13	42.898	57.159	-16.970	1.00	16.83	O
ATOM	104	CG2	THR	A	13	42.470	59.110	-18.284	1.00	16.05	C
ATOM	105	N	THR	A	14	42.493	59.416	-13.629	1.00	11.98	N

WO 2013/076253

PCT/EP2012/073483

6/34

ATOM	106	CA	THR	A	14	42.064	59.004	-12.294	1.00	10.95	C
ATOM	107	C	THR	A	14	40.651	59.576	-12.025	1.00	10.45	C
ATOM	108	O	THR	A	14	40.546	60.807	-12.041	1.00	13.30	O
ATOM	109	CB	THR	A	14	43.030	59.442	-11.159	1.00	10.77	C
ATOM	110	OG1	THR	A	14	44.371	59.027	-11.465	1.00	11.59	O
ATOM	111	CG2	THR	A	14	42.606	58.916	-9.783	1.00	12.01	C
ATOM	112	N	ASP	A	15	39.676	58.734	-11.773	1.00	11.44	N
ATOM	113	CA	ASP	A	15	38.292	59.184	-11.365	1.00	11.52	C
ATOM	114	C	ASP	A	15	38.317	59.124	-9.828	1.00	11.40	C
ATOM	115	O	ASP	A	15	38.133	58.039	-9.252	1.00	11.41	O
ATOM	116	CB	ASP	A	15	37.286	58.227	-12.051	1.00	12.88	C
ATOM	117	CG	ASP	A	15	35.841	58.541	-11.736	1.00	14.20	C
ATOM	118	OD1	ASP	A	15	35.610	59.256	-10.714	1.00	14.70	O
ATOM	119	OD2	ASP	A	15	34.928	57.951	-12.453	1.00	15.80	O
ATOM	120	N	PHE	A	16	38.554	60.278	-9.244	1.00	10.09	N
ATOM	121	CA	PHE	A	16	38.659	60.281	-7.805	1.00	11.05	C
ATOM	122	C	PHE	A	16	37.341	59.995	-7.077	1.00	11.59	C
ATOM	123	O	PHE	A	16	37.351	59.448	-5.992	1.00	11.40	O
ATOM	124	CB	PHE	A	16	39.249	61.616	-7.323	1.00	11.37	C
ATOM	125	CG	PHE	A	16	40.718	61.820	-7.677	1.00	11.11	C
ATOM	126	CD1	PHE	A	16	41.704	61.279	-6.825	1.00	11.74	C
ATOM	127	CD2	PHE	A	16	41.132	62.532	-8.770	1.00	12.41	C
ATOM	128	CE1	PHE	A	16	43.085	61.433	-7.112	1.00	11.70	C
ATOM	129	CE2	PHE	A	16	42.497	62.680	-9.052	1.00	13.90	C
ATOM	130	CZ	PHE	A	16	43.449	62.084	-8.220	1.00	13.42	C
ATOM	131	N	ALA	A	17	36.210	60.423	-7.633	1.00	10.82	N
ATOM	132	CA	ALA	A	17	34.942	60.080	-6.953	1.00	10.30	C
ATOM	133	C	ALA	A	17	34.762	58.591	-6.902	1.00	10.11	C
ATOM	134	O	ALA	A	17	34.277	58.049	-5.895	1.00	10.36	O
ATOM	135	CB	ALA	A	17	33.746	60.751	-7.686	1.00	12.67	C
ATOM	136	N	ARG	A	18	35.133	57.873	-8.012	1.00	10.18	N
ATOM	137	CA	ARG	A	18	34.994	56.406	-8.040	1.00	10.65	C
ATOM	138	C	ARG	A	18	35.947	55.771	-7.012	1.00	9.47	C
ATOM	139	O	ARG	A	18	35.591	54.787	-6.340	1.00	10.53	O
ATOM	140	CB	ARG	A	18	35.152	55.848	-9.463	1.00	11.68	C
ATOM	141	CG	ARG	A	18	34.998	54.353	-9.601	1.00	14.84	C
ATOM	142	CD	ARG	A	18	34.934	54.019	-11.213	1.00	23.23	C
ATOM	143	NE	ARG	A	18	36.181	53.424	-11.776	1.00	30.81	N
ATOM	144	CZ	ARG	A	18	36.950	53.855	-12.782	1.00	34.84	C
ATOM	145	NH1	ARG	A	18	36.678	54.962	-13.481	1.00	48.07	N
ATOM	146	NH2	ARG	A	18	38.019	53.163	-13.085	1.00	40.89	N
ATOM	147	N	ALA	A	19	37.163	56.298	-6.954	1.00	10.43	N
ATOM	148	CA	ALA	A	19	38.146	55.747	-5.988	1.00	10.49	C
ATOM	149	C	ALA	A	19	37.667	55.912	-4.567	1.00	10.46	C
ATOM	150	O	ALA	A	19	37.767	54.993	-3.725	1.00	10.61	O
ATOM	151	CB	ALA	A	19	39.479	56.469	-6.136	1.00	10.90	C
ATOM	152	N	TYR	A	20	37.029	57.052	-4.248	1.00	10.33	N
ATOM	153	CA	TYR	A	20	36.422	57.215	-2.907	1.00	10.48	C
ATOM	154	C	TYR	A	20	35.265	56.297	-2.700	1.00	11.22	C
ATOM	155	O	TYR	A	20	35.116	55.728	-1.618	1.00	11.68	O
ATOM	156	CB	TYR	A	20	36.035	58.689	-2.734	1.00	12.04	C
ATOM	157	CG	TYR	A	20	35.701	59.112	-1.288	1.00	14.10	C
ATOM	158	CD1	TYR	A	20	34.468	58.942	-0.748	1.00	15.45	C
ATOM	159	CD2	TYR	A	20	36.664	59.661	-0.504	1.00	15.36	C

WO 2013/076253

PCT/EP2012/073483

7/34

ATOM	160	CE1	TYR	A	20	34.189	59.287	0.645	1.00	16.04	C
ATOM	161	CE2	TYR	A	20	36.487	60.077	0.853	1.00	16.71	C
ATOM	162	CZ	TYR	A	20	35.219	59.853	1.365	1.00	17.27	C
ATOM	163	OH	TYR	A	20	34.988	60.278	2.723	1.00	23.85	O
ATOM	164	N	ALA	A	21	34.406	56.159	-3.671	1.00	11.74	N
ATOM	165	CA	ALA	A	21	33.302	55.247	-3.572	1.00	12.52	C
ATOM	166	C	ALA	A	21	33.737	53.820	-3.344	1.00	12.22	C
ATOM	167	O	ALA	A	21	33.053	53.052	-2.659	1.00	16.36	O
ATOM	168	CB	ALA	A	21	32.430	55.347	-4.775	1.00	12.22	C
ATOM	169	N	ASN	A	22	34.904	53.431	-3.886	1.00	11.82	N
ATOM	170	CA	ASN	A	22	35.522	52.133	-3.713	1.00	12.76	C
ATOM	171	C	ASN	A	22	36.232	51.958	-2.376	1.00	13.30	C
ATOM	172	O	ASN	A	22	36.641	50.854	-2.066	1.00	15.52	O
ATOM	173	CB	ASN	A	22	36.466	51.834	-4.865	1.00	14.61	C
ATOM	174	CG	ASN	A	22	35.705	51.618	-6.187	1.00	16.35	C
ATOM	175	OD1	ASN	A	22	34.490	51.353	-6.250	1.00	20.40	O
ATOM	176	ND2	ASN	A	22	36.414	51.861	-7.277	1.00	17.12	N
ATOM	177	N	GLY	A	23	36.299	52.980	-1.533	1.00	12.79	N
ATOM	178	CA	GLY	A	23	36.765	52.872	-0.185	1.00	12.56	C
ATOM	179	C	GLY	A	23	38.124	53.522	0.057	1.00	11.65	C
ATOM	180	O	GLY	A	23	38.537	53.611	1.245	1.00	11.63	O
ATOM	181	N	ASP	A	24	38.819	54.020	-0.954	1.00	10.49	N
ATOM	182	CA	ASP	A	24	40.145	54.643	-0.719	1.00	9.49	C
ATOM	183	C	ASP	A	24	39.986	55.980	-0.062	1.00	10.28	C
ATOM	184	O	ASP	A	24	39.021	56.714	-0.358	1.00	10.02	O
ATOM	185	CB	ASP	A	24	40.852	54.758	-2.046	1.00	10.59	C
ATOM	186	CG	ASP	A	24	41.112	53.399	-2.627	1.00	13.93	C
ATOM	187	OD1	ASP	A	24	41.547	52.437	-1.896	1.00	18.04	O
ATOM	188	OD2	ASP	A	24	40.712	53.071	-3.756	1.00	16.80	O
ATOM	189	N	ARG	A	25	40.911	56.339	0.800	1.00	9.08	N
ATOM	190	CA	ARG	A	25	40.813	57.535	1.637	1.00	9.62	C
ATOM	191	C	ARG	A	25	41.960	58.453	1.565	1.00	9.30	C
ATOM	192	O	ARG	A	25	41.887	59.618	2.015	1.00	9.40	O
ATOM	193	CB	ARG	A	25	40.473	57.189	3.092	1.00	10.39	C
ATOM	194	CG	ARG	A	25	39.132	56.446	3.232	1.00	11.66	C
ATOM	195	CD	ARG	A	25	37.938	57.417	3.081	1.00	11.00	C
ATOM	196	NE	ARG	A	25	36.639	56.790	3.142	1.00	12.29	N
ATOM	197	CZ	ARG	A	25	35.958	56.372	2.101	1.00	14.10	C
ATOM	198	NH1	ARG	A	25	36.436	56.341	0.845	1.00	12.17	N
ATOM	199	NH2	ARG	A	25	34.709	55.929	2.338	1.00	16.43	N
ATOM	200	N	PHE	A	26	43.127	58.021	1.051	1.00	8.73	N
ATOM	201	CA	PHE	A	26	44.295	58.891	0.913	1.00	8.40	C
ATOM	202	C	PHE	A	26	44.974	58.552	-0.404	1.00	7.37	C
ATOM	203	O	PHE	A	26	44.852	57.486	-0.942	1.00	7.96	O
ATOM	204	CB	PHE	A	26	45.312	58.739	2.088	1.00	8.06	C
ATOM	205	CG	PHE	A	26	46.004	57.430	2.182	1.00	8.31	C
ATOM	206	CD1	PHE	A	26	45.454	56.316	2.857	1.00	8.64	C
ATOM	207	CD2	PHE	A	26	47.213	57.226	1.502	1.00	8.16	C
ATOM	208	CE1	PHE	A	26	46.057	55.113	2.870	1.00	8.11	C
ATOM	209	CE2	PHE	A	26	47.828	55.988	1.566	1.00	7.96	C
ATOM	210	CZ	PHE	A	26	47.259	54.952	2.208	1.00	8.94	C
ATOM	211	N	VAL	A	27	45.711	59.541	-0.850	1.00	7.64	N
ATOM	212	CA	VAL	A	27	46.523	59.460	-2.088	1.00	7.52	C
ATOM	213	C	VAL	A	27	47.777	60.260	-1.950	1.00	7.09	C

WO 2013/076253

PCT/EP2012/073483

8/34

ATOM	214	O	VAL	A	27	47.736	61.420	-1.473	1.00	7.98	O
ATOM	215	CB	VAL	A	27	45.672	59.836	-3.363	1.00	8.09	C
ATOM	216	CG1	VAL	A	27	45.209	61.270	-3.329	1.00	9.41	C
ATOM	217	CG2	VAL	A	27	46.439	59.558	-4.636	1.00	8.80	C
ATOM	218	N	TYR	A	28	48.912	59.673	-2.384	1.00	6.71	N
ATOM	219	CA	TYR	A	28	50.151	60.394	-2.591	1.00	6.84	C
ATOM	220	C	TYR	A	28	50.405	60.653	-4.094	1.00	6.78	C
ATOM	221	O	TYR	A	28	50.158	59.758	-4.896	1.00	7.27	O
ATOM	222	CB	TYR	A	28	51.346	59.630	-1.977	1.00	6.78	C
ATOM	223	CG	TYR	A	28	51.710	60.032	-0.589	1.00	7.16	C
ATOM	224	CD1	TYR	A	28	52.347	61.208	-0.337	1.00	7.34	C
ATOM	225	CD2	TYR	A	28	51.441	59.201	0.522	1.00	8.73	C
ATOM	226	CE1	TYR	A	28	52.708	61.598	0.963	1.00	8.65	C
ATOM	227	CE2	TYR	A	28	51.785	59.579	1.844	1.00	8.71	C
ATOM	228	CZ	TYR	A	28	52.366	60.802	2.039	1.00	8.09	C
ATOM	229	OH	TYR	A	28	52.719	61.123	3.352	1.00	8.81	O
ATOM	230	N	ILE	A	29	50.843	61.880	-4.393	1.00	6.84	N
ATOM	231	CA	ILE	A	29	50.945	62.326	-5.779	1.00	7.10	C
ATOM	232	C	ILE	A	29	52.325	62.843	-6.004	1.00	7.10	C
ATOM	233	O	ILE	A	29	52.832	63.699	-5.292	1.00	7.44	O
ATOM	234	CB	ILE	A	29	49.869	63.466	-5.998	1.00	8.00	C
ATOM	235	CG1	ILE	A	29	48.478	62.905	-5.783	1.00	9.18	C
ATOM	236	CG2	ILE	A	29	50.010	63.992	-7.409	1.00	9.33	C
ATOM	237	CD1	ILE	A	29	47.377	63.959	-5.554	1.00	10.36	C
ATOM	238	N	LYS	A	30	52.965	62.384	-7.106	1.00	7.18	N
ATOM	239	CA	LYS	A	30	54.313	62.873	-7.399	1.00	7.93	C
ATOM	240	C	LYS	A	30	54.294	64.353	-7.720	1.00	6.65	C
ATOM	241	O	LYS	A	30	53.529	64.811	-8.594	1.00	7.95	O
ATOM	242	CB	LYS	A	30	54.933	62.102	-8.573	1.00	8.53	C
ATOM	243	CG	LYS	A	30	56.411	62.529	-8.763	1.00	8.68	C
ATOM	244	CD	LYS	A	30	57.124	61.691	-9.829	1.00	10.14	C
ATOM	245	CE	LYS	A	30	58.566	62.101	-9.952	1.00	10.51	C
ATOM	246	NZ	LYS	A	30	59.248	61.184	-10.900	1.00	12.74	N
ATOM	247	N	ALA	A	31	55.160	65.127	-7.085	1.00	6.98	N
ATOM	248	CA	ALA	A	31	55.316	66.568	-7.357	1.00	6.99	C
ATOM	249	C	ALA	A	31	56.630	66.827	-8.135	1.00	7.25	C
ATOM	250	O	ALA	A	31	56.592	67.558	-9.167	1.00	7.98	O
ATOM	251	CB	ALA	A	31	55.321	67.387	-6.030	1.00	8.06	C
ATOM	252	N	THR	A	32	57.741	66.364	-7.654	1.00	7.88	N
ATOM	253	CA	THR	A	32	59.065	66.755	-8.127	1.00	7.82	C
ATOM	254	C	THR	A	32	60.043	65.615	-8.162	1.00	7.57	C
ATOM	255	O	THR	A	32	59.849	64.549	-7.503	1.00	7.69	O
ATOM	256	CB	THR	A	32	59.646	67.885	-7.237	1.00	8.16	C
ATOM	257	OG1	THR	A	32	59.569	67.515	-5.842	1.00	8.19	O
ATOM	258	CG2	THR	A	32	58.914	69.212	-7.370	1.00	8.81	C
ATOM	259	N	GLU	A	33	61.155	65.868	-8.861	1.00	8.03	N
ATOM	260	CA	GLU	A	33	62.303	64.921	-8.924	1.00	8.40	C
ATOM	261	C	GLU	A	33	63.566	65.730	-9.100	1.00	7.99	C
ATOM	262	O	GLU	A	33	63.578	66.650	-9.949	1.00	8.75	O
ATOM	263	CB	GLU	A	33	62.096	63.857	-9.962	1.00	8.41	C
ATOM	264	CG	GLU	A	33	63.382	63.017	-10.282	1.00	9.83	C
ATOM	265	CD	GLU	A	33	63.078	61.833	-11.199	1.00	11.04	C
ATOM	266	OE1	GLU	A	33	61.935	61.561	-11.616	1.00	12.71	O
ATOM	267	OE2	GLU	A	33	64.090	61.140	-11.563	1.00	12.87	O

WO 2013/076253

PCT/EP2012/073483

9/34

ATOM	268	N	GLY	A	34	64.620	65.462	-8.339	1.00	8.64	N
ATOM	269	CA	GLY	A	34	65.806	66.261	-8.451	1.00	9.33	C
ATOM	270	C	GLY	A	34	65.514	67.729	-8.235	1.00	9.27	C
ATOM	271	O	GLY	A	34	64.733	68.054	-7.361	1.00	9.88	O
ATOM	272	N	THR	A	35	66.166	68.617	-9.042	1.00	10.45	N
ATOM	273	CA	THR	A	35	65.884	70.091	-8.985	1.00	11.61	C
ATOM	274	C	THR	A	35	65.428	70.537	-10.344	1.00	10.50	C
ATOM	275	O	THR	A	35	65.403	71.751	-10.571	1.00	12.74	O
ATOM	276	CB	THR	A	35	67.050	70.910	-8.499	1.00	14.11	C
ATOM	277	OG1	THR	A	35	68.088	70.721	-9.469	1.00	17.47	O
ATOM	278	CG2	THR	A	35	67.504	70.495	-7.098	1.00	15.95	C
ATOM	279	N	THR	A	36	65.031	69.659	-11.248	1.00	10.56	N
ATOM	280	CA	THR	A	36	64.638	70.030	-12.610	1.00	10.84	C
ATOM	281	C	THR	A	36	63.337	69.440	-13.069	1.00	10.02	C
ATOM	282	O	THR	A	36	62.860	69.810	-14.164	1.00	11.69	O
ATOM	283	CB	THR	A	36	65.734	69.544	-13.614	1.00	14.27	C
ATOM	284	OG1	THR	A	36	65.972	68.132	-13.394	1.00	18.68	O
ATOM	285	CG2	THR	A	36	67.007	70.208	-13.386	1.00	14.24	C
ATOM	286	N	PHE	A	37	62.713	68.489	-12.388	1.00	8.31	N
ATOM	287	CA	PHE	A	37	61.522	67.825	-12.834	1.00	8.29	C
ATOM	288	C	PHE	A	37	60.305	68.305	-11.963	1.00	7.94	C
ATOM	289	O	PHE	A	37	60.361	68.060	-10.688	1.00	8.28	O
ATOM	290	CB	PHE	A	37	61.701	66.278	-12.686	1.00	8.53	C
ATOM	291	CG	PHE	A	37	60.563	65.432	-13.132	1.00	8.21	C
ATOM	292	CD1	PHE	A	37	59.421	65.297	-12.366	1.00	8.63	C
ATOM	293	CD2	PHE	A	37	60.616	64.726	-14.319	1.00	9.40	C
ATOM	294	CE1	PHE	A	37	58.396	64.491	-12.754	1.00	10.26	C
ATOM	295	CE2	PHE	A	37	59.606	63.899	-14.740	1.00	10.70	C
ATOM	296	CZ	PHE	A	37	58.456	63.790	-14.000	1.00	10.11	C
ATOM	297	N	LYS	A	38	59.287	68.793	-12.602	1.00	8.29	N
ATOM	298	CA	LYS	A	38	57.997	69.034	-11.968	1.00	8.93	C
ATOM	299	C	LYS	A	38	56.992	68.183	-12.684	1.00	9.42	C
ATOM	300	O	LYS	A	38	56.937	68.223	-13.970	1.00	9.23	O
ATOM	301	CB	LYS	A	38	57.583	70.514	-12.032	1.00	10.78	C
ATOM	302	CG	LYS	A	38	58.503	71.386	-11.282	1.00	12.80	C
ATOM	303	CD	LYS	A	38	58.201	72.872	-11.390	1.00	15.66	C
ATOM	304	CE	LYS	A	38	59.365	73.752	-10.958	1.00	17.50	C
ATOM	305	NZ	LYS	A	38	58.902	75.226	-10.967	1.00	21.11	N
ATOM	306	N	SER	A	39	56.149	67.405	-12.036	1.00	9.85	N
ATOM	307	CA	SER	A	39	55.181	66.602	-12.705	1.00	9.58	C
ATOM	308	C	SER	A	39	54.119	67.453	-13.368	1.00	11.30	C
ATOM	309	O	SER	A	39	53.433	68.263	-12.736	1.00	11.78	O
ATOM	310	CB	SER	A	39	54.456	65.665	-11.706	1.00	10.00	C
ATOM	311	OG	SER	A	39	53.377	65.029	-12.406	1.00	10.74	O
ATOM	312	N	ASER	A	40	53.962	67.232	-14.671	0.50	12.53	N
ATOM	313	CA	ASER	A	40	52.919	67.883	-15.449	0.50	14.89	C
ATOM	314	C	ASER	A	40	51.514	67.620	-14.930	0.50	14.99	C
ATOM	315	O	ASER	A	40	50.632	68.492	-15.133	0.50	17.47	O
ATOM	316	CB	ASER	A	40	53.036	67.513	-16.952	0.50	15.44	C
ATOM	317	OG	ASER	A	40	54.361	67.827	-17.384	0.50	20.11	O
ATOM	318	N	ALA	A	41	51.280	66.476	-14.289	1.00	12.70	N
ATOM	319	CA	ALA	A	41	49.982	66.046	-13.829	1.00	12.26	C
ATOM	320	C	ALA	A	41	49.666	66.521	-12.416	1.00	11.43	C
ATOM	321	O	ALA	A	41	48.529	66.371	-11.953	1.00	12.05	O

WO 2013/076253

PCT/EP2012/073483

10/34

ATOM	322	CB	ALA	A	41	49.872	64.528	-13.888	1.00	13.05	C
ATOM	323	N	PHE	A	42	50.618	67.045	-11.671	1.00	10.49	N
ATOM	324	CA	PHE	A	42	50.443	67.257	-10.214	1.00	9.59	C
ATOM	325	C	PHE	A	42	49.239	68.120	-9.941	1.00	11.41	C
ATOM	326	O	PHE	A	42	48.420	67.813	-9.068	1.00	11.27	O
ATOM	327	CB	PHE	A	42	51.681	67.912	-9.603	1.00	10.98	C
ATOM	328	CG	PHE	A	42	51.522	68.233	-8.130	1.00	10.34	C
ATOM	329	CD1	PHE	A	42	51.701	67.285	-7.160	1.00	11.18	C
ATOM	330	CD2	PHE	A	42	51.145	69.510	-7.719	1.00	13.14	C
ATOM	331	CE1	PHE	A	42	51.492	67.596	-5.817	1.00	13.91	C
ATOM	332	CE2	PHE	A	42	50.936	69.819	-6.411	1.00	13.48	C
ATOM	333	CZ	PHE	A	42	51.092	68.874	-5.494	1.00	13.70	C
ATOM	334	N	SER	A	43	49.127	69.256	-10.633	1.00	13.53	N
ATOM	335	CA	SER	A	43	47.997	70.142	-10.322	1.00	14.92	C
ATOM	336	C	SER	A	43	46.624	69.521	-10.540	1.00	13.71	C
ATOM	337	O	SER	A	43	45.781	69.583	-9.632	1.00	15.47	O
ATOM	338	CB	SER	A	43	48.103	71.449	-11.166	1.00	19.52	C
ATOM	339	OG	SER	A	43	49.222	72.180	-10.707	1.00	27.08	O
ATOM	340	N	ARG	A	44	46.420	68.872	-11.641	1.00	14.34	N
ATOM	341	CA	ARG	A	44	45.188	68.224	-11.908	1.00	14.39	C
ATOM	342	C	ARG	A	44	44.879	67.216	-10.809	1.00	12.69	C
ATOM	343	O	ARG	A	44	43.722	67.019	-10.369	1.00	13.11	O
ATOM	344	CB	ARG	A	44	45.201	67.548	-13.309	1.00	17.32	C
ATOM	345	CG	ARG	A	44	43.963	66.837	-13.715	1.00	26.99	C
ATOM	346	CD	ARG	A	44	44.270	66.143	-15.064	1.00	28.55	C
ATOM	347	NE	ARG	A	44	45.125	64.951	-14.966	1.00	28.03	N
ATOM	348	CZ	ARG	A	44	46.316	64.697	-15.495	1.00	25.87	C
ATOM	349	NH1	ARG	A	44	47.036	65.597	-16.196	1.00	34.97	N
ATOM	350	NH2	ARG	A	44	46.795	63.452	-15.193	1.00	23.94	N
ATOM	351	N	GLN	A	45	45.907	66.412	-10.474	1.00	11.98	N
ATOM	352	CA	GLN	A	45	45.676	65.276	-9.541	1.00	10.58	C
ATOM	353	C	GLN	A	45	45.412	65.786	-8.120	1.00	10.24	C
ATOM	354	O	GLN	A	45	44.532	65.282	-7.451	1.00	10.44	O
ATOM	355	CB	GLN	A	45	46.968	64.421	-9.615	1.00	10.20	C
ATOM	356	CG	GLN	A	45	47.025	63.669	-10.921	1.00	10.26	C
ATOM	357	CD	GLN	A	45	48.355	62.882	-11.125	1.00	10.50	C
ATOM	358	OE1	GLN	A	45	49.374	63.303	-10.607	1.00	11.51	O
ATOM	359	NE2	GLN	A	45	48.336	61.804	-11.881	1.00	11.82	N
ATOM	360	N	TYR	A	46	46.177	66.756	-7.693	1.00	9.68	N
ATOM	361	CA	TYR	A	46	46.029	67.242	-6.343	1.00	10.74	C
ATOM	362	C	TYR	A	46	44.729	67.984	-6.153	1.00	13.00	C
ATOM	363	O	TYR	A	46	44.033	67.815	-5.133	1.00	12.53	O
ATOM	364	CB	TYR	A	46	47.218	68.113	-5.975	1.00	13.28	C
ATOM	365	CG	TYR	A	46	47.588	68.288	-4.522	1.00	12.16	C
ATOM	366	CD1	TYR	A	46	48.513	67.480	-3.834	1.00	14.68	C
ATOM	367	CD2	TYR	A	46	47.131	69.386	-3.826	1.00	15.86	C
ATOM	368	CE1	TYR	A	46	48.891	67.729	-2.491	1.00	13.30	C
ATOM	369	CE2	TYR	A	46	47.530	69.692	-2.538	1.00	17.31	C
ATOM	370	CZ	TYR	A	46	48.434	68.888	-1.881	1.00	14.36	C
ATOM	371	OH	TYR	A	46	48.872	69.220	-0.585	1.00	16.96	O
ATOM	372	N	THR	A	47	44.294	68.671	-7.222	1.00	13.41	N
ATOM	373	CA	THR	A	47	42.979	69.342	-7.107	1.00	14.05	C
ATOM	374	C	THR	A	47	41.861	68.331	-7.133	1.00	13.35	C
ATOM	375	O	THR	A	47	40.874	68.438	-6.361	1.00	13.78	O

WO 2013/076253

PCT/EP2012/073483

11/34

ATOM	376	CB	THR	A	47	42.809	70.361	-8.274	1.00	16.18	C
ATOM	377	OG1	THR	A	47	43.801	71.395	-8.081	1.00	19.42	O
ATOM	378	CG2	THR	A	47	41.382	70.993	-8.245	1.00	17.40	C
ATOM	379	N	GLY	A	48	41.938	67.307	-7.992	1.00	13.17	N
ATOM	380	CA	GLY	A	48	40.923	66.258	-8.042	1.00	12.41	C
ATOM	381	C	GLY	A	48	40.774	65.502	-6.729	1.00	12.70	C
ATOM	382	O	GLY	A	48	39.671	65.185	-6.266	1.00	12.69	O
ATOM	383	N	ALA	A	49	41.917	65.174	-6.110	1.00	10.75	N
ATOM	384	CA	ALA	A	49	41.896	64.561	-4.815	1.00	10.58	C
ATOM	385	C	ALA	A	49	41.183	65.451	-3.793	1.00	10.40	C
ATOM	386	O	ALA	A	49	40.333	65.007	-3.033	1.00	11.39	O
ATOM	387	CB	ALA	A	49	43.319	64.230	-4.352	1.00	10.62	C
ATOM	388	N	THR	A	50	41.562	66.728	-3.803	1.00	11.17	N
ATOM	389	CA	THR	A	50	41.002	67.675	-2.807	1.00	11.82	C
ATOM	390	C	THR	A	50	39.476	67.809	-2.948	1.00	11.99	C
ATOM	391	O	THR	A	50	38.783	67.725	-1.934	1.00	12.56	O
ATOM	392	CB	THR	A	50	41.651	69.042	-3.024	1.00	12.51	C
ATOM	393	OG1	THR	A	50	43.055	68.971	-2.897	1.00	12.48	O
ATOM	394	CG2	THR	A	50	41.140	70.091	-2.003	1.00	13.54	C
ATOM	395	N	GLN	A	51	38.981	67.889	-4.170	1.00	11.41	N
ATOM	396	CA	GLN	A	51	37.578	68.138	-4.451	1.00	12.92	C
ATOM	397	C	GLN	A	51	36.759	66.932	-4.273	1.00	13.68	C
ATOM	398	O	GLN	A	51	35.521	67.063	-4.280	1.00	16.91	O
ATOM	399	CB	GLN	A	51	37.460	68.681	-5.875	1.00	14.43	C
ATOM	400	CG	GLN	A	51	37.952	70.110	-6.048	1.00	15.58	C
ATOM	401	CD	GLN	A	51	38.029	70.579	-7.542	1.00	17.76	C
ATOM	402	OE1	GLN	A	51	37.966	69.736	-8.486	1.00	20.81	O
ATOM	403	NE2	GLN	A	51	38.159	71.876	-7.775	1.00	16.97	N
ATOM	404	N	ASN	A	52	37.327	65.705	-4.102	1.00	13.02	N
ATOM	405	CA	ASN	A	52	36.614	64.491	-3.958	1.00	12.89	C
ATOM	406	C	ASN	A	52	36.798	63.806	-2.579	1.00	12.65	C
ATOM	407	O	ASN	A	52	36.557	62.658	-2.416	1.00	14.41	O
ATOM	408	CB	ASN	A	52	36.873	63.546	-5.140	1.00	13.03	C
ATOM	409	CG	ASN	A	52	36.279	64.053	-6.392	1.00	13.74	C
ATOM	410	OD1	ASN	A	52	35.033	63.896	-6.528	1.00	15.81	O
ATOM	411	ND2	ASN	A	52	37.048	64.728	-7.209	1.00	13.49	N
ATOM	412	N	GLY	A	53	37.217	64.572	-1.608	1.00	12.97	N
ATOM	413	CA	GLY	A	53	37.214	64.181	-0.208	1.00	14.24	C
ATOM	414	C	GLY	A	53	38.449	63.450	0.319	1.00	12.69	C
ATOM	415	O	GLY	A	53	38.432	62.875	1.418	1.00	13.69	O
ATOM	416	N	PHE	A	54	39.530	63.411	-0.477	1.00	11.36	N
ATOM	417	CA	PHE	A	54	40.763	62.714	-0.049	1.00	10.23	C
ATOM	418	C	PHE	A	54	41.595	63.478	0.904	1.00	10.21	C
ATOM	419	O	PHE	A	54	41.666	64.722	0.845	1.00	11.35	O
ATOM	420	CB	PHE	A	54	41.597	62.343	-1.300	1.00	10.42	C
ATOM	421	CG	PHE	A	54	41.154	61.146	-2.004	1.00	9.27	C
ATOM	422	CD1	PHE	A	54	40.114	61.141	-2.980	1.00	10.98	C
ATOM	423	CD2	PHE	A	54	41.689	59.918	-1.658	1.00	9.96	C
ATOM	424	CE1	PHE	A	54	39.670	59.988	-3.515	1.00	11.65	C
ATOM	425	CE2	PHE	A	54	41.273	58.774	-2.198	1.00	10.85	C
ATOM	426	CZ	PHE	A	54	40.214	58.768	-3.095	1.00	11.71	C
ATOM	427	N	ILE	A	55	42.268	62.750	1.811	1.00	10.66	N
ATOM	428	CA	ILE	A	55	43.455	63.198	2.456	1.00	9.81	C
ATOM	429	C	ILE	A	55	44.617	62.960	1.428	1.00	9.43	C

WO 2013/076253

PCT/EP2012/073483

12/34

ATOM	430	O	ILE	A	55	44.603	61.884	0.778	1.00	10.35	O
ATOM	431	CB	ILE	A	55	43.690	62.478	3.775	1.00	10.15	C
ATOM	432	CG1	ILE	A	55	42.563	62.795	4.768	1.00	10.78	C
ATOM	433	CG2	ILE	A	55	45.068	62.662	4.339	1.00	10.81	C
ATOM	434	CD1	ILE	A	55	42.526	61.905	6.001	1.00	13.46	C
ATOM	435	N	ARG	A	56	45.465	63.910	1.221	1.00	8.57	N
ATOM	436	CA	ARG	A	56	46.534	63.782	0.176	1.00	8.89	C
ATOM	437	C	ARG	A	56	47.782	64.321	0.606	1.00	8.31	C
ATOM	438	O	ARG	A	56	47.876	65.214	1.463	1.00	9.60	O
ATOM	439	CB	ARG	A	56	46.003	64.366	-1.180	1.00	9.99	C
ATOM	440	CG	ARG	A	56	45.898	65.862	-1.164	1.00	10.71	C
ATOM	441	CD	ARG	A	56	44.544	66.392	-0.619	1.00	11.99	C
ATOM	442	NE	ARG	A	56	44.419	67.858	-0.810	1.00	12.28	N
ATOM	443	CZ	ARG	A	56	44.984	68.769	-0.089	1.00	12.95	C
ATOM	444	NH1	ARG	A	56	45.689	68.469	1.015	1.00	15.22	N
ATOM	445	NH2	ARG	A	56	44.859	70.065	-0.454	1.00	15.44	N
ATOM	446	N	GLY	A	57	48.839	63.809	-0.015	1.00	8.65	N
ATOM	447	CA	GLY	A	57	50.142	64.312	0.122	1.00	8.60	C
ATOM	448	C	GLY	A	57	50.926	64.282	-1.202	1.00	7.17	C
ATOM	449	O	GLY	A	57	50.463	63.681	-2.175	1.00	8.31	O
ATOM	450	N	ALA	A	58	52.077	64.871	-1.231	1.00	7.08	N
ATOM	451	CA	ALA	A	58	52.975	64.892	-2.381	1.00	7.20	C
ATOM	452	C	ALA	A	58	54.197	64.068	-2.082	1.00	6.30	C
ATOM	453	O	ALA	A	58	54.594	63.918	-0.903	1.00	7.74	O
ATOM	454	CB	ALA	A	58	53.341	66.359	-2.665	1.00	7.44	C
ATOM	455	N	TYR	A	59	54.920	63.670	-3.121	1.00	7.40	N
ATOM	456	CA	TYR	A	59	56.224	63.016	-2.954	1.00	7.03	C
ATOM	457	C	TYR	A	59	57.260	63.549	-3.940	1.00	6.98	C
ATOM	458	O	TYR	A	59	56.939	64.110	-5.032	1.00	7.63	O
ATOM	459	CB	TYR	A	59	56.116	61.480	-2.956	1.00	6.99	C
ATOM	460	CG	TYR	A	59	55.866	60.785	-4.257	1.00	7.40	C
ATOM	461	CD1	TYR	A	59	56.927	60.434	-5.097	1.00	8.03	C
ATOM	462	CD2	TYR	A	59	54.600	60.367	-4.642	1.00	8.44	C
ATOM	463	CE1	TYR	A	59	56.703	59.715	-6.242	1.00	9.40	C
ATOM	464	CE2	TYR	A	59	54.368	59.643	-5.832	1.00	8.72	C
ATOM	465	CZ	TYR	A	59	55.436	59.293	-6.599	1.00	9.24	C
ATOM	466	OH	TYR	A	59	55.278	58.555	-7.768	1.00	10.37	O
ATOM	467	N	HIS	A	60	58.492	63.403	-3.523	1.00	7.37	N
ATOM	468	CA	HIS	A	60	59.683	63.847	-4.241	1.00	7.12	C
ATOM	469	C	HIS	A	60	60.552	62.654	-4.561	1.00	7.27	C
ATOM	470	O	HIS	A	60	60.915	61.897	-3.631	1.00	7.70	O
ATOM	471	CB	HIS	A	60	60.496	64.780	-3.304	1.00	7.33	C
ATOM	472	CG	HIS	A	60	61.765	65.224	-3.987	1.00	7.71	C
ATOM	473	ND1	HIS	A	60	63.031	64.786	-3.800	1.00	9.42	N
ATOM	474	CD2	HIS	A	60	61.807	66.224	-4.949	1.00	5.89	C
ATOM	475	CE1	HIS	A	60	63.852	65.474	-4.644	1.00	6.33	C
ATOM	476	NE2	HIS	A	60	63.075	66.329	-5.333	1.00	9.96	N
ATOM	477	N	PHE	A	61	60.941	62.471	-5.838	1.00	7.07	N
ATOM	478	CA	PHE	A	61	61.919	61.380	-6.196	1.00	7.73	C
ATOM	479	C	PHE	A	61	63.313	61.917	-5.990	1.00	8.06	C
ATOM	480	O	PHE	A	61	63.806	62.840	-6.730	1.00	8.29	O
ATOM	481	CB	PHE	A	61	61.653	60.892	-7.605	1.00	8.46	C
ATOM	482	CG	PHE	A	61	62.409	59.595	-7.885	1.00	9.48	C
ATOM	483	CD1	PHE	A	61	63.697	59.600	-8.288	1.00	9.86	C

WO 2013/076253

PCT/EP2012/073483

13/34

ATOM	484	CD2	PHE	A	61	61.808	58.377	-7.727	1.00	11.77	C
ATOM	485	CE1	PHE	A	61	64.427	58.372	-8.499	1.00	11.94	C
ATOM	486	CE2	PHE	A	61	62.502	57.172	-7.957	1.00	14.50	C
ATOM	487	CZ	PHE	A	61	63.793	57.190	-8.354	1.00	13.51	C
ATOM	488	N	ALA	A	62	64.031	61.405	-5.027	1.00	7.50	N
ATOM	489	CA	ALA	A	62	65.368	61.827	-4.701	1.00	7.69	C
ATOM	490	C	ALA	A	62	66.375	61.550	-5.821	1.00	7.43	C
ATOM	491	O	ALA	A	62	66.386	60.441	-6.406	1.00	8.44	O
ATOM	492	CB	ALA	A	62	65.860	61.137	-3.434	1.00	8.22	C
ATOM	493	N	GLN	A	63	67.273	62.489	-6.048	1.00	7.84	N
ATOM	494	CA	GLN	A	63	68.416	62.316	-6.955	1.00	8.62	C
ATOM	495	C	GLN	A	63	69.675	62.734	-6.225	1.00	8.31	C
ATOM	496	O	GLN	A	63	70.136	63.896	-6.332	1.00	9.41	O
ATOM	497	CB	GLN	A	63	68.203	63.093	-8.255	1.00	8.63	C
ATOM	498	CG	GLN	A	63	67.154	62.493	-9.170	1.00	9.33	C
ATOM	499	CD	GLN	A	63	67.639	61.242	-9.873	1.00	10.45	C
ATOM	500	OE1	GLN	A	63	68.806	60.810	-9.717	1.00	11.19	O
ATOM	501	NE2	GLN	A	63	66.771	60.645	-10.638	1.00	10.88	N
ATOM	502	N	PRO	A	64	70.231	61.866	-5.327	1.00	8.85	N
ATOM	503	CA	PRO	A	64	71.231	62.330	-4.420	1.00	9.41	C
ATOM	504	C	PRO	A	64	72.537	62.793	-5.002	1.00	10.50	C
ATOM	505	O	PRO	A	64	73.287	63.475	-4.306	1.00	12.39	O
ATOM	506	CB	PRO	A	64	71.455	61.132	-3.482	1.00	9.98	C
ATOM	507	CG	PRO	A	64	70.084	60.427	-3.471	1.00	10.74	C
ATOM	508	CD	PRO	A	64	69.707	60.540	-4.924	1.00	8.09	C
ATOM	509	N	ALA	A	65	72.847	62.402	-6.219	1.00	10.10	N
ATOM	510	CA	ALA	A	65	74.089	62.879	-6.860	1.00	12.06	C
ATOM	511	C	ALA	A	65	73.875	64.199	-7.558	1.00	12.89	C
ATOM	512	O	ALA	A	65	74.882	64.803	-7.956	1.00	14.94	O
ATOM	513	CB	ALA	A	65	74.605	61.838	-7.843	1.00	12.78	C
ATOM	514	N	ALA	A	66	72.676	64.694	-7.721	1.00	12.07	N
ATOM	515	CA	ALA	A	66	72.405	65.878	-8.562	1.00	13.09	C
ATOM	516	C	ALA	A	66	72.550	67.168	-7.837	1.00	12.42	C
ATOM	517	O	ALA	A	66	72.813	68.242	-8.477	1.00	16.34	O
ATOM	518	CB	ALA	A	66	71.040	65.752	-9.214	1.00	13.65	C
ATOM	519	N	ASER	A	67	72.330	67.190	-6.523	0.50	11.82	N
ATOM	520	CA	ASER	A	67	72.331	68.432	-5.685	0.50	12.07	C
ATOM	521	C	ASER	A	67	72.345	68.041	-4.250	0.50	12.63	C
ATOM	522	O	ASER	A	67	72.215	66.848	-3.953	0.50	13.69	O
ATOM	523	CB	ASER	A	67	71.077	69.297	-5.864	0.50	12.18	C
ATOM	524	OG	ASER	A	67	69.993	68.703	-5.109	0.50	10.79	O
ATOM	525	N	SER	A	68	72.365	68.995	-3.367	1.00	12.46	N
ATOM	526	CA	SER	A	68	72.256	68.701	-1.943	1.00	12.29	C
ATOM	527	C	SER	A	68	70.806	68.252	-1.604	1.00	10.64	C
ATOM	528	O	SER	A	68	69.893	68.537	-2.242	1.00	10.44	O
ATOM	529	CB	SER	A	68	72.637	69.937	-1.126	1.00	12.11	C
ATOM	530	OG	SER	A	68	71.660	70.955	-1.274	1.00	12.58	O
ATOM	531	N	GLY	A	69	70.718	67.665	-0.426	1.00	10.53	N
ATOM	532	CA	GLY	A	69	69.422	67.280	0.159	1.00	10.03	C
ATOM	533	C	GLY	A	69	68.597	68.530	0.430	1.00	9.69	C
ATOM	534	O	GLY	A	69	67.391	68.575	0.228	1.00	9.99	O
ATOM	535	N	ALA	A	70	69.278	69.583	0.950	1.00	10.62	N
ATOM	536	CA	ALA	A	70	68.593	70.834	1.246	1.00	10.71	C
ATOM	537	C	ALA	A	70	67.978	71.458	0.005	1.00	9.81	C

WO 2013/076253

PCT/EP2012/073483

14/34

ATOM	538	O	ALA	A	70	66.871	71.945	0.005	1.00	10.60	O
ATOM	539	CB	ALA	A	70	69.532	71.841	1.903	1.00	11.75	C
ATOM	540	N	ALA	A	71	68.752	71.464	-1.107	1.00	11.21	N
ATOM	541	CA	ALA	A	71	68.252	72.058	-2.377	1.00	9.99	C
ATOM	542	C	ALA	A	71	66.961	71.342	-2.826	1.00	9.58	C
ATOM	543	O	ALA	A	71	66.033	71.923	-3.336	1.00	9.64	O
ATOM	544	CB	ALA	A	71	69.344	71.975	-3.445	1.00	11.87	C
ATOM	545	N	GLN	A	72	66.959	69.984	-2.702	1.00	8.82	N
ATOM	546	CA	GLN	A	72	65.807	69.221	-3.134	1.00	7.95	C
ATOM	547	C	GLN	A	72	64.612	69.414	-2.198	1.00	8.37	C
ATOM	548	O	GLN	A	72	63.495	69.416	-2.647	1.00	8.69	O
ATOM	549	CB	GLN	A	72	66.215	67.762	-3.360	1.00	8.44	C
ATOM	550	CG	GLN	A	72	66.941	67.634	-4.725	1.00	8.49	C
ATOM	551	CD	GLN	A	72	67.419	66.267	-5.096	1.00	8.50	C
ATOM	552	OE1	GLN	A	72	66.699	65.238	-5.012	1.00	8.67	O
ATOM	553	NE2	GLN	A	72	68.639	66.212	-5.600	1.00	8.56	N
ATOM	554	N	ALA	A	73	64.873	69.514	-0.899	1.00	8.14	N
ATOM	555	CA	ALA	A	73	63.762	69.801	0.048	1.00	8.54	C
ATOM	556	C	ALA	A	73	63.072	71.122	-0.307	1.00	9.19	C
ATOM	557	O	ALA	A	73	61.864	71.249	-0.280	1.00	9.52	O
ATOM	558	CB	ALA	A	73	64.227	69.753	1.483	1.00	9.22	C
ATOM	559	N	AARG	A	74	63.946	72.136	-0.555	0.25	9.52	N
ATOM	560	CA	AARG	A	74	63.524	73.494	-0.944	0.25	10.04	C
ATOM	561	C	AARG	A	74	62.648	73.411	-2.252	0.25	9.46	C
ATOM	562	O	AARG	A	74	61.561	73.976	-2.326	0.25	10.40	O
ATOM	563	CB	AARG	A	74	64.741	74.503	-1.104	0.25	10.43	C
ATOM	564	CG	AARG	A	74	65.611	74.930	0.119	0.25	10.76	C
ATOM	565	CD	AARG	A	74	66.880	75.785	-0.324	0.25	10.41	C
ATOM	566	NE	AARG	A	74	67.968	75.710	0.602	0.25	10.51	N
ATOM	567	CZ	AARG	A	74	69.232	75.390	0.351	0.25	12.61	C
ATOM	568	NH1AARG	A	74	69.668	75.022	-0.830	0.25	13.39	N	
ATOM	569	NH2AARG	A	74	70.076	75.494	1.324	0.25	14.84	N	
ATOM	570	N	TYR	A	75	63.109	72.693	-3.284	1.00	9.11	N
ATOM	571	CA	TYR	A	75	62.435	72.577	-4.550	1.00	9.25	C
ATOM	572	C	TYR	A	75	61.096	71.861	-4.422	1.00	9.01	C
ATOM	573	O	TYR	A	75	60.084	72.266	-4.991	1.00	9.17	O
ATOM	574	CB	TYR	A	75	63.344	71.842	-5.559	1.00	10.49	C
ATOM	575	CG	TYR	A	75	62.884	71.775	-6.986	1.00	10.09	C
ATOM	576	CD1	TYR	A	75	62.961	72.916	-7.838	1.00	12.15	C
ATOM	577	CD2	TYR	A	75	62.446	70.571	-7.583	1.00	10.31	C
ATOM	578	CE1	TYR	A	75	62.594	72.834	-9.170	1.00	11.74	C
ATOM	579	CE2	TYR	A	75	62.099	70.496	-8.900	1.00	11.50	C
ATOM	580	CZ	TYR	A	75	62.207	71.633	-9.701	1.00	10.99	C
ATOM	581	OH	TYR	A	75	61.881	71.455	-11.025	1.00	13.76	O
ATOM	582	N	PHE	A	76	61.094	70.746	-3.671	1.00	9.00	N
ATOM	583	CA	PHE	A	76	59.869	70.019	-3.403	1.00	8.68	C
ATOM	584	C	PHE	A	76	58.807	70.920	-2.679	1.00	8.88	C
ATOM	585	O	PHE	A	76	57.688	70.967	-3.070	1.00	9.01	O
ATOM	586	CB	PHE	A	76	60.233	68.785	-2.558	1.00	9.06	C
ATOM	587	CG	PHE	A	76	59.069	67.938	-2.067	1.00	7.94	C
ATOM	588	CD1	PHE	A	76	58.095	67.489	-2.907	1.00	8.10	C
ATOM	589	CD2	PHE	A	76	59.045	67.597	-0.748	1.00	9.01	C
ATOM	590	CE1	PHE	A	76	57.101	66.664	-2.442	1.00	7.55	C
ATOM	591	CE2	PHE	A	76	58.051	66.728	-0.235	1.00	8.28	C

WO 2013/076253

PCT/EP2012/073483

15/34

ATOM	592	CZ	PHE	A	76	57.072	66.271	-1.079	1.00	8.68	C
ATOM	593	N	ALA	A	77	59.273	71.512	-1.576	1.00	8.86	N
ATOM	594	CA	ALA	A	77	58.339	72.280	-0.748	1.00	10.42	C
ATOM	595	C	ALA	A	77	57.760	73.481	-1.521	1.00	11.18	C
ATOM	596	O	ALA	A	77	56.623	73.937	-1.206	1.00	12.43	O
ATOM	597	CB	ALA	A	77	58.994	72.765	0.538	1.00	11.12	C
ATOM	598	N	SER	A	78	58.479	74.025	-2.486	1.00	11.58	N
ATOM	599	CA	SER	A	78	58.012	75.143	-3.280	1.00	11.77	C
ATOM	600	C	SER	A	78	57.156	74.776	-4.430	1.00	11.86	C
ATOM	601	O	SER	A	78	56.580	75.649	-5.116	1.00	13.37	O
ATOM	602	CB	SER	A	78	59.183	75.980	-3.789	1.00	14.90	C
ATOM	603	OG	SER	A	78	59.903	76.593	-2.778	1.00	17.91	O
ATOM	604	N	ASN	A	79	57.054	73.491	-4.795	1.00	10.84	N
ATOM	605	CA	ASN	A	79	56.418	73.005	-5.998	1.00	10.87	C
ATOM	606	C	ASN	A	79	55.456	71.859	-5.693	1.00	10.31	C
ATOM	607	O	ASN	A	79	55.312	70.932	-6.463	1.00	11.79	O
ATOM	608	CB	ASN	A	79	57.413	72.619	-7.074	1.00	11.12	C
ATOM	609	CG	ASN	A	79	58.224	73.856	-7.519	1.00	11.45	C
ATOM	610	OD1	ASN	A	79	59.404	74.043	-7.167	1.00	13.66	O
ATOM	611	ND2	ASN	A	79	57.566	74.683	-8.290	1.00	11.51	N
ATOM	612	N	GLY	A	80	54.730	71.939	-4.578	1.00	11.80	N
ATOM	613	CA	GLY	A	80	53.642	71.032	-4.256	1.00	11.06	C
ATOM	614	C	GLY	A	80	53.775	70.281	-2.950	1.00	10.57	C
ATOM	615	O	GLY	A	80	52.776	69.758	-2.464	1.00	10.67	O
ATOM	616	N	GLY	A	81	54.966	70.300	-2.367	1.00	9.97	N
ATOM	617	CA	GLY	A	81	55.275	69.538	-1.131	1.00	10.72	C
ATOM	618	C	GLY	A	81	55.041	70.271	0.176	1.00	11.35	C
ATOM	619	O	GLY	A	81	55.501	69.810	1.226	1.00	13.00	O
ATOM	620	N	GLY	A	82	54.374	71.410	0.136	1.00	10.83	N
ATOM	621	CA	GLY	A	82	54.131	72.164	1.366	1.00	12.82	C
ATOM	622	C	GLY	A	82	53.120	71.480	2.264	1.00	11.72	C
ATOM	623	O	GLY	A	82	52.377	70.583	1.857	1.00	13.80	O
ATOM	624	N	TRP	A	83	53.066	71.870	3.519	1.00	12.35	N
ATOM	625	CA	TRP	A	83	52.143	71.357	4.499	1.00	11.33	C
ATOM	626	C	TRP	A	83	51.465	72.489	5.297	1.00	13.26	C
ATOM	627	O	TRP	A	83	52.144	73.445	5.632	1.00	16.36	O
ATOM	628	CB	TRP	A	83	52.811	70.335	5.450	1.00	11.33	C
ATOM	629	CG	TRP	A	83	51.907	69.733	6.470	1.00	11.71	C
ATOM	630	CD1	TRP	A	83	51.127	68.653	6.360	1.00	10.86	C
ATOM	631	CD2	TRP	A	83	51.597	70.270	7.765	1.00	11.48	C
ATOM	632	NE1	TRP	A	83	50.364	68.462	7.451	1.00	10.78	N
ATOM	633	CE2	TRP	A	83	50.611	69.445	8.359	1.00	11.43	C
ATOM	634	CE3	TRP	A	83	52.024	71.393	8.466	1.00	12.40	C
ATOM	635	CZ2	TRP	A	83	50.111	69.687	9.653	1.00	11.74	C
ATOM	636	CZ3	TRP	A	83	51.502	71.654	9.751	1.00	12.34	C
ATOM	637	CH2	TRP	A	83	50.545	70.848	10.322	1.00	12.45	C
ATOM	638	N	SER	A	84	50.232	72.318	5.611	1.00	13.04	N
ATOM	639	CA	SER	A	84	49.470	73.144	6.579	1.00	14.80	C
ATOM	640	C	SER	A	84	48.511	72.216	7.289	1.00	14.24	C
ATOM	641	O	SER	A	84	48.124	71.162	6.790	1.00	12.43	O
ATOM	642	CB	SER	A	84	48.757	74.292	5.865	1.00	16.01	C
ATOM	643	OG	SER	A	84	47.704	73.769	5.171	1.00	18.96	O
ATOM	644	N	LYS	A	85	48.028	72.695	8.475	1.00	14.99	N
ATOM	645	CA	LYS	A	85	47.088	72.001	9.286	1.00	14.95	C

WO 2013/076253

PCT/EP2012/073483

16/34

ATOM	646	C	LYS	A	85	45.670	72.216	8.849	1.00	15.79	C
ATOM	647	O	LYS	A	85	44.868	72.781	9.636	1.00	19.35	O
ATOM	648	CB	LYS	A	85	47.328	72.386	10.786	1.00	17.68	C
ATOM	649	CG	LYS	A	85	46.766	71.395	11.759	1.00	18.39	C
ATOM	650	CD	LYS	A	85	46.989	71.817	13.189	1.00	21.96	C
ATOM	651	CE	LYS	A	85	46.481	70.749	14.123	1.00	26.50	C
ATOM	652	NZ	LYS	A	85	47.253	71.037	15.362	1.00	36.47	N
ATOM	653	N	ASP	A	86	45.258	71.813	7.671	1.00	16.01	N
ATOM	654	CA	ASP	A	86	43.936	71.863	7.178	1.00	16.15	C
ATOM	655	C	ASP	A	86	43.169	70.593	7.412	1.00	16.81	C
ATOM	656	O	ASP	A	86	42.010	70.481	6.957	1.00	20.25	O
ATOM	657	CB	ASP	A	86	43.921	72.350	5.761	1.00	17.29	C
ATOM	658	CG	ASP	A	86	44.610	71.426	4.772	1.00	18.54	C
ATOM	659	OD1	ASP	A	86	45.129	70.333	5.143	1.00	14.42	O
ATOM	660	OD2	ASP	A	86	44.605	71.815	3.582	1.00	20.76	O
ATOM	661	N	GLY	A	87	43.744	69.565	8.018	1.00	16.40	N
ATOM	662	CA	GLY	A	87	43.092	68.312	8.262	1.00	17.50	C
ATOM	663	C	GLY	A	87	43.147	67.287	7.065	1.00	14.41	C
ATOM	664	O	GLY	A	87	42.744	66.141	7.235	1.00	15.93	O
ATOM	665	N	ILE	A	88	43.630	67.715	5.905	1.00	14.08	N
ATOM	666	CA	ILE	A	88	43.624	66.887	4.681	1.00	11.59	C
ATOM	667	C	ILE	A	88	45.013	66.787	4.025	1.00	10.89	C
ATOM	668	O	ILE	A	88	45.088	66.248	2.923	1.00	10.83	O
ATOM	669	CB	ILE	A	88	42.541	67.321	3.662	1.00	14.22	C
ATOM	670	CG1	ILE	A	88	42.777	68.743	3.166	1.00	14.30	C
ATOM	671	CG2	ILE	A	88	41.201	67.170	4.312	1.00	16.90	C
ATOM	672	CD1	ILE	A	88	42.012	69.106	1.941	1.00	17.67	C
ATOM	673	N	THR	A	89	46.068	67.242	4.678	1.00	9.63	N
ATOM	674	CA	THR	A	89	47.355	67.231	4.043	1.00	10.03	C
ATOM	675	C	THR	A	89	48.290	66.353	4.817	1.00	8.75	C
ATOM	676	O	THR	A	89	48.544	66.561	6.033	1.00	10.00	O
ATOM	677	CB	THR	A	89	47.978	68.650	3.909	1.00	10.40	C
ATOM	678	OG1	THR	A	89	47.004	69.537	3.406	1.00	12.80	O
ATOM	679	CG2	THR	A	89	49.186	68.659	3.004	1.00	10.97	C
ATOM	680	N	LEU	A	90	48.865	65.344	4.178	1.00	8.28	N
ATOM	681	CA	LEU	A	90	49.882	64.496	4.766	1.00	8.25	C
ATOM	682	C	LEU	A	90	51.215	65.155	4.686	1.00	8.41	C
ATOM	683	O	LEU	A	90	51.454	65.939	3.722	1.00	9.95	O
ATOM	684	CB	LEU	A	90	49.941	63.169	4.039	1.00	9.35	C
ATOM	685	CG	LEU	A	90	48.684	62.310	4.242	1.00	10.23	C
ATOM	686	CD1	LEU	A	90	48.639	61.159	3.253	1.00	12.43	C
ATOM	687	CD2	LEU	A	90	48.559	61.794	5.637	1.00	11.63	C
ATOM	688	N	PRO	A	91	52.145	64.896	5.593	1.00	8.62	N
ATOM	689	CA	PRO	A	91	53.528	65.325	5.367	1.00	9.85	C
ATOM	690	C	PRO	A	91	54.055	64.798	4.030	1.00	8.64	C
ATOM	691	O	PRO	A	91	53.732	63.637	3.655	1.00	8.77	O
ATOM	692	CB	PRO	A	91	54.313	64.717	6.552	1.00	10.34	C
ATOM	693	CG	PRO	A	91	53.315	64.363	7.519	1.00	14.04	C
ATOM	694	CD	PRO	A	91	52.048	64.041	6.795	1.00	10.87	C
ATOM	695	N	GLY	A	92	54.837	65.581	3.338	1.00	8.17	N
ATOM	696	CA	GLY	A	92	55.427	65.098	2.083	1.00	8.23	C
ATOM	697	C	GLY	A	92	56.326	63.932	2.297	1.00	7.12	C
ATOM	698	O	GLY	A	92	56.919	63.772	3.347	1.00	8.26	O
ATOM	699	N	ALA	A	93	56.473	63.139	1.223	1.00	7.26	N

WO 2013/076253

PCT/EP2012/073483

17/34

ATOM	700	CA	ALA	A	93	57.296	61.907	1.240	1.00	6.96	C
ATOM	701	C	ALA	A	93	58.540	62.066	0.382	1.00	7.06	C
ATOM	702	O	ALA	A	93	58.493	62.578	-0.754	1.00	7.85	O
ATOM	703	CB	ALA	A	93	56.478	60.722	0.838	1.00	7.38	C
ATOM	704	N	LEU	A	94	59.650	61.591	0.929	1.00	6.95	N
ATOM	705	CA	LEU	A	94	60.928	61.455	0.227	1.00	7.38	C
ATOM	706	C	LEU	A	94	60.996	60.034	-0.354	1.00	7.73	C
ATOM	707	O	LEU	A	94	61.103	59.039	0.403	1.00	7.82	O
ATOM	708	CB	LEU	A	94	62.093	61.670	1.182	1.00	7.34	C
ATOM	709	CG	LEU	A	94	63.468	61.482	0.561	1.00	8.17	C
ATOM	710	CD1	LEU	A	94	63.781	62.470	-0.553	1.00	9.13	C
ATOM	711	CD2	LEU	A	94	64.551	61.492	1.656	1.00	9.66	C
ATOM	712	N	ASP	A	95	60.886	59.888	-1.671	1.00	7.48	N
ATOM	713	CA	ASP	A	95	61.039	58.579	-2.356	1.00	7.68	C
ATOM	714	C	ASP	A	95	62.458	58.389	-2.688	1.00	8.07	C
ATOM	715	O	ASP	A	95	63.031	59.020	-3.618	1.00	7.87	O
ATOM	716	CB	ASP	A	95	60.108	58.629	-3.582	1.00	8.60	C
ATOM	717	CG	ASP	A	95	60.150	57.407	-4.445	1.00	9.41	C
ATOM	718	OD1	ASP	A	95	61.120	56.607	-4.340	1.00	10.64	O
ATOM	719	OD2	ASP	A	95	59.227	57.220	-5.262	1.00	13.82	O
ATOM	720	N	AILE	A	96	63.138	57.586	-1.864	0.50	7.67	N
ATOM	721	CA	AILE	A	96	64.564	57.351	-1.968	0.50	8.73	C
ATOM	722	C	AILE	A	96	64.766	55.855	-2.183	0.50	8.99	C
ATOM	723	O	AILE	A	96	64.504	54.980	-1.319	0.50	9.10	O
ATOM	724	CB	AILE	A	96	65.271	57.946	-0.724	0.50	9.21	C
ATOM	725	CG1	AILE	A	96	66.779	57.722	-0.615	0.50	10.37	C
ATOM	726	CG2	AILE	A	96	64.747	57.482	0.628	0.50	9.70	C
ATOM	727	CD1	AILE	A	96	67.560	58.453	-1.690	0.50	9.27	C
ATOM	728	N	GLU	A	97	65.168	55.514	-3.399	1.00	9.36	N
ATOM	729	CA	GLU	A	97	65.139	54.145	-3.862	1.00	10.45	C
ATOM	730	C	GLU	A	97	66.149	53.955	-5.015	1.00	9.77	C
ATOM	731	O	GLU	A	97	66.906	54.845	-5.340	1.00	9.44	O
ATOM	732	CB	GLU	A	97	63.749	53.794	-4.325	1.00	12.48	C
ATOM	733	CG	GLU	A	97	63.291	54.540	-5.533	1.00	13.18	C
ATOM	734	CD	GLU	A	97	61.975	54.070	-6.077	1.00	14.89	C
ATOM	735	OE1	GLU	A	97	61.998	53.030	-6.839	1.00	19.54	O
ATOM	736	OE2	GLU	A	97	60.942	54.617	-5.821	1.00	12.80	O
ATOM	737	N	TYR	A	98	66.149	52.741	-5.569	1.00	10.39	N
ATOM	738	CA	TYR	A	98	67.091	52.397	-6.627	1.00	12.01	C
ATOM	739	C	TYR	A	98	67.276	53.433	-7.670	1.00	12.50	C
ATOM	740	O	TYR	A	98	66.271	53.888	-8.306	1.00	14.68	O
ATOM	741	CB	TYR	A	98	66.617	51.141	-7.364	1.00	16.65	C
ATOM	742	CG	TYR	A	98	66.208	50.115	-6.445	1.00	17.77	C
ATOM	743	CD1	TYR	A	98	67.124	49.226	-5.891	1.00	19.15	C
ATOM	744	CD2	TYR	A	98	64.875	49.981	-6.089	1.00	18.63	C
ATOM	745	CE1	TYR	A	98	66.712	48.258	-4.960	1.00	16.76	C
ATOM	746	CE2	TYR	A	98	64.463	49.064	-5.169	1.00	18.78	C
ATOM	747	CZ	TYR	A	98	65.402	48.174	-4.607	1.00	19.88	C
ATOM	748	OH	TYR	A	98	64.930	47.290	-3.720	1.00	19.97	O
ATOM	749	N	ASN	A	99	68.494	53.729	-8.014	1.00	11.97	N
ATOM	750	CA	ASN	A	99	68.776	54.605	-9.131	1.00	12.55	C
ATOM	751	C	ASN	A	99	68.311	54.029	-10.474	1.00	12.72	C
ATOM	752	O	ASN	A	99	68.726	53.014	-10.854	1.00	12.92	O
ATOM	753	CB	ASN	A	99	70.285	54.824	-9.147	1.00	11.83	C

WO 2013/076253

PCT/EP2012/073483

18/34

ATOM	754	CG	ASN	A	99	70.766	55.807	-10.153	1.00	11.60	C
ATOM	755	OD1	ASN	A	99	69.898	56.454	-10.861	1.00	12.34	O
ATOM	756	ND2	ASN	A	99	71.963	56.011	-10.239	1.00	10.95	N
ATOM	757	N	PRO	A	100	67.296	54.639	-11.108	1.00	15.65	N
ATOM	758	CA	PRO	A	100	66.918	54.121	-12.458	1.00	15.08	C
ATOM	759	C	PRO	A	100	67.981	54.353	-13.521	1.00	13.33	C
ATOM	760	O	PRO	A	100	67.742	53.769	-14.582	1.00	15.23	O
ATOM	761	CB	PRO	A	100	65.674	54.910	-12.803	1.00	18.14	C
ATOM	762	CG	PRO	A	100	66.009	56.229	-12.290	1.00	22.90	C
ATOM	763	CD	PRO	A	100	66.676	55.941	-10.862	1.00	18.86	C
ATOM	764	N	ASN	A	101	69.032	55.088	-13.343	1.00	12.02	N
ATOM	765	CA	ASN	A	101	69.949	55.313	-14.321	1.00	12.72	C
ATOM	766	C	ASN	A	101	71.367	55.419	-13.726	1.00	15.62	C
ATOM	767	O	ASN	A	101	71.873	56.520	-13.516	1.00	17.93	O
ATOM	768	CB	ASN	A	101	69.475	56.709	-14.858	1.00	18.85	C
ATOM	769	CG	ASN	A	101	70.385	57.293	-15.865	1.00	17.73	C
ATOM	770	OD1	ASN	A	101	71.098	56.545	-16.623	1.00	20.16	O
ATOM	771	ND2	ASN	A	101	70.362	58.656	-15.995	1.00	19.41	N
ATOM	772	N	GLY	A	102	71.905	54.303	-13.309	1.00	12.57	N
ATOM	773	CA	GLY	A	102	73.278	54.223	-12.866	1.00	13.26	C
ATOM	774	C	GLY	A	102	73.404	53.304	-11.631	1.00	11.80	C
ATOM	775	O	GLY	A	102	72.579	52.493	-11.360	1.00	12.62	O
ATOM	776	N	ALA	A	103	74.474	53.515	-10.888	1.00	12.41	N
ATOM	777	CA	ALA	A	103	74.773	52.678	-9.700	1.00	11.68	C
ATOM	778	C	ALA	A	103	73.623	52.803	-8.654	1.00	10.44	C
ATOM	779	O	ALA	A	103	73.120	53.915	-8.442	1.00	11.37	O
ATOM	780	CB	ALA	A	103	76.022	53.098	-9.136	1.00	13.80	C
ATOM	781	N	THR	A	104	73.297	51.695	-8.031	1.00	10.31	N
ATOM	782	CA	THR	A	104	72.172	51.571	-7.118	1.00	11.19	C
ATOM	783	C	THR	A	104	72.136	52.713	-6.121	1.00	10.01	C
ATOM	784	O	THR	A	104	71.041	53.315	-5.879	1.00	9.67	O
ATOM	785	CB	THR	A	104	72.290	50.224	-6.322	1.00	12.71	C
ATOM	786	OG1	THR	A	104	72.292	49.156	-7.295	1.00	16.30	O
ATOM	787	CG2	THR	A	104	71.213	50.017	-5.299	1.00	14.79	C
ATOM	788	N	CYS	A	105	73.274	53.063	-5.552	1.00	9.25	N
ATOM	789	CA	CYS	A	105	73.389	54.035	-4.460	1.00	10.50	C
ATOM	790	C	CYS	A	105	73.922	55.406	-4.909	1.00	9.74	C
ATOM	791	O	CYS	A	105	74.329	56.201	-4.107	1.00	10.10	O
ATOM	792	CB	CYS	A	105	74.210	53.485	-3.286	1.00	11.41	C
ATOM	793	SG	CYS	A	105	73.668	51.873	-2.630	1.00	10.45	S
ATOM	794	N	TYR	A	106	73.844	55.674	-6.256	1.00	9.49	N
ATOM	795	CA	TYR	A	106	74.035	57.001	-6.851	1.00	10.00	C
ATOM	796	C	TYR	A	106	75.438	57.441	-6.732	1.00	11.56	C
ATOM	797	O	TYR	A	106	75.758	58.631	-6.894	1.00	14.32	O
ATOM	798	CB	TYR	A	106	73.039	58.071	-6.258	1.00	10.81	C
ATOM	799	CG	TYR	A	106	71.590	57.764	-6.435	1.00	9.35	C
ATOM	800	CD1	TYR	A	106	70.906	57.041	-5.542	1.00	9.32	C
ATOM	801	CD2	TYR	A	106	70.863	58.253	-7.551	1.00	9.87	C
ATOM	802	CE1	TYR	A	106	69.586	56.769	-5.680	1.00	9.87	C
ATOM	803	CE2	TYR	A	106	69.606	58.035	-7.720	1.00	10.96	C
ATOM	804	CZ	TYR	A	106	68.872	57.261	-6.801	1.00	10.72	C
ATOM	805	OH	TYR	A	106	67.530	57.019	-6.996	1.00	10.26	O
ATOM	806	N	GLY	A	107	76.385	56.554	-6.391	1.00	11.03	N
ATOM	807	CA	GLY	A	107	77.768	56.968	-6.220	1.00	12.59	C

WO 2013/076253

PCT/EP2012/073483

19/34

ATOM	808	C	GLY	A	107	78.190	57.500	-4.857	1.00	11.20	C
ATOM	809	O	GLY	A	107	79.286	58.018	-4.646	1.00	14.43	O
ATOM	810	N	LEU	A	108	77.245	57.526	-3.883	1.00	10.39	N
ATOM	811	CA	LEU	A	108	77.508	57.986	-2.537	1.00	9.99	C
ATOM	812	C	LEU	A	108	77.920	56.876	-1.604	1.00	9.21	C
ATOM	813	O	LEU	A	108	77.282	55.742	-1.704	1.00	9.80	O
ATOM	814	CB	LEU	A	108	76.247	58.685	-1.955	1.00	9.30	C
ATOM	815	CG	LEU	A	108	75.989	60.110	-2.420	1.00	10.75	C
ATOM	816	CD1	LEU	A	108	75.524	60.291	-3.813	1.00	15.28	C
ATOM	817	CD2	LEU	A	108	74.931	60.803	-1.539	1.00	11.39	C
ATOM	818	N	SER	A	109	78.815	57.109	-0.676	1.00	8.87	N
ATOM	819	CA	SER	A	109	79.074	56.135	0.359	1.00	9.15	C
ATOM	820	C	SER	A	109	77.829	56.057	1.297	1.00	7.80	C
ATOM	821	O	SER	A	109	76.972	56.914	1.285	1.00	8.60	O
ATOM	822	CB	SER	A	109	80.252	56.543	1.186	1.00	10.32	C
ATOM	823	OG	SER	A	109	79.984	57.755	1.911	1.00	10.88	O
ATOM	824	N	GLN	A	110	77.810	55.028	2.137	1.00	7.95	N
ATOM	825	CA	GLN	A	110	76.715	54.903	3.123	1.00	7.58	C
ATOM	826	C	GLN	A	110	76.658	56.143	3.994	1.00	8.71	C
ATOM	827	O	GLN	A	110	75.552	56.684	4.261	1.00	8.84	O
ATOM	828	CB	GLN	A	110	76.921	53.651	3.941	1.00	7.60	C
ATOM	829	CG	GLN	A	110	76.760	52.393	3.115	1.00	8.40	C
ATOM	830	CD	GLN	A	110	77.021	51.082	3.855	1.00	9.00	C
ATOM	831	OE1	GLN	A	110	77.699	51.100	4.920	1.00	10.48	O
ATOM	832	NE2	GLN	A	110	76.608	49.967	3.350	1.00	8.64	N
ATOM	833	N	SER	A	111	77.802	56.618	4.503	1.00	8.60	N
ATOM	834	CA	SER	A	111	77.792	57.817	5.335	1.00	9.61	C
ATOM	835	C	SER	A	111	77.354	59.029	4.621	1.00	9.15	C
ATOM	836	O	SER	A	111	76.634	59.863	5.192	1.00	9.47	O
ATOM	837	CB	SER	A	111	79.162	57.973	6.040	1.00	12.91	C
ATOM	838	OG	SER	A	111	80.169	58.111	5.150	1.00	19.00	O
ATOM	839	N	ALA	A	112	77.808	59.221	3.389	1.00	9.14	N
ATOM	840	CA	ALA	A	112	77.399	60.368	2.593	1.00	9.79	C
ATOM	841	C	ALA	A	112	75.901	60.343	2.346	1.00	9.22	C
ATOM	842	O	ALA	A	112	75.233	61.401	2.317	1.00	8.94	O
ATOM	843	CB	ALA	A	112	78.192	60.462	1.308	1.00	10.13	C
ATOM	844	N	MET	A	113	75.361	59.143	2.111	1.00	8.20	N
ATOM	845	CA	MET	A	113	73.885	59.048	1.848	1.00	8.63	C
ATOM	846	C	MET	A	113	73.092	59.415	3.117	1.00	7.61	C
ATOM	847	O	MET	A	113	72.093	60.123	3.031	1.00	8.51	O
ATOM	848	CB	MET	A	113	73.552	57.619	1.390	1.00	7.57	C
ATOM	849	CG	MET	A	113	72.082	57.459	0.964	1.00	7.91	C
ATOM	850	SD	MET	A	113	71.579	58.481	-0.421	1.00	9.00	S
ATOM	851	CE	MET	A	113	72.337	57.570	-1.790	1.00	9.78	C
ATOM	852	N	VAL	A	114	73.503	58.943	4.266	1.00	8.04	N
ATOM	853	CA	VAL	A	114	72.868	59.331	5.538	1.00	8.49	C
ATOM	854	C	VAL	A	114	72.925	60.837	5.710	1.00	8.02	C
ATOM	855	O	VAL	A	114	71.888	61.463	6.057	1.00	8.75	O
ATOM	856	CB	VAL	A	114	73.441	58.578	6.736	1.00	9.15	C
ATOM	857	CG1	VAL	A	114	72.924	59.133	8.059	1.00	10.10	C
ATOM	858	CG2	VAL	A	114	73.169	57.078	6.657	1.00	9.71	C
ATOM	859	N	ASN	A	115	74.066	61.441	5.440	1.00	8.59	N
ATOM	860	CA	ASN	A	115	74.141	62.876	5.553	1.00	9.24	C
ATOM	861	C	ASN	A	115	73.242	63.620	4.611	1.00	8.73	C

WO 2013/076253

PCT/EP2012/073483

20/34

ATOM	862	O	ASN	A	115	72.671	64.669	4.918	1.00	9.44	O
ATOM	863	CB	ASN	A	115	75.605	63.368	5.441	1.00	10.80	C
ATOM	864	CG	ASN	A	115	76.477	62.881	6.557	1.00	13.66	C
ATOM	865	OD1	ASN	A	115	76.051	62.579	7.624	1.00	16.56	O
ATOM	866	ND2	ASN	A	115	77.785	62.800	6.252	1.00	17.62	N
ATOM	867	N	TRP	A	116	73.128	63.135	3.350	1.00	8.90	N
ATOM	868	CA	TRP	A	116	72.249	63.711	2.358	1.00	8.54	C
ATOM	869	C	TRP	A	116	70.783	63.662	2.807	1.00	8.75	C
ATOM	870	O	TRP	A	116	70.060	64.662	2.748	1.00	8.80	O
ATOM	871	CB	TRP	A	116	72.424	63.016	0.985	1.00	8.29	C
ATOM	872	CG	TRP	A	116	71.742	63.646	-0.153	1.00	9.22	C
ATOM	873	CD1	TRP	A	116	72.373	64.440	-1.092	1.00	10.31	C
ATOM	874	CD2	TRP	A	116	70.393	63.560	-0.562	1.00	9.03	C
ATOM	875	NE1	TRP	A	116	71.430	64.909	-1.980	1.00	9.79	N
ATOM	876	CE2	TRP	A	116	70.207	64.423	-1.673	1.00	9.29	C
ATOM	877	CE3	TRP	A	116	69.254	62.913	-0.064	1.00	9.14	C
ATOM	878	CZ2	TRP	A	116	68.987	64.609	-2.306	1.00	9.93	C
ATOM	879	CZ3	TRP	A	116	68.058	63.131	-0.674	1.00	9.73	C
ATOM	880	CH2	TRP	A	116	67.927	63.939	-1.809	1.00	10.03	C
ATOM	881	N	ILE	A	117	70.352	62.482	3.261	1.00	8.73	N
ATOM	882	CA	ILE	A	117	68.968	62.340	3.765	1.00	8.12	C
ATOM	883	C	ILE	A	117	68.754	63.248	4.992	1.00	8.10	C
ATOM	884	O	ILE	A	117	67.700	63.892	5.036	1.00	8.83	O
ATOM	885	CB	ILE	A	117	68.676	60.863	4.048	1.00	8.65	C
ATOM	886	CG1	ILE	A	117	68.797	60.016	2.767	1.00	8.78	C
ATOM	887	CG2	ILE	A	117	67.266	60.728	4.679	1.00	9.28	C
ATOM	888	CD1	ILE	A	117	68.858	58.495	3.031	1.00	9.31	C
ATOM	889	N	GLU	A	118	69.709	63.338	5.892	1.00	8.67	N
ATOM	890	CA	GLU	A	118	69.583	64.235	7.049	1.00	8.77	C
ATOM	891	C	GLU	A	118	69.370	65.639	6.581	1.00	9.08	C
ATOM	892	O	GLU	A	118	68.543	66.398	7.151	1.00	10.18	O
ATOM	893	CB	GLU	A	118	70.809	64.066	7.944	1.00	9.38	C
ATOM	894	CG	GLU	A	118	70.802	64.938	9.212	1.00	12.22	C
ATOM	895	CD	GLU	A	118	69.749	64.507	10.171	1.00	12.30	C
ATOM	896	OE1	GLU	A	118	69.614	63.321	10.515	1.00	13.71	O
ATOM	897	OE2	GLU	A	118	69.061	65.433	10.725	1.00	17.08	O
ATOM	898	N	ASP	A	119	70.122	66.104	5.585	1.00	9.58	N
ATOM	899	CA	ASP	A	119	69.987	67.442	5.043	1.00	10.53	C
ATOM	900	C	ASP	A	119	68.602	67.668	4.468	1.00	9.55	C
ATOM	901	O	ASP	A	119	67.975	68.735	4.705	1.00	10.25	O
ATOM	902	CB	ASP	A	119	71.144	67.684	4.016	1.00	10.87	C
ATOM	903	CG	ASP	A	119	71.413	69.172	3.624	1.00	12.17	C
ATOM	904	OD1	ASP	A	119	71.115	70.035	4.516	1.00	14.59	O
ATOM	905	OD2	ASP	A	119	71.856	69.391	2.504	1.00	12.68	O
ATOM	906	N	PHE	A	120	68.066	66.737	3.707	1.00	8.85	N
ATOM	907	CA	PHE	A	120	66.721	66.836	3.185	1.00	8.22	C
ATOM	908	C	PHE	A	120	65.704	66.925	4.321	1.00	8.37	C
ATOM	909	O	PHE	A	120	64.844	67.786	4.346	1.00	8.31	O
ATOM	910	CB	PHE	A	120	66.402	65.636	2.245	1.00	8.22	C
ATOM	911	CG	PHE	A	120	65.041	65.751	1.572	1.00	8.32	C
ATOM	912	CD1	PHE	A	120	63.862	65.423	2.290	1.00	8.64	C
ATOM	913	CD2	PHE	A	120	64.916	66.175	0.276	1.00	9.11	C
ATOM	914	CE1	PHE	A	120	62.645	65.620	1.711	1.00	9.54	C
ATOM	915	CE2	PHE	A	120	63.672	66.323	-0.327	1.00	9.92	C

WO 2013/076253

PCT/EP2012/073483

21/34

ATOM	916	CZ	PHE	A	120	62.543	66.032	0.389	1.00	9.92	C
ATOM	917	N	AVAL	A	121	65.762	65.958	5.258	0.50	9.46	N
ATOM	918	CA	AVAL	A	121	64.701	65.905	6.268	0.50	9.79	C
ATOM	919	C	AVAL	A	121	64.713	67.123	7.213	0.50	9.73	C
ATOM	920	O	AVAL	A	121	63.670	67.650	7.559	0.50	9.67	O
ATOM	921	CB	AVAL	A	121	64.571	64.556	7.024	0.50	11.08	C
ATOM	922	CG1	AVAL	A	121	64.992	63.355	6.213	0.50	12.21	C
ATOM	923	CG2	AVAL	A	121	65.579	64.456	8.127	0.50	11.83	C
ATOM	924	N	THR	A	122	65.902	67.544	7.606	1.00	9.71	N
ATOM	925	CA	THR	A	122	66.015	68.744	8.484	1.00	11.38	C
ATOM	926	C	THR	A	122	65.606	69.977	7.770	1.00	10.39	C
ATOM	927	O	THR	A	122	64.872	70.837	8.341	1.00	11.71	O
ATOM	928	CB	THR	A	122	67.459	68.854	9.046	1.00	14.29	C
ATOM	929	OG1	THR	A	122	67.737	67.751	9.912	1.00	18.37	O
ATOM	930	CG2	THR	A	122	67.608	70.113	9.885	1.00	16.34	C
ATOM	931	N	THR	A	123	65.918	70.172	6.505	1.00	10.23	N
ATOM	932	CA	THR	A	123	65.466	71.308	5.735	1.00	10.48	C
ATOM	933	C	THR	A	123	63.964	71.291	5.591	1.00	10.11	C
ATOM	934	O	THR	A	123	63.303	72.336	5.735	1.00	10.51	O
ATOM	935	CB	THR	A	123	66.217	71.359	4.395	1.00	10.14	C
ATOM	936	OG1	THR	A	123	67.662	71.459	4.616	1.00	11.42	O
ATOM	937	CG2	THR	A	123	65.754	72.540	3.585	1.00	11.46	C
ATOM	938	N	TYR	A	124	63.379	70.173	5.180	1.00	10.12	N
ATOM	939	CA	TYR	A	124	61.956	70.070	5.018	1.00	9.13	C
ATOM	940	C	TYR	A	124	61.198	70.415	6.349	1.00	9.03	C
ATOM	941	O	TYR	A	124	60.199	71.112	6.304	1.00	9.86	O
ATOM	942	CB	TYR	A	124	61.574	68.631	4.546	1.00	9.40	C
ATOM	943	CG	TYR	A	124	60.113	68.484	4.180	1.00	8.91	C
ATOM	944	CD1	TYR	A	124	59.614	68.889	2.943	1.00	9.63	C
ATOM	945	CD2	TYR	A	124	59.216	68.013	5.103	1.00	8.82	C
ATOM	946	CE1	TYR	A	124	58.289	68.867	2.655	1.00	9.97	C
ATOM	947	CE2	TYR	A	124	57.860	67.964	4.827	1.00	9.19	C
ATOM	948	CZ	TYR	A	124	57.387	68.373	3.588	1.00	9.03	C
ATOM	949	OH	TYR	A	124	56.012	68.290	3.361	1.00	9.94	O
ATOM	950	N	HIS	A	125	61.651	69.859	7.411	1.00	9.44	N
ATOM	951	CA	HIS	A	125	61.058	70.142	8.761	1.00	10.58	C
ATOM	952	C	HIS	A	125	61.170	71.644	9.055	1.00	11.81	C
ATOM	953	O	HIS	A	125	60.218	72.249	9.621	1.00	12.74	O
ATOM	954	CB	HIS	A	125	61.688	69.226	9.786	1.00	11.51	C
ATOM	955	CG	HIS	A	125	61.239	69.507	11.188	1.00	12.78	C
ATOM	956	ND1	HIS	A	125	61.898	70.422	11.990	1.00	15.33	N
ATOM	957	CD2	HIS	A	125	60.284	68.922	11.930	1.00	12.80	C
ATOM	958	CE1	HIS	A	125	61.311	70.382	13.179	1.00	16.12	C
ATOM	959	NE2	HIS	A	125	60.322	69.510	13.176	1.00	14.84	N
ATOM	960	N	GLY	A	126	62.298	72.277	8.736	1.00	11.41	N
ATOM	961	CA	GLY	A	126	62.458	73.722	9.004	1.00	11.57	C
ATOM	962	C	GLY	A	126	61.480	74.515	8.205	1.00	12.31	C
ATOM	963	O	GLY	A	126	61.026	75.598	8.638	1.00	14.25	O
ATOM	964	N	ILE	A	127	61.083	74.119	7.024	1.00	12.46	N
ATOM	965	CA	ILE	A	127	60.117	74.815	6.207	1.00	12.54	C
ATOM	966	C	ILE	A	127	58.717	74.566	6.641	1.00	12.68	C
ATOM	967	O	ILE	A	127	57.905	75.503	6.743	1.00	14.70	O
ATOM	968	CB	ILE	A	127	60.275	74.412	4.705	1.00	13.53	C
ATOM	969	CG1	ILE	A	127	61.669	74.809	4.163	1.00	13.85	C

WO 2013/076253

PCT/EP2012/073483

22/34

ATOM	970	CG2	ILE	A	127	59.184	75.008	3.826	1.00	14.90	C
ATOM	971	CD1	ILE	A	127	62.022	74.089	2.871	1.00	14.58	C
ATOM	972	N	THR	A	128	58.339	73.306	6.889	1.00	12.52	N
ATOM	973	CA	THR	A	128	56.946	72.946	7.045	1.00	12.24	C
ATOM	974	C	THR	A	128	56.505	72.709	8.488	1.00	13.19	C
ATOM	975	O	THR	A	128	55.254	72.617	8.668	1.00	13.85	O
ATOM	976	CB	THR	A	128	56.665	71.626	6.249	1.00	12.84	C
ATOM	977	OG1	THR	A	128	57.303	70.520	6.883	1.00	11.04	O
ATOM	978	CG2	THR	A	128	57.048	71.724	4.816	1.00	12.42	C
ATOM	979	N	SER	A	129	57.401	72.443	9.416	1.00	11.97	N
ATOM	980	CA	SER	A	129	57.175	71.982	10.761	1.00	13.64	C
ATOM	981	C	SER	A	129	56.949	70.464	10.895	1.00	12.90	C
ATOM	982	O	SER	A	129	56.785	69.948	12.004	1.00	14.05	O
ATOM	983	CB	SER	A	129	56.053	72.720	11.539	1.00	14.54	C
ATOM	984	OG	SER	A	129	54.765	72.223	11.190	1.00	16.89	O
ATOM	985	N	ARG	A	130	56.991	69.730	9.762	1.00	10.94	N
ATOM	986	CA	ARG	A	130	56.762	68.306	9.769	1.00	10.71	C
ATOM	987	C	ARG	A	130	58.030	67.565	9.330	1.00	10.16	C
ATOM	988	O	ARG	A	130	58.689	67.989	8.356	1.00	10.37	O
ATOM	989	CB	ARG	A	130	55.607	67.874	8.845	1.00	10.59	C
ATOM	990	CG	ARG	A	130	54.279	68.550	9.134	1.00	11.26	C
ATOM	991	CD	ARG	A	130	53.784	68.290	10.538	1.00	12.79	C
ATOM	992	NE	ARG	A	130	53.631	66.867	10.835	1.00	12.36	N
ATOM	993	CZ	ARG	A	130	52.550	66.140	10.549	1.00	12.83	C
ATOM	994	NH1	ARG	A	130	51.444	66.604	9.972	1.00	11.32	N
ATOM	995	NH2	ARG	A	130	52.538	64.860	10.914	1.00	14.28	N
ATOM	996	N	TRP	A	131	58.264	66.447	9.946	1.00	9.44	N
ATOM	997	CA	TRP	A	131	59.262	65.490	9.431	1.00	8.88	C
ATOM	998	C	TRP	A	131	58.610	64.823	8.210	1.00	9.12	C
ATOM	999	O	TRP	A	131	57.472	64.395	8.285	1.00	9.54	O
ATOM	1000	CB	TRP	A	131	59.613	64.438	10.478	1.00	10.04	C
ATOM	1001	CG	TRP	A	131	60.284	65.038	11.712	1.00	10.34	C
ATOM	1002	CD1	TRP	A	131	59.733	65.107	12.962	1.00	11.76	C
ATOM	1003	CD2	TRP	A	131	61.531	65.707	11.785	1.00	10.87	C
ATOM	1004	NE1	TRP	A	131	60.588	65.767	13.809	1.00	13.72	N
ATOM	1005	CE2	TRP	A	131	61.707	66.165	13.130	1.00	12.63	C
ATOM	1006	CE3	TRP	A	131	62.574	65.953	10.854	1.00	12.39	C
ATOM	1007	CZ2	TRP	A	131	62.873	66.899	13.544	1.00	15.27	C
ATOM	1008	CZ3	TRP	A	131	63.674	66.709	11.274	1.00	14.83	C
ATOM	1009	CH2	TRP	A	131	63.822	67.124	12.606	1.00	15.77	C
ATOM	1010	N	PRO	A	132	59.344	64.618	7.125	1.00	8.23	N
ATOM	1011	CA	PRO	A	132	58.778	63.955	5.927	1.00	7.68	C
ATOM	1012	C	PRO	A	132	58.664	62.461	6.180	1.00	7.58	C
ATOM	1013	O	PRO	A	132	59.403	61.865	6.998	1.00	8.41	O
ATOM	1014	CB	PRO	A	132	59.788	64.254	4.822	1.00	8.62	C
ATOM	1015	CG	PRO	A	132	61.077	64.386	5.556	1.00	8.76	C
ATOM	1016	CD	PRO	A	132	60.782	64.989	6.921	1.00	8.46	C
ATOM	1017	N	VAL	A	133	57.744	61.824	5.451	1.00	7.38	N
ATOM	1018	CA	VAL	A	133	57.689	60.382	5.332	1.00	6.94	C
ATOM	1019	C	VAL	A	133	58.882	59.913	4.508	1.00	6.61	C
ATOM	1020	O	VAL	A	133	59.257	60.610	3.526	1.00	8.50	O
ATOM	1021	CB	VAL	A	133	56.351	60.015	4.688	1.00	7.75	C
ATOM	1022	CG1	VAL	A	133	56.276	58.556	4.287	1.00	8.23	C
ATOM	1023	CG2	VAL	A	133	55.216	60.382	5.622	1.00	8.86	C

WO 2013/076253

PCT/EP2012/073483

23/34

ATOM	1024	N	ILE	A	134	59.494	58.781	4.799	1.00	6.68	N
ATOM	1025	CA	ILE	A	134	60.532	58.179	3.972	1.00	6.71	C
ATOM	1026	C	ILE	A	134	59.951	56.964	3.295	1.00	6.93	C
ATOM	1027	O	ILE	A	134	59.496	55.999	3.980	1.00	7.12	O
ATOM	1028	CB	ILE	A	134	61.777	57.810	4.778	1.00	7.98	C
ATOM	1029	CG1	ILE	A	134	62.516	59.087	5.219	1.00	8.90	C
ATOM	1030	CG2	ILE	A	134	62.734	56.867	3.967	1.00	9.20	C
ATOM	1031	CD1	ILE	A	134	63.671	58.875	6.138	1.00	9.68	C
ATOM	1032	N	TYR	A	135	59.917	56.952	1.964	1.00	6.56	N
ATOM	1033	CA	TYR	A	135	59.539	55.804	1.120	1.00	6.92	C
ATOM	1034	C	TYR	A	135	60.800	55.142	0.611	1.00	6.99	C
ATOM	1035	O	TYR	A	135	61.690	55.781	0.012	1.00	7.70	O
ATOM	1036	CB	TYR	A	135	58.701	56.276	-0.077	1.00	7.76	C
ATOM	1037	CG	TYR	A	135	58.477	55.173	-1.131	1.00	7.38	C
ATOM	1038	CD1	TYR	A	135	59.415	54.959	-2.122	1.00	8.41	C
ATOM	1039	CD2	TYR	A	135	57.369	54.378	-1.110	1.00	8.41	C
ATOM	1040	CE1	TYR	A	135	59.198	53.975	-3.136	1.00	9.21	C
ATOM	1041	CE2	TYR	A	135	57.125	53.445	-2.100	1.00	8.26	C
ATOM	1042	CZ	TYR	A	135	58.054	53.217	-3.103	1.00	7.91	C
ATOM	1043	OH	TYR	A	135	57.872	52.270	-4.109	1.00	9.54	O
ATOM	1044	N	THR	A	136	60.912	53.858	0.876	1.00	6.49	N
ATOM	1045	CA	THR	A	136	62.069	53.075	0.440	1.00	6.83	C
ATOM	1046	C	THR	A	136	61.738	51.610	0.432	1.00	6.62	C
ATOM	1047	O	THR	A	136	60.628	51.182	0.745	1.00	7.62	O
ATOM	1048	CB	THR	A	136	63.285	53.386	1.350	1.00	7.97	C
ATOM	1049	OG1	THR	A	136	64.519	52.978	0.707	1.00	8.30	O
ATOM	1050	CG2	THR	A	136	63.210	52.792	2.746	1.00	8.09	C
ATOM	1051	N	THR	A	137	62.757	50.771	0.106	1.00	7.48	N
ATOM	1052	CA	THR	A	137	62.734	49.326	0.272	1.00	7.21	C
ATOM	1053	C	THR	A	137	63.764	48.939	1.274	1.00	7.67	C
ATOM	1054	O	THR	A	137	64.814	49.601	1.396	1.00	7.95	O
ATOM	1055	CB	THR	A	137	62.922	48.525	-1.024	1.00	8.63	C
ATOM	1056	OG1	THR	A	137	64.268	48.686	-1.443	1.00	9.97	O
ATOM	1057	CG2	THR	A	137	61.921	48.980	-2.122	1.00	10.50	C
ATOM	1058	N	THR	A	138	63.576	47.820	1.983	1.00	7.47	N
ATOM	1059	CA	THR	A	138	64.583	47.402	2.967	1.00	8.57	C
ATOM	1060	C	THR	A	138	65.897	47.063	2.271	1.00	8.48	C
ATOM	1061	O	THR	A	138	66.964	47.414	2.830	1.00	8.95	O
ATOM	1062	CB	THR	A	138	64.065	46.280	3.826	1.00	8.38	C
ATOM	1063	OG1	THR	A	138	62.916	46.734	4.491	1.00	9.26	O
ATOM	1064	CG2	THR	A	138	65.082	45.788	4.856	1.00	9.62	C
ATOM	1065	N	ASP	A	139	65.848	46.465	1.131	1.00	8.54	N
ATOM	1066	CA	ASP	A	139	67.118	46.092	0.490	1.00	10.12	C
ATOM	1067	C	ASP	A	139	67.896	47.364	0.098	1.00	9.94	C
ATOM	1068	O	ASP	A	139	69.150	47.396	0.254	1.00	10.41	O
ATOM	1069	CB	ASP	A	139	66.823	45.289	-0.790	1.00	14.63	C
ATOM	1070	CG	ASP	A	139	66.244	43.916	-0.561	1.00	18.33	C
ATOM	1071	OD1	ASP	A	139	66.517	43.410	0.538	1.00	23.27	O
ATOM	1072	OD2	ASP	A	139	65.589	43.443	-1.552	1.00	24.60	O
ATOM	1073	N	TRP	A	140	67.247	48.356	-0.491	1.00	8.66	N
ATOM	1074	CA	TRP	A	140	67.967	49.571	-0.890	1.00	8.35	C
ATOM	1075	C	TRP	A	140	68.510	50.232	0.364	1.00	7.65	C
ATOM	1076	O	TRP	A	140	69.678	50.686	0.405	1.00	8.16	O
ATOM	1077	CB	TRP	A	140	67.022	50.529	-1.700	1.00	8.69	C

WO 2013/076253

PCT/EP2012/073483

24/34

ATOM	1078	CG	TRP	A	140	67.802	51.715	-2.215	1.00	8.94	C
ATOM	1079	CD1	TRP	A	140	68.398	51.786	-3.461	1.00	9.42	C
ATOM	1080	CD2	TRP	A	140	68.129	52.960	-1.537	1.00	8.00	C
ATOM	1081	NE1	TRP	A	140	69.032	52.991	-3.594	1.00	9.29	N
ATOM	1082	CE2	TRP	A	140	68.933	53.724	-2.422	1.00	7.92	C
ATOM	1083	CE3	TRP	A	140	67.856	53.473	-0.255	1.00	7.84	C
ATOM	1084	CZ2	TRP	A	140	69.451	54.933	-2.091	1.00	8.67	C
ATOM	1085	CZ3	TRP	A	140	68.388	54.667	0.098	1.00	8.42	C
ATOM	1086	CH2	TRP	A	140	69.201	55.418	-0.821	1.00	8.52	C
ATOM	1087	N	TRP	A	141	67.686	50.366	1.377	1.00	7.82	N
ATOM	1088	CA	TRP	A	141	68.090	51.078	2.601	1.00	7.33	C
ATOM	1089	C	TRP	A	141	69.286	50.382	3.285	1.00	6.82	C
ATOM	1090	O	TRP	A	141	70.229	51.002	3.748	1.00	7.73	O
ATOM	1091	CB	TRP	A	141	66.908	51.109	3.581	1.00	7.11	C
ATOM	1092	CG	TRP	A	141	67.115	52.042	4.728	1.00	7.72	C
ATOM	1093	CD1	TRP	A	141	67.533	51.755	6.031	1.00	7.83	C
ATOM	1094	CD2	TRP	A	141	66.965	53.443	4.704	1.00	6.56	C
ATOM	1095	NE1	TRP	A	141	67.602	52.865	6.760	1.00	7.80	N
ATOM	1096	CE2	TRP	A	141	67.290	53.935	5.996	1.00	6.97	C
ATOM	1097	CE3	TRP	A	141	66.572	54.345	3.741	1.00	7.06	C
ATOM	1098	CZ2	TRP	A	141	67.224	55.249	6.300	1.00	8.00	C
ATOM	1099	CZ3	TRP	A	141	66.520	55.652	4.038	1.00	7.96	C
ATOM	1100	CH2	TRP	A	141	66.818	56.117	5.325	1.00	7.62	C
ATOM	1101	N	THR	A	142	69.265	49.050	3.247	1.00	7.39	N
ATOM	1102	CA	THR	A	142	70.350	48.286	3.901	1.00	8.14	C
ATOM	1103	C	THR	A	142	71.668	48.507	3.156	1.00	8.17	C
ATOM	1104	O	THR	A	142	72.698	48.887	3.801	1.00	8.63	O
ATOM	1105	CB	THR	A	142	69.951	46.821	3.957	1.00	8.43	C
ATOM	1106	OG1	THR	A	142	68.790	46.668	4.795	1.00	9.41	O
ATOM	1107	CG2	THR	A	142	71.070	45.956	4.560	1.00	9.86	C
ATOM	1108	N	AGLN	A	143	71.693	48.444	1.832	0.50	9.27	N
ATOM	1109	CA	AGLN	A	143	72.973	48.615	1.159	0.50	10.79	C
ATOM	1110	C	AGLN	A	143	73.413	50.088	1.067	0.50	9.53	C
ATOM	1111	O	AGLN	A	143	74.593	50.432	1.188	0.50	10.97	O
ATOM	1112	CB	AGLN	A	143	72.912	47.844	-0.130	0.50	14.10	C
ATOM	1113	CG	AGLN	A	143	73.316	48.615	-1.314	0.50	16.88	C
ATOM	1114	CD	AGLN	A	143	73.552	47.829	-2.587	0.50	14.74	C
ATOM	1115	OE1	AGLN	A	143	74.335	48.269	-3.420	0.50	16.26	O
ATOM	1116	NE2	AGLN	A	143	72.839	46.724	-2.794	0.50	11.84	N
ATOM	1117	N	CYS	A	144	72.461	50.992	0.878	1.00	7.66	N
ATOM	1118	CA	CYS	A	144	72.846	52.345	0.586	1.00	7.76	C
ATOM	1119	C	CYS	A	144	73.069	53.220	1.798	1.00	7.70	C
ATOM	1120	O	CYS	A	144	73.740	54.251	1.732	1.00	9.47	O
ATOM	1121	CB	CYS	A	144	71.927	53.008	-0.459	1.00	7.71	C
ATOM	1122	SG	CYS	A	144	71.792	52.160	-2.007	1.00	9.72	S
ATOM	1123	N	THR	A	145	72.447	52.882	2.942	1.00	7.57	N
ATOM	1124	CA	THR	A	145	72.617	53.623	4.157	1.00	7.94	C
ATOM	1125	C	THR	A	145	73.407	52.881	5.204	1.00	8.83	C
ATOM	1126	O	THR	A	145	73.609	53.378	6.330	1.00	9.32	O
ATOM	1127	CB	THR	A	145	71.334	54.193	4.781	1.00	8.11	C
ATOM	1128	OG1	THR	A	145	70.596	53.130	5.416	1.00	8.01	O
ATOM	1129	CG2	THR	A	145	70.459	54.900	3.756	1.00	8.69	C
ATOM	1130	N	GLY	A	146	73.755	51.621	4.962	1.00	9.09	N
ATOM	1131	CA	GLY	A	146	74.297	50.777	6.019	1.00	8.91	C

WO 2013/076253

PCT/EP2012/073483

25/34

ATOM	1132	C	GLY	A	146	73.187	50.362	6.994	1.00	9.60	C
ATOM	1133	O	GLY	A	146	73.489	50.083	8.190	1.00	11.18	O
ATOM	1134	N	ASN	A	147	71.955	50.352	6.536	1.00	9.50	N
ATOM	1135	CA	ASN	A	147	70.827	50.086	7.402	1.00	8.82	C
ATOM	1136	C	ASN	A	147	70.738	51.048	8.567	1.00	8.59	C
ATOM	1137	O	ASN	A	147	70.702	50.627	9.762	1.00	10.07	O
ATOM	1138	CB	ASN	A	147	70.735	48.606	7.833	1.00	8.94	C
ATOM	1139	CG	ASN	A	147	69.297	48.147	8.061	1.00	9.13	C
ATOM	1140	OD1	ASN	A	147	68.328	48.862	7.823	1.00	9.32	O
ATOM	1141	ND2	ASN	A	147	69.170	46.924	8.534	1.00	10.40	N
ATOM	1142	N	SER	A	148	70.722	52.329	8.275	1.00	8.22	N
ATOM	1143	CA	SER	A	148	70.748	53.331	9.312	1.00	9.16	C
ATOM	1144	C	SER	A	148	69.428	53.486	10.059	1.00	7.72	C
ATOM	1145	O	SER	A	148	68.355	53.561	9.438	1.00	8.80	O
ATOM	1146	CB	SER	A	148	71.059	54.714	8.669	1.00	10.29	C
ATOM	1147	OG	SER	A	148	71.070	55.715	9.623	1.00	10.25	O
ATOM	1148	N	ASN	A	149	69.528	53.603	11.383	1.00	7.82	N
ATOM	1149	CA	ASN	A	149	68.345	53.940	12.216	1.00	8.52	C
ATOM	1150	C	ASN	A	149	68.249	55.388	12.503	1.00	8.47	C
ATOM	1151	O	ASN	A	149	67.396	55.761	13.366	1.00	9.50	O
ATOM	1152	CB	ASN	A	149	68.340	53.102	13.496	1.00	8.53	C
ATOM	1153	CG	ASN	A	149	69.595	53.301	14.334	1.00	8.72	C
ATOM	1154	OD1	ASN	A	149	70.345	54.218	14.149	1.00	9.62	O
ATOM	1155	ND2	ASN	A	149	69.763	52.393	15.331	1.00	9.48	N
ATOM	1156	N	ARG	A	150	68.956	56.273	11.812	1.00	9.14	N
ATOM	1157	CA	ARG	A	150	68.995	57.666	12.132	1.00	9.87	C
ATOM	1158	C	ARG	A	150	67.665	58.436	12.083	1.00	10.12	C
ATOM	1159	O	ARG	A	150	67.516	59.452	12.770	1.00	10.54	O
ATOM	1160	CB	ARG	A	150	70.005	58.372	11.176	1.00	12.81	C
ATOM	1161	CG	ARG	A	150	70.094	59.809	11.483	1.00	17.89	C
ATOM	1162	CD	ARG	A	150	70.991	60.511	10.736	1.00	27.57	C
ATOM	1163	NE	ARG	A	150	72.183	60.272	11.381	1.00	30.26	N
ATOM	1164	CZ	ARG	A	150	73.019	61.229	11.506	1.00	29.85	C
ATOM	1165	NH1	ARG	A	150	72.599	62.385	11.112	1.00	26.18	N
ATOM	1166	NH2	ARG	A	150	74.228	60.972	11.904	1.00	24.41	N
ATOM	1167	N	PHE	A	151	66.727	57.975	11.234	1.00	8.94	N
ATOM	1168	CA	PHE	A	151	65.511	58.699	10.942	1.00	9.20	C
ATOM	1169	C	PHE	A	151	64.316	58.046	11.592	1.00	9.78	C
ATOM	1170	O	PHE	A	151	63.206	58.629	11.487	1.00	10.61	O
ATOM	1171	CB	PHE	A	151	65.318	58.834	9.394	1.00	9.54	C
ATOM	1172	CG	PHE	A	151	66.549	59.379	8.730	1.00	8.97	C
ATOM	1173	CD1	PHE	A	151	66.962	60.676	8.930	1.00	9.62	C
ATOM	1174	CD2	PHE	A	151	67.395	58.554	8.064	1.00	10.03	C
ATOM	1175	CE1	PHE	A	151	68.177	61.087	8.425	1.00	11.75	C
ATOM	1176	CE2	PHE	A	151	68.612	58.988	7.570	1.00	11.10	C
ATOM	1177	CZ	PHE	A	151	68.989	60.246	7.734	1.00	11.24	C
ATOM	1178	N	ALA	A	152	64.446	56.924	12.216	1.00	9.12	N
ATOM	1179	CA	ALA	A	152	63.303	56.122	12.653	1.00	10.60	C
ATOM	1180	C	ALA	A	152	62.451	56.794	13.716	1.00	10.88	C
ATOM	1181	O	ALA	A	152	61.282	56.398	13.820	1.00	14.19	O
ATOM	1182	CB	ALA	A	152	63.765	54.770	13.117	1.00	12.67	C
ATOM	1183	N	ASN	A	153	63.002	57.683	14.492	1.00	9.62	N
ATOM	1184	CA	ASN	A	153	62.207	58.355	15.571	1.00	10.68	C
ATOM	1185	C	ASN	A	153	61.743	59.711	15.129	1.00	10.51	C

WO 2013/076253

PCT/EP2012/073483

26/34

ATOM	1186	O	ASN	A	153	61.183	60.499	15.944	1.00	12.66	O
ATOM	1187	CB	ASN	A	153	62.963	58.309	16.915	1.00	12.44	C
ATOM	1188	CG	ASN	A	153	63.022	56.856	17.500	1.00	13.49	C
ATOM	1189	OD1	ASN	A	153	62.043	56.431	18.122	1.00	17.87	O
ATOM	1190	ND2	ASN	A	153	64.009	56.095	17.257	1.00	15.95	N
ATOM	1191	N	ARG	A	154	61.844	60.072	13.840	1.00	9.21	N
ATOM	1192	CA	ARG	A	154	61.306	61.260	13.287	1.00	10.27	C
ATOM	1193	C	ARG	A	154	60.346	61.001	12.128	1.00	9.25	C
ATOM	1194	O	ARG	A	154	59.260	61.571	12.057	1.00	10.51	O
ATOM	1195	CB	ARG	A	154	62.407	62.252	12.858	1.00	10.77	C
ATOM	1196	CG	ARG	A	154	63.126	62.870	14.059	1.00	11.16	C
ATOM	1197	CD	ARG	A	154	64.319	63.706	13.595	1.00	12.25	C
ATOM	1198	NE	ARG	A	154	65.378	62.841	13.090	1.00	10.50	N
ATOM	1199	CZ	ARG	A	154	66.431	63.233	12.360	1.00	12.16	C
ATOM	1200	NH1	ARG	A	154	66.593	64.510	12.096	1.00	12.15	N
ATOM	1201	NH2	ARG	A	154	67.383	62.386	12.052	1.00	11.85	N
ATOM	1202	N	CYS	A	155	60.821	60.285	11.119	1.00	8.58	N
ATOM	1203	CA	CYS	A	155	60.159	60.147	9.835	1.00	8.25	C
ATOM	1204	C	CYS	A	155	59.308	58.880	9.830	1.00	8.71	C
ATOM	1205	O	CYS	A	155	59.844	57.783	10.008	1.00	9.78	O
ATOM	1206	CB	CYS	A	155	61.200	60.012	8.737	1.00	9.18	C
ATOM	1207	SG	CYS	A	155	62.277	61.473	8.622	1.00	10.10	S
ATOM	1208	N	PRO	A	156	57.982	59.004	9.520	1.00	7.59	N
ATOM	1209	CA	PRO	A	156	57.171	57.776	9.323	1.00	7.63	C
ATOM	1210	C	PRO	A	156	57.740	56.961	8.141	1.00	7.08	C
ATOM	1211	O	PRO	A	156	58.209	57.549	7.155	1.00	8.52	O
ATOM	1212	CB	PRO	A	156	55.799	58.326	9.005	1.00	9.24	C
ATOM	1213	CG	PRO	A	156	55.772	59.736	9.551	1.00	9.64	C
ATOM	1214	CD	PRO	A	156	57.200	60.233	9.381	1.00	8.70	C
ATOM	1215	N	LEU	A	157	57.655	55.646	8.223	1.00	7.48	N
ATOM	1216	CA	LEU	A	157	58.126	54.741	7.164	1.00	6.89	C
ATOM	1217	C	LEU	A	157	57.026	54.382	6.206	1.00	6.26	C
ATOM	1218	O	LEU	A	157	55.948	53.904	6.626	1.00	7.26	O
ATOM	1219	CB	LEU	A	157	58.696	53.491	7.799	1.00	6.90	C
ATOM	1220	CG	LEU	A	157	59.187	52.421	6.824	1.00	7.83	C
ATOM	1221	CD1	LEU	A	157	60.389	52.941	6.000	1.00	8.27	C
ATOM	1222	CD2	LEU	A	157	59.550	51.157	7.544	1.00	8.16	C
ATOM	1223	N	TRP	A	158	57.286	54.580	4.908	1.00	6.49	N
ATOM	1224	CA	TRP	A	158	56.466	54.080	3.802	1.00	6.34	C
ATOM	1225	C	TRP	A	158	57.290	53.006	3.112	1.00	6.40	C
ATOM	1226	O	TRP	A	158	58.234	53.312	2.375	1.00	7.33	O
ATOM	1227	CB	TRP	A	158	56.068	55.233	2.902	1.00	6.66	C
ATOM	1228	CG	TRP	A	158	55.190	54.925	1.733	1.00	6.59	C
ATOM	1229	CD1	TRP	A	158	54.599	53.725	1.392	1.00	6.90	C
ATOM	1230	CD2	TRP	A	158	54.777	55.881	0.750	1.00	6.88	C
ATOM	1231	NE1	TRP	A	158	53.859	53.893	0.250	1.00	7.46	N
ATOM	1232	CE2	TRP	A	158	53.964	55.189	-0.150	1.00	6.74	C
ATOM	1233	CE3	TRP	A	158	55.099	57.218	0.486	1.00	7.30	C
ATOM	1234	CZ2	TRP	A	158	53.498	55.823	-1.351	1.00	7.99	C
ATOM	1235	CZ3	TRP	A	158	54.625	57.810	-0.639	1.00	8.48	C
ATOM	1236	CH2	TRP	A	158	53.784	57.105	-1.530	1.00	8.40	C
ATOM	1237	N	ILE	A	159	57.010	51.729	3.427	1.00	6.44	N
ATOM	1238	CA	ILE	A	159	57.780	50.624	2.931	1.00	6.68	C
ATOM	1239	C	ILE	A	159	57.152	50.030	1.686	1.00	6.52	C

WO 2013/076253

PCT/EP2012/073483

27/34

ATOM	1240	O	ILE	A	159	55.949	49.858	1.633	1.00	6.82	O
ATOM	1241	CB	ILE	A	159	57.999	49.575	4.060	1.00	7.44	C
ATOM	1242	CG1	ILE	A	159	59.088	48.568	3.749	1.00	9.07	C
ATOM	1243	CG2	ILE	A	159	56.674	48.854	4.442	1.00	8.52	C
ATOM	1244	CD1	ILE	A	159	60.462	49.157	3.713	1.00	10.33	C
ATOM	1245	N	ALA	A	160	57.973	49.648	0.707	1.00	6.90	N
ATOM	1246	CA	ALA	A	160	57.491	48.996	-0.507	1.00	6.93	C
ATOM	1247	C	ALA	A	160	57.891	47.536	-0.503	1.00	7.44	C
ATOM	1248	O	ALA	A	160	59.114	47.234	-0.415	1.00	7.83	O
ATOM	1249	CB	ALA	A	160	57.957	49.663	-1.770	1.00	7.55	C
ATOM	1250	N	ARG	A	161	56.971	46.633	-0.681	1.00	7.07	N
ATOM	1251	CA	ARG	A	161	57.228	45.182	-0.876	1.00	7.64	C
ATOM	1252	C	ARG	A	161	55.983	44.552	-1.476	1.00	7.38	C
ATOM	1253	O	ARG	A	161	54.926	44.551	-0.851	1.00	7.18	O
ATOM	1254	CB	ARG	A	161	57.653	44.446	0.426	1.00	11.16	C
ATOM	1255	CG	ARG	A	161	57.996	42.952	-0.048	1.00	14.52	C
ATOM	1256	CD	ARG	A	161	59.288	42.073	0.020	1.00	24.94	C
ATOM	1257	NE	ARG	A	161	58.613	40.938	0.630	1.00	20.34	N
ATOM	1258	CZ	ARG	A	161	58.679	39.746	1.150	1.00	16.04	C
ATOM	1259	NH1	ARG	A	161	59.148	38.679	0.549	1.00	16.05	N
ATOM	1260	NH2	ARG	A	161	57.833	39.613	2.161	1.00	13.84	N
ATOM	1261	N	TYR	A	162	56.119	44.000	-2.682	1.00	8.12	N
ATOM	1262	CA	TYR	A	162	54.983	43.506	-3.402	1.00	8.21	C
ATOM	1263	C	TYR	A	162	54.855	41.986	-3.156	1.00	8.93	C
ATOM	1264	O	TYR	A	162	55.403	41.152	-3.889	1.00	10.04	O
ATOM	1265	CB	TYR	A	162	55.088	43.818	-4.902	1.00	7.99	C
ATOM	1266	CG	TYR	A	162	55.204	45.268	-5.248	1.00	7.52	C
ATOM	1267	CD1	TYR	A	162	54.938	46.288	-4.332	1.00	7.57	C
ATOM	1268	CD2	TYR	A	162	55.684	45.666	-6.502	1.00	9.27	C
ATOM	1269	CE1	TYR	A	162	55.107	47.628	-4.631	1.00	8.40	C
ATOM	1270	CE2	TYR	A	162	55.824	47.025	-6.812	1.00	9.38	C
ATOM	1271	CZ	TYR	A	162	55.548	47.985	-5.863	1.00	8.85	C
ATOM	1272	OH	TYR	A	162	55.737	49.326	-6.217	1.00	10.83	O
ATOM	1273	N	ALA	A	163	54.227	41.622	-2.043	1.00	8.15	N
ATOM	1274	CA	ALA	A	163	54.183	40.282	-1.516	1.00	8.27	C
ATOM	1275	C	ALA	A	163	52.980	40.193	-0.543	1.00	8.13	C
ATOM	1276	O	ALA	A	163	52.344	41.159	-0.207	1.00	8.47	O
ATOM	1277	CB	ALA	A	163	55.493	39.965	-0.777	1.00	9.16	C
ATOM	1278	N	SER	A	164	52.721	38.965	-0.080	1.00	8.68	N
ATOM	1279	CA	SER	A	164	51.592	38.716	0.806	1.00	7.85	C
ATOM	1280	C	SER	A	164	51.825	39.183	2.243	1.00	8.63	C
ATOM	1281	O	SER	A	164	50.897	39.277	3.049	1.00	9.04	O
ATOM	1282	CB	SER	A	164	51.249	37.204	0.799	1.00	9.72	C
ATOM	1283	OG	SER	A	164	52.337	36.471	1.284	1.00	9.90	O
ATOM	1284	N	SER	A	165	53.070	39.535	2.600	1.00	8.88	N
ATOM	1285	CA	SER	A	165	53.404	40.129	3.902	1.00	9.17	C
ATOM	1286	C	SER	A	165	54.514	41.118	3.656	1.00	8.98	C
ATOM	1287	O	SER	A	165	55.255	41.083	2.656	1.00	9.75	O
ATOM	1288	CB	SER	A	165	53.842	39.054	4.942	1.00	12.90	C
ATOM	1289	OG	SER	A	165	54.912	38.405	4.555	1.00	15.18	O
ATOM	1290	N	AVAL	A	166	54.629	42.037	4.612	0.50	8.77	N
ATOM	1291	CA	AVAL	A	166	55.534	43.181	4.447	0.50	9.54	C
ATOM	1292	C	AVAL	A	166	57.000	42.831	4.522	0.50	10.75	C
ATOM	1293	O	AVAL	A	166	57.773	43.606	3.860	0.50	12.11	O

WO 2013/076253

PCT/EP2012/073483

28/34

ATOM	1294	CB	AVAL	A	166	55.128	44.287	5.416	0.50	8.19	C
ATOM	1295	CG1	AVAL	A	166	55.552	43.990	6.845	0.50	8.43	C
ATOM	1296	CG2	AVAL	A	166	55.707	45.620	4.988	0.50	7.62	C
ATOM	1297	N	GLY	A	167	57.390	41.725	5.168	1.00	12.46	N
ATOM	1298	CA	GLY	A	167	58.759	41.276	5.308	1.00	14.46	C
ATOM	1299	C	GLY	A	167	59.561	42.132	6.335	1.00	13.77	C
ATOM	1300	O	GLY	A	167	59.065	42.864	7.135	1.00	13.29	O
ATOM	1301	N	THR	A	168	60.856	41.993	6.254	1.00	13.21	N
ATOM	1302	CA	THR	A	168	61.802	42.705	7.112	1.00	13.24	C
ATOM	1303	C	THR	A	168	61.705	44.244	6.971	1.00	9.41	C
ATOM	1304	O	THR	A	168	61.718	44.700	5.854	1.00	10.41	O
ATOM	1305	CB	THR	A	168	63.247	42.293	6.731	1.00	17.02	C
ATOM	1306	OG1	THR	A	168	63.348	40.839	6.618	1.00	21.31	O
ATOM	1307	CG2	THR	A	168	64.316	42.899	7.626	1.00	16.56	C
ATOM	1308	N	LEU	A	169	61.674	44.967	8.053	1.00	10.02	N
ATOM	1309	CA	LEU	A	169	61.696	46.472	8.038	1.00	9.92	C
ATOM	1310	C	LEU	A	169	63.142	46.991	8.199	1.00	9.72	C
ATOM	1311	O	LEU	A	169	63.971	46.249	8.806	1.00	10.04	O
ATOM	1312	CB	LEU	A	169	60.813	47.079	9.151	1.00	11.30	C
ATOM	1313	CG	LEU	A	169	59.293	46.687	9.101	1.00	11.70	C
ATOM	1314	CD1	LEU	A	169	58.578	47.410	10.210	1.00	14.19	C
ATOM	1315	CD2	LEU	A	169	58.688	47.077	7.787	1.00	12.13	C
ATOM	1316	N	PRO	A	170	63.430	48.172	7.745	1.00	9.14	N
ATOM	1317	CA	PRO	A	170	64.754	48.771	7.988	1.00	10.04	C
ATOM	1318	C	PRO	A	170	64.960	48.963	9.445	1.00	9.71	C
ATOM	1319	O	PRO	A	170	64.016	49.198	10.258	1.00	10.63	O
ATOM	1320	CB	PRO	A	170	64.699	50.062	7.202	1.00	10.89	C
ATOM	1321	CG	PRO	A	170	63.530	49.957	6.271	1.00	11.93	C
ATOM	1322	CD	PRO	A	170	62.545	49.071	6.946	1.00	10.87	C
ATOM	1323	N	ASN	A	171	66.228	48.999	9.806	1.00	9.70	N
ATOM	1324	CA	ASN	A	171	66.669	49.204	11.197	1.00	10.74	C
ATOM	1325	C	ASN	A	171	66.103	50.420	11.847	1.00	10.33	C
ATOM	1326	O	ASN	A	171	66.118	51.533	11.337	1.00	12.60	O
ATOM	1327	CB	ASN	A	171	68.227	49.284	11.178	1.00	11.62	C
ATOM	1328	CG	ASN	A	171	68.890	49.260	12.525	1.00	11.64	C
ATOM	1329	OD1	ASN	A	171	68.348	48.691	13.479	1.00	13.55	O
ATOM	1330	ND2	ASN	A	171	70.004	49.926	12.624	1.00	10.94	N
ATOM	1331	N	GLY	A	172	65.528	50.210	13.065	1.00	11.34	N
ATOM	1332	CA	GLY	A	172	65.016	51.262	13.880	1.00	11.48	C
ATOM	1333	C	GLY	A	172	63.554	51.419	13.853	1.00	10.15	C
ATOM	1334	O	GLY	A	172	62.960	51.958	14.802	1.00	12.67	O
ATOM	1335	N	TRP	A	173	62.887	51.061	12.746	1.00	10.63	N
ATOM	1336	CA	TRP	A	173	61.461	51.236	12.661	1.00	10.59	C
ATOM	1337	C	TRP	A	173	60.768	49.998	13.232	1.00	11.55	C
ATOM	1338	O	TRP	A	173	60.910	48.979	12.720	1.00	14.79	O
ATOM	1339	CB	TRP	A	173	60.983	51.522	11.247	1.00	9.71	C
ATOM	1340	CG	TRP	A	173	61.137	52.904	10.763	1.00	9.75	C
ATOM	1341	CD1	TRP	A	173	60.311	53.978	11.033	1.00	9.20	C
ATOM	1342	CD2	TRP	A	173	62.119	53.413	9.862	1.00	10.01	C
ATOM	1343	NE1	TRP	A	173	60.688	55.081	10.372	1.00	9.35	N
ATOM	1344	CE2	TRP	A	173	61.789	54.777	9.627	1.00	9.12	C
ATOM	1345	CE3	TRP	A	173	63.225	52.869	9.215	1.00	10.16	C
ATOM	1346	CZ2	TRP	A	173	62.522	55.550	8.723	1.00	10.17	C
ATOM	1347	CZ3	TRP	A	173	63.928	53.652	8.339	1.00	10.89	C

WO 2013/076253

PCT/EP2012/073483

29/34

ATOM	1348	CH2	TRP	A	173	63.577	54.973	8.102	1.00	10.55	C
ATOM	1349	N	GLY	A	174	59.988	50.201	14.299	1.00	12.50	N
ATOM	1350	CA	GLY	A	174	59.205	49.082	14.913	1.00	14.09	C
ATOM	1351	C	GLY	A	174	57.992	48.728	14.034	1.00	12.53	C
ATOM	1352	O	GLY	A	174	57.648	47.578	14.031	1.00	13.52	O
ATOM	1353	N	PHE	A	175	57.451	49.701	13.256	1.00	11.87	N
ATOM	1354	CA	PHE	A	175	56.250	49.480	12.455	1.00	10.90	C
ATOM	1355	C	PHE	A	175	56.347	50.310	11.196	1.00	9.24	C
ATOM	1356	O	PHE	A	175	56.949	51.389	11.235	1.00	11.32	O
ATOM	1357	CB	PHE	A	175	54.986	49.969	13.228	1.00	13.68	C
ATOM	1358	CG	PHE	A	175	54.850	49.467	14.592	1.00	17.07	C
ATOM	1359	CD1	PHE	A	175	54.292	48.286	14.791	1.00	19.93	C
ATOM	1360	CD2	PHE	A	175	55.370	50.184	15.635	1.00	18.63	C
ATOM	1361	CE1	PHE	A	175	54.204	47.742	16.106	1.00	21.75	C
ATOM	1362	CE2	PHE	A	175	55.278	49.711	16.964	1.00	23.00	C
ATOM	1363	CZ	PHE	A	175	54.701	48.481	17.191	1.00	22.98	C
ATOM	1364	N	TYR	A	176	55.688	49.899	10.126	1.00	9.12	N
ATOM	1365	CA	TYR	A	176	55.482	50.778	8.946	1.00	8.30	C
ATOM	1366	C	TYR	A	176	54.295	51.699	9.302	1.00	7.30	C
ATOM	1367	O	TYR	A	176	53.379	51.370	10.081	1.00	8.52	O
ATOM	1368	CB	TYR	A	176	55.285	50.039	7.644	1.00	9.38	C
ATOM	1369	CG	TYR	A	176	54.009	49.216	7.537	1.00	10.20	C
ATOM	1370	CD1	TYR	A	176	52.830	49.779	7.177	1.00	10.70	C
ATOM	1371	CD2	TYR	A	176	54.037	47.860	7.757	1.00	13.14	C
ATOM	1372	CE1	TYR	A	176	51.654	49.040	7.067	1.00	12.14	C
ATOM	1373	CE2	TYR	A	176	52.856	47.122	7.666	1.00	16.11	C
ATOM	1374	CZ	TYR	A	176	51.726	47.753	7.315	1.00	14.00	C
ATOM	1375	OH	TYR	A	176	50.589	46.919	7.222	1.00	20.16	O
ATOM	1376	N	THR	A	177	54.291	52.874	8.692	1.00	7.60	N
ATOM	1377	CA	THR	A	177	53.117	53.789	8.650	1.00	7.06	C
ATOM	1378	C	THR	A	177	52.300	53.504	7.395	1.00	7.51	C
ATOM	1379	O	THR	A	177	51.054	53.421	7.465	1.00	7.70	O
ATOM	1380	CB	THR	A	177	53.544	55.243	8.784	1.00	7.48	C
ATOM	1381	OG1	THR	A	177	54.183	55.407	10.075	1.00	9.04	O
ATOM	1382	CG2	THR	A	177	52.402	56.179	8.710	1.00	8.24	C
ATOM	1383	N	PHE	A	178	52.953	53.436	6.217	1.00	6.45	N
ATOM	1384	CA	PHE	A	178	52.341	53.017	4.988	1.00	6.80	C
ATOM	1385	C	PHE	A	178	53.070	51.855	4.408	1.00	7.00	C
ATOM	1386	O	PHE	A	178	54.297	51.738	4.555	1.00	6.88	O
ATOM	1387	CB	PHE	A	178	52.309	54.159	3.916	1.00	7.21	C
ATOM	1388	CG	PHE	A	178	51.620	55.432	4.359	1.00	7.27	C
ATOM	1389	CD1	PHE	A	178	50.256	55.546	4.204	1.00	7.79	C
ATOM	1390	CD2	PHE	A	178	52.316	56.510	4.854	1.00	8.41	C
ATOM	1391	CE1	PHE	A	178	49.631	56.753	4.599	1.00	8.66	C
ATOM	1392	CE2	PHE	A	178	51.649	57.683	5.184	1.00	8.92	C
ATOM	1393	CZ	PHE	A	178	50.353	57.793	5.073	1.00	8.63	C
ATOM	1394	N	TRP	A	179	52.365	50.935	3.688	1.00	6.17	N
ATOM	1395	CA	TRP	A	179	52.929	49.816	2.980	1.00	6.36	C
ATOM	1396	C	TRP	A	179	52.382	49.808	1.568	1.00	6.69	C
ATOM	1397	O	TRP	A	179	51.165	49.697	1.329	1.00	6.44	O
ATOM	1398	CB	TRP	A	179	52.566	48.503	3.661	1.00	6.82	C
ATOM	1399	CG	TRP	A	179	52.955	47.232	2.949	1.00	6.55	C
ATOM	1400	CD1	TRP	A	179	53.937	47.069	2.040	1.00	6.41	C
ATOM	1401	CD2	TRP	A	179	52.317	45.975	3.109	1.00	8.05	C

WO 2013/076253

PCT/EP2012/073483

30/34

ATOM	1402	NE1	TRP	A	179	53.942	45.743	1.585	1.00	7.23	N
ATOM	1403	CE2	TRP	A	179	52.928	45.079	2.198	1.00	7.26	C
ATOM	1404	CE3	TRP	A	179	51.235	45.533	3.881	1.00	8.81	C
ATOM	1405	CZ2	TRP	A	179	52.558	43.732	2.085	1.00	8.97	C
ATOM	1406	CZ3	TRP	A	179	50.838	44.177	3.703	1.00	9.56	C
ATOM	1407	CH2	TRP	A	179	51.482	43.322	2.817	1.00	9.98	C
ATOM	1408	N	GLN	A	180	53.278	50.006	0.584	1.00	6.00	N
ATOM	1409	CA	GLN	A	180	52.971	49.854	-0.845	1.00	6.10	C
ATOM	1410	C	GLN	A	180	53.133	48.402	-1.210	1.00	6.73	C
ATOM	1411	O	GLN	A	180	54.222	47.834	-1.234	1.00	6.86	O
ATOM	1412	CB	GLN	A	180	53.929	50.716	-1.687	1.00	6.67	C
ATOM	1413	CG	GLN	A	180	53.363	50.921	-3.123	1.00	7.13	C
ATOM	1414	CD	GLN	A	180	54.416	51.718	-3.949	1.00	7.63	C
ATOM	1415	OE1	GLN	A	180	54.211	52.939	-4.165	1.00	10.06	O
ATOM	1416	NE2	GLN	A	180	55.494	51.140	-4.249	1.00	6.69	N
ATOM	1417	N	TYR	A	181	51.975	47.712	-1.473	1.00	6.71	N
ATOM	1418	CA	TYR	A	181	51.921	46.249	-1.616	1.00	7.80	C
ATOM	1419	C	TYR	A	181	51.712	45.817	-3.030	1.00	7.74	C
ATOM	1420	O	TYR	A	181	51.853	44.599	-3.273	1.00	8.31	O
ATOM	1421	CB	TYR	A	181	50.911	45.655	-0.610	1.00	8.76	C
ATOM	1422	CG	TYR	A	181	49.480	46.025	-0.854	1.00	9.45	C
ATOM	1423	CD1	TYR	A	181	48.943	47.142	-0.310	1.00	9.52	C
ATOM	1424	CD2	TYR	A	181	48.620	45.199	-1.584	1.00	10.91	C
ATOM	1425	CE1	TYR	A	181	47.614	47.549	-0.474	1.00	10.25	C
ATOM	1426	CE2	TYR	A	181	47.289	45.564	-1.776	1.00	12.17	C
ATOM	1427	CZ	TYR	A	181	46.804	46.698	-1.221	1.00	12.20	C
ATOM	1428	OH	TYR	A	181	45.452	47.072	-1.389	1.00	14.26	O
ATOM	1429	N	ASN	A	182	51.408	46.689	-3.981	1.00	7.33	N
ATOM	1430	CA	ASN	A	182	51.450	46.382	-5.408	1.00	7.90	C
ATOM	1431	C	ASN	A	182	51.615	47.632	-6.190	1.00	7.49	C
ATOM	1432	O	ASN	A	182	51.474	48.772	-5.673	1.00	7.74	O
ATOM	1433	CB	ASN	A	182	50.249	45.509	-5.851	1.00	8.26	C
ATOM	1434	CG	ASN	A	182	48.934	46.233	-5.948	1.00	7.94	C
ATOM	1435	OD1	ASN	A	182	48.824	47.393	-6.384	1.00	8.24	O
ATOM	1436	ND2	ASN	A	182	47.899	45.520	-5.540	1.00	11.05	N
ATOM	1437	N	ASP	A	183	51.949	47.462	-7.481	1.00	8.23	N
ATOM	1438	CA	ASP	A	183	52.020	48.523	-8.433	1.00	8.47	C
ATOM	1439	C	ASP	A	183	50.913	48.441	-9.453	1.00	8.65	C
ATOM	1440	O	ASP	A	183	51.068	48.810	-10.636	1.00	10.80	O
ATOM	1441	CB	ASP	A	183	53.396	48.535	-9.178	1.00	10.41	C
ATOM	1442	CG	ASP	A	183	53.727	47.244	-9.899	1.00	13.30	C
ATOM	1443	OD1	ASP	A	183	52.995	46.317	-9.884	1.00	14.47	O
ATOM	1444	OD2	ASP	A	183	54.877	47.310	-10.471	1.00	17.15	O
ATOM	1445	N	LYS	A	184	49.744	47.981	-9.021	1.00	9.23	N
ATOM	1446	CA	LYS	A	184	48.592	47.699	-9.880	1.00	9.58	C
ATOM	1447	C	LYS	A	184	47.300	48.201	-9.315	1.00	9.73	C
ATOM	1448	O	LYS	A	184	46.306	47.476	-9.234	1.00	11.04	O
ATOM	1449	CB	LYS	A	184	48.485	46.223	-10.210	1.00	13.16	C
ATOM	1450	CG	LYS	A	184	49.740	45.580	-10.781	1.00	19.34	C
ATOM	1451	CD	LYS	A	184	49.664	44.027	-10.706	1.00	28.70	C
ATOM	1452	CE	LYS	A	184	48.509	43.440	-11.542	1.00	41.22	C
ATOM	1453	NZ	LYS	A	184	48.302	41.938	-11.590	1.00	45.49	N
ATOM	1454	N	TYR	A	185	47.257	49.419	-8.827	1.00	9.07	N
ATOM	1455	CA	TYR	A	185	46.011	50.018	-8.446	1.00	9.69	C

WO 2013/076253

PCT/EP2012/073483

31/34

ATOM	1456	C	TYR	A	185	45.069	49.926	-9.675	1.00	9.31	C
ATOM	1457	O	TYR	A	185	45.508	50.233	-10.806	1.00	10.58	O
ATOM	1458	CB	TYR	A	185	46.230	51.498	-8.038	1.00	10.36	C
ATOM	1459	CG	TYR	A	185	44.956	52.124	-7.529	1.00	9.99	C
ATOM	1460	CD1	TYR	A	185	44.398	51.737	-6.346	1.00	10.62	C
ATOM	1461	CD2	TYR	A	185	44.250	53.084	-8.256	1.00	10.54	C
ATOM	1462	CE1	TYR	A	185	43.209	52.270	-5.856	1.00	12.78	C
ATOM	1463	CE2	TYR	A	185	43.060	53.619	-7.811	1.00	12.38	C
ATOM	1464	CZ	TYR	A	185	42.527	53.202	-6.650	1.00	12.47	C
ATOM	1465	OH	TYR	A	185	41.327	53.806	-6.187	1.00	13.72	O
ATOM	1466	N	PRO	A	186	43.752	49.611	-9.495	1.00	11.49	N
ATOM	1467	CA	PRO	A	186	42.920	49.334	-10.684	1.00	14.07	C
ATOM	1468	C	PRO	A	186	42.821	50.448	-11.726	1.00	13.26	C
ATOM	1469	O	PRO	A	186	42.700	50.165	-12.914	1.00	15.98	O
ATOM	1470	CB	PRO	A	186	41.536	48.995	-10.085	1.00	17.71	C
ATOM	1471	CG	PRO	A	186	41.843	48.528	-8.724	1.00	19.79	C
ATOM	1472	CD	PRO	A	186	43.075	49.272	-8.236	1.00	13.91	C
ATOM	1473	N	GLN	A	187	42.805	51.701	-11.335	1.00	11.15	N
ATOM	1474	CA	GLN	A	187	42.775	52.850	-12.234	1.00	11.00	C
ATOM	1475	C	GLN	A	187	44.118	53.269	-12.736	1.00	10.32	C
ATOM	1476	O	GLN	A	187	44.231	54.297	-13.469	1.00	10.71	O
ATOM	1477	CB	GLN	A	187	42.069	54.045	-11.593	1.00	10.60	C
ATOM	1478	CG	GLN	A	187	40.650	53.829	-11.195	1.00	12.08	C
ATOM	1479	CD	GLN	A	187	39.927	55.099	-10.953	1.00	11.42	C
ATOM	1480	OE1	GLN	A	187	40.005	56.003	-11.795	1.00	12.87	O
ATOM	1481	NE2	GLN	A	187	39.212	55.203	-9.839	1.00	11.74	N
ATOM	1482	N	GLY	A	188	45.184	52.643	-12.284	1.00	9.98	N
ATOM	1483	CA	GLY	A	188	46.535	53.041	-12.565	1.00	10.05	C
ATOM	1484	C	GLY	A	188	47.208	53.598	-11.311	1.00	9.45	C
ATOM	1485	O	GLY	A	188	46.582	54.334	-10.565	1.00	9.93	O
ATOM	1486	N	GLY	A	189	48.451	53.243	-11.087	1.00	8.73	N
ATOM	1487	CA	GLY	A	189	49.240	53.656	-9.907	1.00	8.57	C
ATOM	1488	C	GLY	A	189	49.484	52.471	-8.973	1.00	7.37	C
ATOM	1489	O	GLY	A	189	49.376	51.291	-9.375	1.00	8.36	O
ATOM	1490	N	ASP	A	190	49.900	52.788	-7.757	1.00	8.00	N
ATOM	1491	CA	ASP	A	190	50.283	51.749	-6.763	1.00	7.41	C
ATOM	1492	C	ASP	A	190	49.331	51.716	-5.614	1.00	6.96	C
ATOM	1493	O	ASP	A	190	48.703	52.764	-5.333	1.00	8.20	O
ATOM	1494	CB	ASP	A	190	51.712	52.080	-6.230	1.00	8.03	C
ATOM	1495	CG	ASP	A	190	52.688	52.329	-7.321	1.00	9.94	C
ATOM	1496	OD1	ASP	A	190	52.871	51.537	-8.212	1.00	12.53	O
ATOM	1497	OD2	ASP	A	190	53.313	53.508	-7.331	1.00	12.54	O
ATOM	1498	N	SER	A	191	49.182	50.576	-4.980	1.00	6.60	N
ATOM	1499	CA	SER	A	191	48.241	50.389	-3.887	1.00	7.29	C
ATOM	1500	C	SER	A	191	48.954	50.423	-2.539	1.00	6.67	C
ATOM	1501	O	SER	A	191	50.008	49.786	-2.375	1.00	6.82	O
ATOM	1502	CB	SER	A	191	47.512	49.068	-4.024	1.00	7.69	C
ATOM	1503	OG	SER	A	191	46.860	48.949	-5.284	1.00	8.91	O
ATOM	1504	N	ASN	A	192	48.354	51.091	-1.558	1.00	6.40	N
ATOM	1505	CA	ASN	A	192	48.928	51.245	-0.196	1.00	6.69	C
ATOM	1506	C	ASN	A	192	47.937	50.892	0.867	1.00	6.96	C
ATOM	1507	O	ASN	A	192	46.704	51.118	0.778	1.00	7.83	O
ATOM	1508	CB	ASN	A	192	49.358	52.697	0.027	1.00	7.65	C
ATOM	1509	CG	ASN	A	192	50.411	53.131	-0.928	1.00	6.92	C

WO 2013/076253

PCT/EP2012/073483

32/34

ATOM	1510	OD1	ASN	A	192	51.522	52.656	-0.955	1.00	7.75	O
ATOM	1511	ND2	ASN	A	192	50.061	54.143	-1.767	1.00	9.80	N
ATOM	1512	N	TRP	A	193	48.461	50.456	2.004	1.00	7.35	N
ATOM	1513	CA	TRP	A	193	47.767	50.442	3.306	1.00	7.07	C
ATOM	1514	C	TRP	A	193	48.357	51.501	4.230	1.00	7.17	C
ATOM	1515	O	TRP	A	193	49.601	51.621	4.316	1.00	8.16	O
ATOM	1516	CB	TRP	A	193	47.930	49.079	3.978	1.00	7.75	C
ATOM	1517	CG	TRP	A	193	47.214	47.971	3.389	1.00	9.37	C
ATOM	1518	CD1	TRP	A	193	47.761	46.821	2.865	1.00	12.13	C
ATOM	1519	CD2	TRP	A	193	45.814	47.890	3.244	1.00	10.95	C
ATOM	1520	NE1	TRP	A	193	46.763	46.027	2.376	1.00	14.80	N
ATOM	1521	CE2	TRP	A	193	45.562	46.624	2.574	1.00	12.79	C
ATOM	1522	CE3	TRP	A	193	44.756	48.667	3.686	1.00	11.10	C
ATOM	1523	CZ2	TRP	A	193	44.241	46.183	2.352	1.00	18.46	C
ATOM	1524	CZ3	TRP	A	193	43.421	48.233	3.405	1.00	13.88	C
ATOM	1525	CH2	TRP	A	193	43.234	47.004	2.711	1.00	15.40	C
ATOM	1526	N	PHE	A	194	47.507	52.182	4.982	1.00	6.79	N
ATOM	1527	CA	PHE	A	194	47.885	52.941	6.167	1.00	7.26	C
ATOM	1528	C	PHE	A	194	47.675	52.069	7.375	1.00	7.54	C
ATOM	1529	O	PHE	A	194	46.563	51.501	7.572	1.00	8.32	O
ATOM	1530	CB	PHE	A	194	47.056	54.228	6.281	1.00	8.09	C
ATOM	1531	CG	PHE	A	194	47.231	54.909	7.610	1.00	7.24	C
ATOM	1532	CD1	PHE	A	194	48.371	55.592	7.884	1.00	8.02	C
ATOM	1533	CD2	PHE	A	194	46.229	54.837	8.566	1.00	7.43	C
ATOM	1534	CE1	PHE	A	194	48.558	56.220	9.127	1.00	8.63	C
ATOM	1535	CE2	PHE	A	194	46.395	55.471	9.805	1.00	8.66	C
ATOM	1536	CZ	PHE	A	194	47.543	56.145	10.082	1.00	8.42	C
ATOM	1537	N	ASN	A	195	48.686	51.998	8.231	1.00	7.88	N
ATOM	1538	CA	ASN	A	195	48.669	51.100	9.391	1.00	9.52	C
ATOM	1539	C	ASN	A	195	47.984	51.743	10.587	1.00	9.29	C
ATOM	1540	O	ASN	A	195	48.627	52.172	11.556	1.00	12.58	O
ATOM	1541	CB	ASN	A	195	50.142	50.789	9.746	1.00	10.38	C
ATOM	1542	CG	ASN	A	195	50.285	49.580	10.614	1.00	11.58	C
ATOM	1543	OD1	ASN	A	195	49.281	48.941	11.061	1.00	14.71	O
ATOM	1544	ND2	ASN	A	195	51.518	49.238	10.933	1.00	12.69	N
ATOM	1545	N	GLY	A	196	46.682	51.848	10.527	1.00	9.81	N
ATOM	1546	CA	GLY	A	196	45.872	52.399	11.610	1.00	9.60	C
ATOM	1547	C	GLY	A	196	44.515	52.734	11.105	1.00	10.19	C
ATOM	1548	O	GLY	A	196	44.157	52.567	9.909	1.00	10.19	O
ATOM	1549	N	ASP	A	197	43.647	53.154	12.055	1.00	10.60	N
ATOM	1550	CA	ASP	A	197	42.248	53.498	11.691	1.00	10.54	C
ATOM	1551	C	ASP	A	197	42.147	54.956	11.176	1.00	11.06	C
ATOM	1552	O	ASP	A	197	43.133	55.712	11.091	1.00	10.63	O
ATOM	1553	CB	ASP	A	197	41.306	53.247	12.926	1.00	11.49	C
ATOM	1554	CG	ASP	A	197	41.575	54.081	14.083	1.00	14.06	C
ATOM	1555	OD1	ASP	A	197	42.169	55.149	14.080	1.00	14.18	O
ATOM	1556	OD2	ASP	A	197	41.116	53.622	15.239	1.00	16.55	O
ATOM	1557	N	ALA	A	198	40.912	55.387	10.807	1.00	10.79	N
ATOM	1558	CA	ALA	A	198	40.708	56.675	10.245	1.00	11.15	C
ATOM	1559	C	ALA	A	198	41.171	57.821	11.121	1.00	10.52	C
ATOM	1560	O	ALA	A	198	41.656	58.887	10.694	1.00	11.59	O
ATOM	1561	CB	ALA	A	198	39.246	56.848	9.814	1.00	12.22	C
ATOM	1562	N	SER	A	199	40.920	57.678	12.449	1.00	11.04	N
ATOM	1563	CA	SER	A	199	41.335	58.645	13.407	1.00	11.12	C

WO 2013/076253

PCT/EP2012/073483

33/34

ATOM	1564	C	SER	A	199	42.852	58.840	13.444	1.00	10.69	C
ATOM	1565	O	SER	A	199	43.352	59.923	13.569	1.00	10.29	O
ATOM	1566	CB	SER	A	199	40.714	58.332	14.767	1.00	12.41	C
ATOM	1567	OG	SER	A	199	41.162	59.194	15.740	1.00	14.69	O
ATOM	1568	N	ARG	A	200	43.561	57.730	13.392	1.00	10.83	N
ATOM	1569	CA	ARG	A	200	45.044	57.793	13.371	1.00	11.14	C
ATOM	1570	C	ARG	A	200	45.558	58.453	12.047	1.00	9.88	C
ATOM	1571	O	ARG	A	200	46.533	59.158	12.060	1.00	9.99	O
ATOM	1572	CB	ARG	A	200	45.703	56.410	13.575	1.00	12.14	C
ATOM	1573	CG	ARG	A	200	47.199	56.364	13.824	1.00	26.57	C
ATOM	1574	CD	ARG	A	200	47.908	54.989	13.821	1.00	36.82	C
ATOM	1575	NE	ARG	A	200	47.298	53.997	14.731	1.00	49.33	N
ATOM	1576	CZ	ARG	A	200	47.678	52.715	14.871	1.00	48.20	C
ATOM	1577	NH1	ARG	A	200	48.699	52.200	14.186	1.00	52.47	N
ATOM	1578	NH2	ARG	A	200	47.030	51.944	15.723	1.00	43.45	N
ATOM	1579	N	LEU	A	201	44.842	58.222	10.939	1.00	8.93	N
ATOM	1580	CA	LEU	A	201	45.222	58.878	9.673	1.00	8.97	C
ATOM	1581	C	LEU	A	201	45.018	60.381	9.751	1.00	9.31	C
ATOM	1582	O	LEU	A	201	45.889	61.191	9.374	1.00	10.10	O
ATOM	1583	CB	LEU	A	201	44.431	58.260	8.530	1.00	9.95	C
ATOM	1584	CG	LEU	A	201	44.761	58.849	7.150	1.00	9.95	C
ATOM	1585	CD1	LEU	A	201	46.239	58.619	6.786	1.00	10.73	C
ATOM	1586	CD2	LEU	A	201	43.885	58.204	6.132	1.00	11.41	C
ATOM	1587	N	ARG	A	202	43.891	60.823	10.368	1.00	10.01	N
ATOM	1588	CA	ARG	A	202	43.675	62.248	10.588	1.00	10.87	C
ATOM	1589	C	ARG	A	202	44.732	62.779	11.521	1.00	10.44	C
ATOM	1590	O	ARG	A	202	45.225	63.919	11.350	1.00	11.02	O
ATOM	1591	CB	ARG	A	202	42.287	62.561	11.132	1.00	12.31	C
ATOM	1592	CG	ARG	A	202	41.210	62.401	10.130	1.00	12.95	C
ATOM	1593	CD	ARG	A	202	39.812	62.815	10.642	1.00	12.62	C
ATOM	1594	NE	ARG	A	202	39.296	61.984	11.725	1.00	13.10	N
ATOM	1595	CZ	ARG	A	202	38.573	60.909	11.559	1.00	12.94	C
ATOM	1596	NH1	ARG	A	202	38.260	60.461	10.346	1.00	15.56	N
ATOM	1597	NH2	ARG	A	202	38.135	60.254	12.642	1.00	14.72	N
ATOM	1598	N	ALA	A	203	45.146	62.068	12.547	1.00	10.66	N
ATOM	1599	CA	ALA	A	203	46.176	62.492	13.457	1.00	11.61	C
ATOM	1600	C	ALA	A	203	47.520	62.751	12.723	1.00	10.39	C
ATOM	1601	O	ALA	A	203	48.260	63.667	13.017	1.00	12.24	O
ATOM	1602	CB	ALA	A	203	46.406	61.538	14.653	1.00	12.32	C
ATOM	1603	N	LEU	A	204	47.851	61.873	11.776	1.00	10.20	N
ATOM	1604	CA	LEU	A	204	49.062	62.058	10.967	1.00	9.80	C
ATOM	1605	C	LEU	A	204	48.978	63.313	10.128	1.00	9.40	C
ATOM	1606	O	LEU	A	204	49.929	64.100	9.995	1.00	10.59	O
ATOM	1607	CB	LEU	A	204	49.292	60.770	10.110	1.00	9.49	C
ATOM	1608	CG	LEU	A	204	50.559	60.891	9.214	1.00	10.94	C
ATOM	1609	CD1	LEU	A	204	51.823	60.990	10.047	1.00	11.83	C
ATOM	1610	CD2	LEU	A	204	50.639	59.662	8.324	1.00	11.42	C
ATOM	1611	N	ALA	A	205	47.841	63.542	9.493	1.00	9.80	N
ATOM	1612	CA	ALA	A	205	47.642	64.760	8.704	1.00	10.22	C
ATOM	1613	C	ALA	A	205	47.745	66.046	9.548	1.00	10.88	C
ATOM	1614	O	ALA	A	205	48.361	67.019	9.176	1.00	11.53	O
ATOM	1615	CB	ALA	A	205	46.291	64.744	8.012	1.00	10.87	C
ATOM	1616	N	ASN	A	206	47.226	65.967	10.769	1.00	11.39	N
ATOM	1617	CA	ASN	A	206	47.225	67.136	11.703	1.00	12.74	C

